# Report on Carcinogens Monograph o n 1-Bromopropane

September 2 013



# Br CH 3 

# H 2 

# C C H 2

# Report on Carcinogens

Monograph on 1-Bromopropane

September 25 , 2013

Office of the Report on Carcinogens Division of the National Toxicology Program National Institute of Environmental Health Sciences U.S. Department of Health and Human Services

NIH Publication No. 13- 5982

ISSN 2331

- 267X9/25/13 RoC Monograph on 1

- Bromopropane

This Page Intentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13

i 

### FOREWORD

The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Co ntrol and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public.
The Report on Carcinogens (RoC) is prepared in response to Section 301 of the Public Health Service Act
, as amended. The RoC contains a list of identified substances (i) that either are known to be human carcinogens or are reasonably anticipated to be human carcinogens and (ii) to which a significant number of persons residing in the United States are exposed. The Secretary, Department of HHS, has delegated responsibility for preparation of the RoC to the NTP, which prepares the report with assistance from other Federal health and regulat ory agencies and nongovernmental institutions. The most recent RoC, the 12th Edition (2011), is available at http://ntp.niehs.nih.gov/go/roc12

. Nominations for (1) listing a new substance, (2) reclassifying the listing status for a substance already listed, or (3) removing a substance already listed in the RoC are

eva l uated in a scientific review process ( http://ntp.niehs.nih.gov/go/rocprocess ) with multiple opportunities for scienti fic and public input using established l isting criteria ( http://ntp.niehs. nih.gov/go/15209 ). A list of candidate substances under consideration for listing in (or delisting from) the RoC can be obtained by accessing http://ntp.niehs.nih.gov/go/37893

.9/25/13 RoC Monograph on 1

- Bromopropane

ii 

### INTRODUCTION

1

- Bromopropane ( n

- propyl bromide, CASRN 106

- 94

- 5) is a brominated hydrocarbon that is currently used as a solvent in a variety of industrial and commercial applications. Exposure to workers has been increasing in the past few years due to several new applications in whic h 1

- bromopropane has been substituted for substances identified as suspect carcinogens or ozone

- depleting chemicals. The available o ccupational exposure data indicate that workers can be exposed to high levels of 1

- bromopropane

.
1

- Bromopropane was selected as a candidate substance for the R eport o n C arcinogens (RoC) due to the potential for substantial human exposure to 1

- bromopropane in the United States , and an adequate database to evaluate its potential carcinogenicity. 1

- Bromopropane has been tested for carcinogenicity in rodents in a 2

- year inhalation study ( NTP 2011a ) . In addition, 1

- bromopropane causes toxicity in people and experimental animals. Structurally related ha lo alkanes are carcinogenic in experimental animals.
Monograph contents

The RoC M

onograph on 1

- B romopropane consists of the following components: (Part 1)
t he cancer evaluation component that reviews the relevant scientific information , assesses its quality, applies the RoC listing criteria to the scientific information, and gives the RoC listing status for 1

- bromopropane , and (Part 2) the RoC monograph’s substance profile containing the NTP’s listing status decision , a summary of the s cientific evidence considered key to reaching that decision , and data on properties, use, production, exposure, and Federal regulations and guidelines to reduce exposure to 1

- bromopropane

. The cancer evaluation component for 1

- bromopropane provides informa tion on the following topics : human exposure and properties ( Section 1 )
, disposition and toxicokinetics ( Section 2 ) , cancer stu dies in experimental animals ( Section 4 ) , and studies of mechanisms and other related effects ( Section 5 ) , including relevant tox icological effects, genetic toxicology, and mechanisms of carcinogenicity. When human cancer studies are reviewed, they are discussed in Section 3; however, no cancer studies in humans with exposure specifically to 1

- bromopropane were identified . The infor mation in Sections 2 through 5 is synthesized in Section 6.
The information reviewed in Sections 2 through 5 (and synthesized in Section 6) c a me from publicly available, peer

- reviewed sources. Information in Section 1, including chemical and physical prope rties, analytical methods, production, use, and occurrence

came from publicly available, published or unpublished sources

.
The cancer evaluation for 1

- bromopropane focuses on the evaluation of the cancer studies in experimental animals and mechanis tic data
, and also whether there is any evidence that the potential modes of action by which 1

- bromopropane m ight cause cancer are not relevant to humans.RoC Monograph on 1

- Bromopropane 9/25/13

iii Process for preparation of the cancer evaluation component The process for preparing t he cancer evaluatio n component of the monograph included approaches for obtaining public and scientific input and using systematic meth ods (e.g., standardized methods for identifying the literature, inclusion/exclusion criteria, extraction of data and evaluation of study qua lity using specific guidelines [see Appendix A ] , and assessment of the level of evidence for carcinogenicity using established criteria)

.
The Office of the Report on Carcinogens ( ORoC ) followed the approaches outlined in the

c oncept document, which discusses the scientific issues and questions relevant to the evaluation of 1

- bromopropane carcinogenicity, the scope and focus of the monograph, and the approaches to obtain scientific and public input to address the key scientific questions and issues, for preparing the cancer evaluation component of the draft monograph. The ORoC presented the draft concept document on 1

- bromopropane to the NTP Board of Scientific Counselors (BSC) at the June 21

– 22, 2012 meeting that provided opport unity for written and oral public comments ; the concept document is available on the RoC website ( http://ntp.niehs.nih.gov/go/37896 ). The draft monograph was peer reviewed in a public forum in March 2013 (see ‘Peer Review of the Draft RoC Monograph on 1

- Bromopropane ’ below)

, revised accordingly, and presented to the BSC at a June 2013 meeting.

Key s cientific q uestions and i ssues r elevant for the c

ancer e valuation The cancer evaluation component of the mon ograph focus es on studies of 1

- bromopropane in experimental animals and mechanistic data. It also identifies and discuss es human a nd animal studies of non

- cancer endpoints, such as neurological or reproductive/developmental toxicity
, immunosuppression
, and studies of structurally related compounds and metabolites, to determine whether th is information can inform mechanisms of carcinogenicity of 1

- bromopropane.
The key scientific questions identified in the concept, which concern the results in experimental animals and mechanisms of carcinogenicity are :

What is the level of evidence (sufficient or not sufficient) for the carcinogenicity of 1

- bromopropane from studies in experimental animals? What are the tissue sites? What are potential mechanisms by which 1

- bromopropane may cause cancer?

o Do the mechanistic data in experimental animals support the cancer findings in humans?

o Are there mechanistic data to suggest that the cancer findings in experimental animals are not relevant to humans?

o Does immunomodulati on play a role in 1

- bromopropane carcinogenicity ?
Approach for obtaining scientific and public input
Additional scientific input was obtained for exposure and disposition and toxicokinetics of 1

- bromopropane

. (Technical advisors are identified on the “CONTRIBUTORS” page.)9/25/13 RoC Monograph on 1

- Bromopropane

iv Public comments on scientific issues were requested on 1

- bromopropane by Federal Register notices at several times prior to and during the development of the final RoC monograph , including a request for information on the nomination, and for comment on the draft concept document ( which outlined the rationale and approach for conducting the scientific review ) and comment on the draft R o C monograph . In addition, the NTP posted its preliminary li terature search strategy and list of references for public input on the RoC webpage for 1

- bromopropane ( http://ntp.niehs.nih.gov/go/3789 6 ) several months prior to the release of the draft monograph. F our p u blic comments were received in response to the Federal Register notices and are available at http://ntp.niehs.nih.gov/go/37663

. Methods for writing the cancer evaluation component of the monograph

The procedures by which relevant literature were identified, data were systematically extracted and summarized, and the monograph was written, together with the processes for scientific review, quality assurance, and assessment and synthesis of data, are descr ibed below.
The preparation of the RoC M onograph on 1

- B romopropane began with development of a literature search strategy for 1

- bromopropane to obtain information relevant to the topics for monograph sections, as discussed above, using search terms develop ed in collaboration with a reference librarian (see Appendix A for a detailed description of the literature search strategy). The citations ( N = 1
, 689 ) identified from these searches were uploaded to a web

- based systematic rev iew system for evaluation by two reviewers using inclusion/exclusion criteria
, and 1 5 8 references were selected for final inclusion in the monograph using these criteria

.
Information for the exposure, relevant cancer, and mechanistic sections w as systematically extracted in tabular format and/or summarized in the text, following specific procedur es developed by ORoC, from studies selected for inclusion in the monograph. All sections of the monograph underwent scientific review and quality

assuranc e (QA) (i.e., assuring that all the relevant data and factual information extracted from the publications have been reported accurately) by a separate reviewer. A ny discrepancies between the writer and the reviewer were resolved by mutual discussion in ref erence to the original data source

. Strengths, weaknesses, and data quality of the cancer studies for 1

- bromopropane in experimental animals were assessed based on a series of questions related to characterization of the substance tested, the features of animal husbandry, the design of the study, the methods for clinical observations and necropsy, and the manner in which the data were reported (see Appendix C ). Relevant genotoxicity and mechanistic studies were also assessed fo r their strengths and weaknesses.RoC Monograph on 1

- Bromopropane 9/25/13

v Human exposure information was assessed to determine whether the evidence indicates that a significant number of persons residing in the United States are exposed to 1

- bromopropane (see Foreword for information regarding the congressional mandate for the RoC). However, for many substances, this information is not available, and typically, U.S. exposure can be inferred from data on use, production volume
, occupational monitoring, environmental (occurrence), estimated daily intake, and biomonitoring. Because cancer has a long latency period, past exposure is also considered in the
assessment.

RoC l isting c riteria (see text box ) were applied to the availabl e database of carcinogenicity data to assess the level of evidence (sufficient or not sufficient) for the carcinogenicity of 1

- bromopropane from studies in experimental animals

. This initial conclusion does not integrate the experimental animal and mechani sm data. The evaluation of the mechanistic data included a discussion and assessment of the strength of evidence for potential modes of action of 1

- bromopropane

– induced neoplasia, including metabolic activation , cytotoxicity, and genetic effects and immunosuppression. In addition, human a nd animal studies of non

cancerous endpoints, such as neurological or reproductive/developmental toxicity, as well as studies of structurally related compounds and metabolites, may be informative. The RoC listing crit eria were then applied to the available body of knowledge for 1

- bromopropane to reach a listing recommendation. RoC Listing Criteria Known To Be Human Carcinogen : There is sufficient evidence of carcinogenicity from studies in humans*, which indicates a causal relationship between exposure to the agent, substance, or mixture, and human
cancer. Reasonably Anticipated To Be Human Carcinogen : There is limited evidence of carcinogenicity from studies in humans*, which indicates that causal interpretation is credible, but that alternative explanations, such as chance, bias, or confounding factors, could not adequately be excluded, OR

there is su fficient evidence of carcinogenicity from studies in experimental animals, which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors (1) in multiple species or at multiple tissue sites, or (2) by multi ple routes of exposure, or (3) to an unusual degree with regard to incidence, site, or type of tumor, or age at onset, OR there is less than sufficient evidence of carcinogenicity in humans or laboratory animals; however, the agent, substance, or mixture b elongs to a well

- defined, structurally related class of substances whose members are listed in a previous Report on Carcinogens as either known to be a human carcinogen or reasonably anticipated to be a human carcinogen, or there is convincing relevant inf ormation that the agent acts through mechanisms indicating it would likely cause cancer in humans. Conclusions regarding carcinogenicity in humans or experimental animals are based on scientific judgment, with consideration given to all relevant informati on. Relevant information includes, but is not limited to, dose response, route of exposure, chemical structure, metabolism, pharmacokinetics, sensitive sub

- populations, genetic effects, or other data relating to mechanism of action or factors that may be u nique to a given substance. For example, there may be substances for which there is evidence of carcinogenicity in laboratory animals, but there are compelling data indicating that the agent acts through mechanisms which do not operate in humans and would therefore not reasonably be anticipated to cause cancer in humans.

* This evidence can include traditional cancer epidemiology studies, data from clinical studies, and/or data derived from the study of tissues or cells from humans exposed to the substance in question that can be useful for evaluating whether a relevant cancer mechanism is operating in people.9/25/13 RoC Monograph on 1

- Bromopropane

vi CONTRIBUTORS
Office of the Report on Carcinogens (ORoC), Division of the National Toxicology Program (NTP)

Conducted technical review and ev aluation
Diane L. Spencer, MS (Project Lead)
Ruth M. Lunn, DrPH (Director, ORoC)
Gloria D. Jahnke, DVM, DABT Integrated Laboratory Systems, Inc. (Support provided through NIEHS Contract Number HHSN273201100004C)

Conducted technical review and evaluation Sanford Garner, PhD (Principal Investigator) Stanley Atwood, MS, DABT Andrew Ewens, PhD, DABT Jennifer Ratcliffe, Ph D Alton Peters, MS Provided administrative support Ella Darden, B S Tracy Saunders, BS
Technical Advisors: National Institute for Occupational Safety and Health Provided scientific input on specific sections of the monograph Kevin Hanley, MSPH, CIH, REHS, RS Centers for Disease Control, National Institute for Occupational Safety and Health Division of Surveillance, Hazard Evaluatio ns, and Field Studies

G. Scott Dotson, PhD, CIH Centers for Disease Control, National Institute for Occupational Safety and Health Education and Information Division
Editorial Advisor Provided editorial support for the substance profile and key sections of the monograph Susan Dakin, PhD Independent Consultant in Technical & Scientific Writing & EditingRoC Monograph on 1

- Bromopropane 9/25/13

vii Peer Review of the Draft RoC Monograph on 1

- Bromopropane

Peer review of the Draft RoC Monograph on 1

- Bromopropane was conducted by an ad hoc expert panel at a public meeting held March 21

– 22, 2013, at the National Institute of Environmental Health Sciences, Keystone Building, Research Triangle Park, NC (see http://ntp.niehs.nih.gov/go/38854 ) for materials, minutes, and panel recommendations from the peer review meeting). The selection of panel members and conduct of the peer review were performed in accordance with the Federal Advisory Committee Act and Federal policies and regulations. The panel members ser ved as independent scientists, not as representatives of any institution, company, or governmental agency.
In this capacity, panel members had the following major responsibilities in reviewing the draft RoC m

onograph : (1) to comment on the draft cancer eva luation components for 1

- bromopropane , specifically, whether they are technically correct and clearly stated, whether the NTP has objectively presented and assessed the scientific evidence, and whether the scientific evidence is adequate for applying the R oC listing criteria, and (2) to comment on the draft substance profile for 1

- bromopropane , specifically, whether the scientific justification presented in the substance profile supports the NTP’s preliminary policy decision on the RoC listing status of 1

- b romopropane . The panel was also asked to vote on the following questions: (1) whether the scientific evidence supports the NTP’s conclusion on the level of evidence for carcinogenicity from experimental animal studies

on 1

- bromopropane and (2) whether the scientific evidence supports the NTP’s preliminary listing decision for 1

- bromopropane in the RoC. The panel agreed with the NTP conclusions that 1

- bromopropane should be listed in the RoC based on sufficient evidence of carcinogenicity from studies in exp erimental animals , which found skin tumors in male rats, large intestine tumors in female and male rats, and lung tumors in female mice.9/25/13 RoC Monograph on 1

- Bromopropane

viii Peer Review Panel Members
Lucy Anderson, PhD, DABT (Chair) Consultant for Biomedical Sciences and Toxicology Catons ville, Maryland

Leo Thomas Burka, PhD Consultant Cary, North Carolina

Michael Elwell, DVM, PhD Senior Pathologist Department of Pathology Nonclinical Safety Assessment Covance Laboratories Inc. Chantilly, Virginia
Terry Gordon, PhD Professor Department of Environmental Medicine New York University School of Medicine New York, New York

Lawrence H. Lash, PhD Professor and Associate Chair Department of Pharmacology Wayne State University School of Medicine Detroit, Michigan
Stephen Nesnow, PhD Consultant Chapel Hill, North Carolina
Wayne T. Sanderson PhD, CIH Professor and Chair Department of Epidemiology College of Public Health University of Kentucky Lexington, Kentucky
MaryJane K. Selgrade, PhD Senior Toxicologist ICF International Environmental Risk and Toxicology Durham, North Carolina

Paul A. White, PhD Leader, Genetic Toxicology Group Environmental Health Sciences and Research Bureau Health Canada Ottawa, Ontario, CanadaRoC Monograph on 1

- Bromopropane 9/25/13

ix 

# Part 1

RoC Cancer Evaluation

Properties and Human Exposure
Dispos i tion (ADME) and Toxicokinetics

Human Cancer Studies
Studies in Experimental Animals

Mechanisms and Other Relevant Effects

Overall Cancer Evaluation9/25/13 RoC Monograph on 1

- Bromopropane

x This Page Intentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13

xi 

## Table of Contents

1 Properties and Human Exposure

................................ ................................ ................ 1 1.1 Chemical identification and properties

................................ ................................ 1 1.2 Uses and production

................................ ................................ ............................ 2 1.3 Biological indices of exposure

................................ ................................ ............. 3 1.4 Characterization of exposure in the workplace

................................ .................... 3 1.4.1 Adhesives use

................................ ................................ ............................... 6 1.4.2 1

- Bromopropane manufacturing

................................ ................................ ... 9 1.4.3 Dry cleaning

................................ ................................ ................................ . 9 1.4.4 Aerosol solvents

................................ ................................ ......................... 10 1.4.5 Vapor degreasing

................................ ................................ ........................ 10 1.4.6 Cleaning and painting workshops

................................ ............................... 11 1.5 Potential for environmental exposure

................................ ................................ 12 1.5.1 Release of 1

- bromopropane to the environment

................................ .......... 12 1.5.2 Fate, occurrence, and exposure

................................ ................................ ... 12 1.6 Potential for exposure from other sources: consumer products

.......................... 12 1.7 Exposure levels for people

................................ ................................ ................ 12 1.8 Synthesis and summa ry

................................ ................................ ..................... 12

2 Disposition and Toxicokinetics

................................ ................................ ............... 15 2.1 Absorption, distribution, and excretion

................................ .............................. 15 2.1.1 Absorption

................................ ................................ ................................ .. 15 2.1.2 Distribution

................................ ................................ ................................ 15 2.1.3 Excretion

................................ ................................ ................................ .... 16 2.2 Metabolism

................................ ................................ ................................ ....... 16 2.2.1 Metabolites detected in humans

................................ ................................ .. 17 2.2.2 In vivo studies in experimental animals

................................ ....................... 17 2.2.3 In vitro studies

................................ ................................ ............................ 21 2.2.4 Studies of metabolizing enzymes

................................ ................................ 22 2.2.5 Differences in metabolic pathways

................................ .............................. 23 2.3 Synthesis and summary

................................ ................................ ..................... 24
3 Human Cancer Studies

................................ ................................ ............................ 25

4 Studies of Cancer in Experimental Animals

................................ ............................. 27 4.1 Studies in experimental animals: characteristi cs, methodology, and relevant non

neoplastic findings

................................ ................................ ................................ ..... 27 4.1.1 Rats

................................ ................................ ................................ ............ 27 4.1.2 Mice

................................ ................................ ................................ ........... 28 4.2 Assessment of neoplastic findings

................................ ................................ ....... 29 4.3 NTP level of evidence conclusion

................................ ................................ ....... 33
5 Mechanistic Data and Other Relevant Effects

................................ .......................... 35 5.1 Genetic and related effects

................................ ................................ ................ 35 5.1.1 DNA and protein adducts

................................ ................................ ............ 35 5.1.2 In vitro studies in bacteria

................................ ................................ ........... 36 5.1.3 In vitro studies in mammalian cells

................................ ............................. 37 5.1.4 In vivo studies in rodents

................................ ................................ ............ 379/25/13 RoC Monograph on 1

- Bromopropane

xii 5.1.5 Studies in exposed workers

................................ ................................ ......... 37 5.1.6 Genotoxic effects of 1

- bromopropane metabolites

................................ ...... 38 5.1.7 Synthesis of results

................................ ................................ ..................... 39 5.2 Relevant toxicological effects

................................ ................................ ........... 40 5.3 Mechanistic considerations

................................ ................................ ............... 40 5.3.1 Metabolic activation and genotoxicity

................................ ......................... 41 5.3.2 Oxidative stress

................................ ................................ .......................... 41 5.3.3 Immunosuppression and other facto rs

................................ ......................... 42 5.3.4 Sex differences in chemical carcinogenesis

................................ ................. 43 5.4 Carcinogenicity of 1

- bromopropane metabolites and analogues

......................... 44 5.4.1 Metabolites

................................ ................................ ................................ . 45 5.4.2 Analogues

................................ ................................ ................................ ... 45

6 Overall Cancer Evaluation

– Synthesis of Animal, Human, and Mechanistic Data

.......

................................ ................................ ................................ ................................ 47 6.1 Cancer studies in experimental animals

................................ ............................. 47 6.2 Mechanistic and other relevant data

................................ ................................ ... 47 6.3 NTP listing recommendation

................................ ................................ ............. 49
References

................................ ................................ ................................ ..................... 51 Appendix A: Literature Search Strategy

................................ ................................ ...... A

- 1 Appendix B: Human Exposure Tables and Regulations and G uidelines

..................... A

- 17 Appendix C: Assessment of the Quality of the Individual Animal Cancer Studies

..... A

- 31 Appendix D: Genotoxicity Studies

................................ ................................ ............ A

- 35 Appendix E: Relevant Toxicological Effects

................................ ............................. A

- 45

List of Tables

Table 1

- 1. Chemical identification of 1

- bromopropane

................................ .................... 1 Table 1

- 2. Physical and chemical properties of 1

- bromopropane

................................ ..... 2 Table 1

- 3. Production data for 1

- bromopropane

................................ ............................... 3 Table 2

- 1. 1

- Bromopropane metabolites

................................ ................................ ........ 18 Table 4

- 1. Large intestine tumors observed in Fischer 344/N rats exposed to

1

- bromopropane by inhalation for 2 years

................................ ................... 30 Table 4

- 2. Skin tumors observed in Fischer 344/N rats exposed to 1

- bromopropane by

inhalation for 2 years

................................ ................................ .................. 31 Table 4

- 3. Malignant mesotheliomas and pancreatic islet

- cell tumors observed in Fischer

344/N rats exposed to 1

- bromopropane by inhalation for 2 years

................ 32 Table 4

- 4. Lung tum

ors observed in B6C3F 1 mice exposed to 1

- bromopropane by inhalation for 2 years

................................ ................................ .................. 33 Table 5

- 1. Summary of 1

- bromopropane genotoxicity information

................................ 39 Table 5

- 2. Summary of genotoxicity data for 1

- bromopropane metabolites a

.................. 40 Table A

- 1. General sources checklist for: 1

- Bromopropane

................................ A

- 10 Table A

- 2. Exposure

- related sourc es checklist for: 1

- Bromopropane

......................... A

- 12RoC Monograph on 1

- Bromopropane 9/25/13

xiii Table A

- 3. Data sources for 1

- bromopropane searches

................................ .............. A

- 13 Table A

- 4. Literature search approach for 1

- bromopropane

................................ ....... A

- 13 Table A

- 5. Search terms for monogra ph topics for 1

- bromopropane

.......................... A

- 14 Table B

- 1. Adhesives applications

– personal samples of 1

- bromopropane in air, urinary

biomarkers (AcPrCys and Br), and 1

- bromopr opane in blood and exhaled air

................................ ................................ ................................ ............... A

- 17 Table B

- 2. Adhesives applications

– area samples

................................ ..................... A

- 22 Table B

- 3. 1

- Bromopropane manufacturing

– personal samples

................................ A

- 23 Table B

- 4. 1

- Bromopropane manufac turing

– area samples

................................ ....... A

- 23 Table B

- 5. Dry

- cleaning applications

– personal samples of 1

- bromopropane

........... A

- 24 Table B

- 6. Dry

- cleaning applications

– area samples of 1

- bromopropane in air

......... A

- 24 Table B

- 7. Vapo r degreasing applications

– personal samples of 1

- bromopropane in air,

of urinary biomarkers (AcPrCys and Br - ), and of 1

- bromopropane in exhaled air

................................ ................................ ................................ ........... A

- 26 Table B

- 8 . Vapor degreasing applications

– area samples

................................ .......... A

- 28 Table B

- 9. Existing U.S. standards and guidelines with exposure limits for 1

-

bromopropane (ppm) a

................................ ................................ ............. A

- 29 Table B

- 10. EPA SNAP program determinations regarding different end uses of

1

- bromopropane

................................ ................................ ..................... A

- 30 Table D

- 1. In vitro studies of 1

- bromopropane mutagenicity in bacteria

.................... A

- 35 Table D

- 2. In vitro studies of 1

- bromopropane in mammalian cells

........................... A

- 38 Table D

- 3. In vivo studies of cytogenetic effects of 1

- bromopropane in rodents

......... A

- 39 Table D

- 4. In vivo studies of 1

- bromopropane in humans

................................ .......... A

- 41 Table D

- 5. Summary of in vitro and in vivo studies of 1

- bromopropane metabolites

..........

................................ ................................ ................................ ............... A

- 43 Table E

- 1a. 1

- Bromopropane effects on sperm motility and glutathione levels in wild

type or Cyp2e1 – /

– mice

................................ ................................ ............ A

- 46 Table E

- 1b. Sperm motility following 2

- hour incubations with 1

- bromopropane or 1

-

bromo

- 2

- hydroxypropane

................................ ................................ ....... A

- 46 Table E

- 2. 1

- Bromopropane effects on serum enzymes in male ICR mice

................. A

- 50 Table E

- 3. 1

- Bromopropane effects on hepatic GSH and GSH conjugate ( S

- propyl GSH)

levels in female BALB/c mice

................................ ................................ A

- 51 Table E

- 4. Comparison of liver histopathology among three mouse strains exposed to

1

- bromopropane

................................ ................................ ..................... A

- 52 Table E

- 5. Comparison of liver necrotic area in wild

- type and Nrf2

- null mice exposed to

1

- bromopropane

................................ ................................ ..................... A

- 53 Table E

- 6. 1

- Bromopropane effects on plasma enzymes in male Wistar rats

.............. A

- 54 Table E

- 7. Supp ression of splenic IgM response to sheep RBC in rodents after inhalation

exposure to 1

- bromopropane for 10 weeks

................................ .............. A

- 55

List of Figures
Figure 1

- 1. Chemical structure of 1

- bromopropane

................................ .......................... 1 Figure 1

- 2. TWA 1

- bromopropane air concentrations across industry sectors

.................. 5 Figure 1

- 3. 1

- Bromopropane air concentrations for first and second NIOSH facility

surveys in the adhesives use sector

................................ ............................... 89/25/13 RoC Monograph on 1

- Bromopropane

xiv Figure 2

- 1. 1

- Bromopropane metabolism in male F344 rats and B6C3F 1 mice following

inhalation exposure

................................ ................................ ..................... 20 Figure 2

- 2. Metabolic pathways of 1

- bromopropane in male Sprague

- Dawley rats

following oral exposure

................................ ................................ .............. 21 Figure A

- 1. Literature search strategy and review

................................ ........................ A

- 2RoC Monograph on 1-Bromopropane 9/25/13

1 

## 1 Properties and Human Exposure

1 -Bromopropane is a brominated hydrocarbon currently used as a solvent in several industrial sectors including adhesives, dry cleaning, vapor degreasing, and aerosol solvents. In recent years, occupational exposures to 1-bromopropane have increased due to new industrial and commercial applications for 1-bromopropane involving its use as a substitute for ozone-depleting chemicals or suspect carcinogens.
This section describes the chemical and physical properties of 1-bromopropane (Section 1.1); its uses and production (Section 1.2); biological indices of exposure (Section 1.3); characterization of exposure in the workplace (Section 1.4); potential for environmental exposure, including sources of release of 1-bromopropane to the environment, and its fate, occurrence, and exposure (Section 1.5); potential for exposure from other sources such as consumer products (Section 1.6 ); and exposure levels for people (Section 1.7). Section 1.8 summarizes the information in Sections 1.1 to 1.7. Data tables with occupational exposure to 1-bromopropane are provided in Appendix B , and include individual (e.g., personal breathing zone [PBZ], urinary biomarker, serum bromide, and exhaled breath) and area concentration measurements in various industrial sectors. U.S. regulations and guidelines that potentially limit exposure to 1-bromopropane are also reported in Appendix B

.
1.1 Chemical identification and properties
1 -Bromopropane (Figure 1 -1) is a bromoalkane or alkyl bromide. Table 1 -1 contains some chemical identification information for 1-bromopropane.

Figure 1-1. Chemical structure of 1-bromopropane

Table 1 -1. Chemical identification of 1-bromopropane

Characteristic Information

Chemical Abstracts ind ex name 1

- Bromopropane a CAS Registry number 106

- 94

- 5 a
Molecular formula C 3 H 7 Br b Synonyms 1

- BP b ; Propyl bromide b ; n

- Propyl b romide b ; Propane, 1

- bromo

b ; normal propyl bromide c ; nPB d
Sources: a NTP 2003a
, b HSDB 2006
, c UNEP 2001
, d EPA 2007

.9/25/13 RoC Monograph on 1

- Bromopropane

2 1

- Bromopropane exists as a colorless to pale yellow liquid with a strong, characteristic odor ( NTP 2011 a ) . It is slightly soluble in water and in most organic solvents including acetone, ethanol, ether, benzene, chloroform, and carbon tetrachloride. It is less flammable than many other halogenated alkanes at room temperature. 1

- Bromopropane’s thermal decomposition produces hydrogen bromide. 1

- Bromopropane can react with oxidizing agents to form hazardous flammable compounds and with water to produce acids. Some physical and chemical properties for 1

- bromopropane ar e listed in Table 1

- 2.

Table 1

- 2. Physical and chemical properties of 1

- bromopropane
Property Information Molecular weight 123.0 b Melting point

- 110 C b Boiling point 64.7 C b Vapor pressure (mm Hg ) 110.8 at 20 C b Vapor density 4.25 a Specific gravity 1.353 at 20 C b Solubility in water (20 °C) 2,450 mg/L a
Octanol/water partition coefficient (log K ow ) 2.10 a Henry’s law constant 0.0073 atm

- m 3 /mol at 25 C a Conversion factors (1

- bromopropane in air) parts per million (ppm) to μg/m 3 μg/m 3 to parts per million (ppm) g/m 3 = 5,030.7 (ppm) c ppm = 1.988 10 - 4 ( g/m 3 ) c
Sources: a HSDB 2006
, b NTP 2003a
, c SMA RTe.org 2012

.
1.2 Use s and production
1

- Bromopropane is used primarily as a solvent cleaner in vapor and immersion degreasing operations to clean optics, electronics
, and metals and as a solvent vehicle in industries using aerosol

- applied adhesives such as foam cushion manufacturing ; however, these uses might be impacted by an EPA proposed rule listing certain uses as unacceptable (see Appendix B, Table B

- 10 ) . In recent years, 1

- bromopropane usage has increased due to new industrial applications involving its use as a substitute for ozone

- depleting chemicals or suspect carcinogens. For example, increased use of 1

- bromo propane in the dry

- clea ning industry has occurred in response to states considering and pursuing actions to ban the use of tetrachloroethylene ( perchloroethylene or PERC) ( Blando et al. 2010 )

. 1

- Bromopropane also has been reported to have other advantages as a replacement for other halogenated solvents
, including lower energy costs due to lower boiling point and reduced drying time, low Global Warming Potential (GWP), and reduced water consumption ( Craft 2013 )

. 1

- Bromopropane also has potential application as a spot remover in the textile industry , but an evaluation of 1

- bromopropane as a substitute for trichloroethylene ( TCE ) c oncluded that chronic toxicity data were lacking and use of 1

- bromopropane was not recommended until more data were available ( Mirza et al. 2000 )

. In the past, 1

- bromopropane was used primarily as a solvent for fats, waxes, or r esins and as anRoC Monograph on 1

- Bromopropane 9/25/13

3 intermediate in the synthesis of pharmaceuticals, insecticides, quaternary ammonium compounds, flavors, or fragrances in generally well

- controlled, closed processes ( Hanley et al. 2006a
, NTP 2003a )

.
1

- Bromopropane is p roduced by reacting n

- propyl alcohol with hydrogen bromide and then removing the water that forms in the process. 1

- Bromopropane can also be produced by dehydrating propanol with bromine or hydrogen bromide in the presence of sulfur catalyst ( NTP 2003a )

. In 2012, 1

- bromopropane was manufactured by at least 21 companies worldwide, including at least 1 company in the United States (SRI 2012). Production data for 1

- bromopropane are listed in Table 1

- 3. Production data are based on Internet searches of sources dated as noted; data are subject to change.

Table 1

- 3. Production data for 1

- bromopropane Category Years c overed Quantity in pounds a

U.S. EPA Chemical Data Reporting Rule b 2006 2002, 1998 1994 1990, 1986 > 1 million to 10 million 1 million to < 10 million > 500K to 1 million 10K to 500K U.S. imports (recent) c 2011 10 .3 million U.S. imports (historical) c 2007 10.9 million

U.S. exports (recent) c 2011 15 .1 million U.S. exports (historical) c 2007 8.8 million Sources: EPA 2012
, SRI 2012
, USITC 2012

. a From 10 /2012 Internet searches; data subject to change.
b Formerly called Inventory Update Rule.

c Reported as brominated derivatives of acyclic hydrocarbons , which includes other chemic als in addition to 1

- bromopropane

.
1.3 Biological indices of exposure Potential biological indices of exposure to 1

- bromopropane inclu de measurements of bromide ion ( Br (

- ) )
, N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine (AcPrCys) (see Section 2.2 for a description of the metabolism of 1

- bromopropane) , and 1

- bromopropane in urine, and serum bromide level s ( Eisenberg and Ramsey 2010
, Hanley et al. 2006a
, Hanley et al. 2009
, Kawai et al. 2001
, Valentine et al. 2007 ) . Urinary 3

- bromopropionic acid (3

- BPA) was not found to be an effective urinary biomarker for occupational exposure to 1

- brom opropane from spray adhesives
, because it was not detected in heavily exposed workers at foam cushion manufacturers. However, AcPrCys and bromide ion were effective biomarkers ( Mathias et al. 2012 )

.
1.4 Characterization of exposure in the workplace Occupational exposure to 1

- bromopropane may occur through inhalation and dermal contact at workplaces where 1

- bromopropane is produced or used ( HSDB 2006 ) , and e xtensive 1

- bro mopropane occupational exp osure

- monitoring data are available. Many of the data either9/25/13 RoC Monograph on 1

- Bromopropane

4 were submitted to the EPA under the Significant New Alternatives Policy (SNAP) program or collected during studies conducted under the NIOSH Health Hazard Evaluation (HHE) or Industrywide Studies Branch (IWSB) program s

. ( S ee Appendix B , Tables B

- 1 to B

- 8 for personal sample s ( e.g., personal breathing zone [ PBZ ] , urinary biomarker, serum bromide, and exhaled breath ) as well as area sample s for 1

- bromopropane concentrations in various industrial sectors.)

Based on the available occupational exposure (as described in Tables B

- 1 to B

- 8 ), 8

- to 12

- hr time

- weighted average ( TWA ) 1

- bromopropane air concentrations a cross all sectors ranged from not detected to 380 p pm. Jobs requiring workers to spray 1

- bromopropane adhesives have the highest exposures and jobs requiring workers to clean and assemble small parts used in radio frequency and microwave communication instruments (vapor degreasing operations) have the lowe st exposures. In extreme cases, 1

- bromopropane air concentrations during vapor degreasing may be as much as four orders of magnitude lower than during adhesives use. This could be due in part to exposure to 1

- bromopropane during only part of the workday. F or example
, Hanley et al. ( 2010 ) reported that parts were cleaned on an as

- needed basis in the facilities that they sampled, and use of degreasers was limited to 90 minutes or less for an entire work shift. Figure 1

- 2 graphically depicts TWA 1

- bromopropane air concentr ations across indus try sectors. The figure does not include all data for occupation exposure ; thus, the highest air concentration shown is less than the maximum reported of 380 ppm.RoC Monograph on 1-Bromopropane 9/25/13

5 Figure 1 -2. TWA 1-bromopropane air concentrations across industry sectors From Eisenberg and Ramsey 2010
, Graul 2012
, Hanley et al. 2006b
, Hanley

et al. 2010
, Ichihara et al. 2004a
, Kawai et al. 2001

. Time-weightedaverage 1-bromopropane exposure levels as geometric means (Adhesives, Other, and Vap. Deg.); arithmetic mean (Dry Cln.); or not reported (Manuf. and Aer. Solv.). Note: the dashed, vertical line represents the ACGIH threshold limit value

– time-weighted average (TLV-TWA) of 10 ppm.9/25/13 RoC Monograp h on 1

- Bromopropane

6 The Occupational Safety and Health Administration ( OSHA ) Chemical Exposure Health Dataset contains OSHA compliance monitoring program industrial hygiene samples. 1

- Bromopropane concentration sampling data are available for 1998 to 2011. Of the 164 total sample points for 1

- bromopropane, 126 were personal breathing zone (PBZ) samples with detectable values from 18 facilities

. PBZ samples with detectable values ranged from 0.0477 t o 423 ppm. Sixty

- two (62) samples from 9 of the facilities were above the American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit value (TLV) of 10 ppm. Most of those facilities (7 of 9) were in the vapor degreasing or adhesives u se sector ( OSHA 2011 )

.

1.4.1 Adhesives use 1

- Bromopropane

– based adhesives are used most widely as spray adhesives for foam cushion manufacturing (e.g., the furniture industry) and to a lesser extent in laminate adhesives ( FR 2007 ) ; however, no exposure data were identified for laminate adhesives. In furniture foam cushion manufacturing plants, cushions are generally assembled by gluing together pieces of cut flexible foam ( Harney et al. 2002
, Harney et al. 2003 ) . Once the foam pieces are glu ed together, workers hand press the pieces to achieve a proper bond. The adhesive is spray

- applied using a compressed air spray gun. Data were also identified for one adhesives and coatings manufacturer ( Hanley et al. 2007
, Hanley et al. 2010 )

. Personal samples (available data for personal breathing zone and exhaled breath concentrations for 1

- bromopropane as well as urinary biomarker and serum bromi d e concentrations for the adhesives use sector ) are provided in Appendix B, Table B

- 1

. Eight

- to twelve

- h ou r TWA 1

- bromopropane air concentrations for adhesives use ranged from 0.1 to 380 ppm . These data indicate that workers engaged in adhesive spraying are consistently exposed to higher concentrations than non

- sprayers, in some cases by as much as three orders of magnitude. The higher exposures are re flected in higher levels of urinary biomarkers for both urinary Br (

- ) ( Hanley et al. 2006a ) and urinary AcPrCys concentrations ( Hanley et al. 2009 )

.
Pre

- and post

- shift 1

- bromopropane breath concentrations have been measured for adhesives use. Available b reath monitoring data indicate that post

- shift 1

- bromopropane concentrations were consistently higher than pre

- shift concentrations, in many cases, more than 10 times high er . For example, Hanley et al. ( 2005 ) reported a pre

- shift mean breath concentration of 0.96 ppm and a post

- shift mean breath concentration of 15.4 ppm for a polyurethane seat cushion manufacturing plant. Further, breath concentrations for sprayers wer e consistently higher than concentrations for workers performing other jobs.

Serum bromide concentration data indicate d that concentrations are highest in the adhesives sector, for which values as high as 1,700 mg/L have been reported ( Majersik et al. 2007 ) (see Appendix B, Tabl e B

- 1 )

. Based on NIOSH HHE data for one facility, the average difference between end

- of

- week and start

- of

- week serum bromide concentrations for exposed workers was 23 mg/L compared with 3 mg/L for unexposed workers ( Harney et al. 2003 )

.RoC Monograph on 1

- Bromopropane 9/25/13

7 1

- Bromopropane air concentrations differed considerably before and after engineering controls (i.e., ventilation improvements, enclosure of spray tables, etc.) were implemented at two facilities studie d in the NIOSH HHE program. Figure 1

- 3 depicts 1

- bromopropane air concentrations for first and second NIOSH facility surveys for the three known facilities in the adhesives use sector at which NIOSH conducted HHE assessments. In two cases (Custom Products and STN Cushion Company) , the facilities adopted NIOSH recommendations concerning addition of engineering controls and TWAs decreased by 8 0% or greater

. The results demonstrated reductions of mean TWA 1

- bromopropane air concentration from 168.9 ppm (N = 69) to 19.0 ppm (N = 30) for all workers at Custom Products Inc. and from 65.9 ppm (N = 12) to 16.6 ppm (N = 11) for sprayers at STN Cushion Company ( Reh et al. 2002 )

. NIOSH also recommended similar controls for the third facility (Marx Industries) , but the agency reported that they w ere unaware of any changes in controls or employee use of personal protective equipme nt during the time interval between the first and second survey for this facility, and only slight change in exposure for sprayers occurred between the first and second surveys

. The mean TWA 1

- bromopropane air concentration for all sprayers for the first s urvey (N = 12) was 107.6 ppm, and the mean for the second survey (N = 8) was 101.4 ppm ( Harney et al. 2003 )

. According to a summary of workplace exposure data for 1

- bromopropane submitted to EPA for the SNAP program ( Graul 2012 ) , initially, fewer than half the personal breathing zone (PBZ) sample concentrations were below 50 ppm (8

- hr TWA); however, after ventilation improvements, 97% of the PBZ samples were less than 50 ppm and 78% were ≤ 25 ppm. Further, the initial mean concentration was 141.7 ppm; after ventilation improvements, the mean concentration was 18. 3 ppm ( Graul 2012 )

.9/25/13 RoC Monograph on 1

- Bromopropane

8 Figure 1

- 3. 1

- Bromopropane air concentrations for first and second NIOSH facility surveys in the adhesives use sector TWA concentration s reported for Custom Products, Inc. and STN Cushion Company are arithmetic means, and those reported for Marx Industries, In c. are geometric means.RoC Monograph on 1

- Bromopropane 9/25/13

9 C oncentration measurements for the adhesives use sector are shown in Appendix B, Table B

- 2

. Area samples for 1

- bromopropane for adhesives use ranged from 0.01 to 176 ppm

. The range of area samples reflects variation between facilities; however, differences within a facility appear to vary only minimally for the same task

.

1.4.2 1

- Bromopropane manufacturing Personal samples ( from the available data for personal breathing zone concentrations of 1

- bromopropane ) for the manufacturing sector in China are provided in Appendi x B, Table B

- 3

. No 1

- bromopropane air concentration data were identified for 1

- bromopropane manufacturing plants in the United States , but Patent Number 5,773,672 (June 30, 1998), which is assigned to a U.S. manufacturer of 1

- bromopropane, contains descriptions of numerous control processes to contain 1

- bromopropane in contrast with the more open processes described below

. Eight

- to twelve

- h ou r TWA 1

- bromopropane air concentrations for these facilities ranged from not detected to 170 ppm. Worker exposure was reported to occur from (1) adding chemicals into reaction pots, (2) sitting close to reaction pots when observing and recording the temperature, (3) removing crude product, (4) adding hydrogen carbonate and stirring, and (5) pouring the product into 1000 L drums ( Li et al. 2010 b ) . In one plant, the highest concentrations we re measured during the transfer of processed product into containers ( Ichihara et al. 2004a )

.
Area sample concentration s of 1

- bromopropane for 1

- bromopropane manufacturing ranged from not detected to 90.2 ppm ( s ee Appendix B, Table B

- 4 ).
One study also examined biomarkers of 1

- bromopropane exposure. Valentine et al. ( 2007 ) measured globin S

- propylcysteine (PrCys) adducts and urinary N

- acetyl

- S

propylcysteine ( N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine or AcPrCys) for workers in a Chinese 1

- bromopropane manufacturing facility and reported a significant ( P < 0.01) increase in PrCys adducts on 1

- bromopropane manufacturing workers ’ globin (1.52 pmol/mg globin) compared with control fact ory workers (0.11 pmol/mg globin) (N = 32 controls, N = 26 exposed). Further, Valentine et al. ( 2007 ) determined that urinary AcPrCys levels increased as 1

- bromopropane ambient exposure levels increased (N = 47 exposed) ; the exposure levels ranged from 0 to 170.54 ppm

.

1.4.3 Dry cleaning The increased u se of 1

- bromopropane in the dry

- cleaning industry has occurred in response to states considering and pursuing actions to ban the use of PERC ( Blando et al. 2010 ) . 1

- Bromopropane has been reported to be the only PERC alternative that can be used in the original PERC machines with alterations ; other cleaners would require the purchase of new machines ( Eisenberg and Ramsey 2010 )

.
Personal full

- and partial

- shift samples (available data for personal breathing zone concentrations of 1

- bromopropane ) for the dry

- cleaning sector are provided in Appendix B, Table B

- 5 . Eight

- to twelve

- h ou r TWA 1

- bromopropane air concentration data identified in these dry

- cleaning facilities ranged from < 0.004 to 56 ppm. Eisenberg and Ramsey ( 2010 ) reported a mean serum bromide conc entration of 144 mg/L for a dry

cleaning facility owner who was converting his machine from PERC to 1

- bromopropane (value reported as 144 mcg/mL ) . Worker exposure could occur from introduction of9/25/13 RoC Monograph on 1

- Bromopropane

10 solvent to the cleani ng machine, machine maintenance, unloading and handling of recently cleaned clothes, interrupting the machine wash cycle, and “cooking” the solvent ( i.e., boiling the solvent to remove impurities) ( Blando et al. 2010
, Eisenberg and Ramsey 2010 ) . Further, exposure could occur due to leaks resulting from normal machine

wear w ith time, poor maintenance, and incompatibility of 1

- bromopropane with system gasket materials and poor ventilation ( Bla ndo et al. 2010 )

. Reduced exposure due to improved ventilation procedures also has been illust rated for dry

- cleanin g applications. For example, Blando et al. ( 2010 ) (see Appendix B, Table B

6 ) note d that building size, exhaust fan capacity and operation, and natural ventilation (i.e., opening doors and windows) were the determining factors for operator air concentrations in two of the three shop s studied differing by as much as 4 orders of magnitude

. Other studies have shown that dry cleaning operators often use natural ventilation (i.e., opening doors and windows) to control 1

- bromopropane exposures

. H owever, weather conditi ons may prevent use of natural ventilation ( Eisenberg and Ramsey 2010 )
, which typically is not as effective as mechanical ventilation

.
Area sample concentrations for 1

- bromopropane for dry cleaning ranged from < 0.004 to 170 ppm and differences were mainly explai ned by characteristics of the individual facilit ies (see Appendix B, Table B

- 6 ). Area samples at Facility 1 in Eisenberg and Ramsey (2010) varied between morning and afternoon measurements. Measurements taken in the morning were higher because the facility closed the doors and did not operate the ventilation system at this time; only the front windows were open. However, in the aftern oon, the facility operated the ventilation system and opened the back door. Variation in area samples at Facility 4 in Eisenberg and Ramsey (2010) m ight have been due to machine leaks as the owner converted the machine himself and reported that he had diff iculties finding the correct conversion materials. Further, opening the front door and operating the exhaust fan produced a marked decrease in solvent odor at this facility (Eisenberg and Ramsey 2010). Findings reported by Blando et al. ( 2010) for dry

- clea ning Shops A, B, and C were discussed above.

1.4.4 Aerosol solvents 1

- Bromopropane has been reported to be used as a solvent in aerosol lubricants, coatings, or cleaning fluids for electrical or electronic equipment or aircraft maintenance, or in spinnerette l

ubricants and cleaning sprays used in synthetic fiber production ( FR 2007 )

. Spray

- can a erosol solvents are normally used intermittently and for short periods of time (i.e., 1 to 2 minutes). In so me cases, aerosol product s are used in confined spaces without ventilation or fans where short

- term worker exposure can be high. Although emissions from aerosol solvents typically are not controlled via engineering controls, aerosol users can reduce exposure levels through use of fu me hoods and improving ventilation ( FR 2003 ) . Eight

- to twelve

- h ou r TWA 1

- bromopropane air concentration data identified for aerosol solvents ranged from 5 to 30.2 ppm ( Graul 2012 ) . Fifteen

- minute STEL sample data ranged from 45.1 to 254 ppm.

1.4.5 Vapor degreasing In general, v apor degreasers use a refrigerated cooling coil around the top of the interior of the vapor chamber to condense hea ted 1

- bromopropane vapor into liquid droplets onRoC Monograph on 1

- Bromopropane 9/25/13

11 the cooler surface of parts to remove dirt, grease, and surface contaminants ( Hanley and Dunn 2006 ) . Excess 1

- bromopropane drips back into the solvent sump and is recycled as the parts ascend from the vapor to condensing zones. Another function of the cooling coil is to control solvent vapor emissions by “capping” the heated vapor zone with a refrigerated air space.

Fo r the vapor de greasing sector
, personal samples of 1

- bromopropane are provided in Appendix B, Table B

- 7

. Eight

- to twelve

- h ou r GM TWA 1

- bromopropane air concentration for vapor degreasing ranged from 0.077 to 21 ppm. In Hanley et al. ( 2010 )
, workers near degreasers had personal breathing zone TWA 1

- bromopropane concentrations higher (GM = 2.6 ppm ) than workers away from degreasers (GM = 0

. 31 ppm ) , and urinary bromide and AcPrCys concentrations showed the same tren d.
A NIOSH HHE was conducted at a facility that used 1

- bromopropane below its boiling point as a vapor degreaser ( Reh and Nemhauser 2001 ) . Eight

- to twelve

- h ou r TWA 1

- bromopropane air concentration data for this f acility ranged from 0.01 to 0.63 ppm. Fifteen

- minute sample data identified ranged from 2.3 to 8.4 ppm. This facility’s cleaning system was located in a special, enclosed room with a local exhaust ventilation system ( FR 2003 )

. T he design of most vapor degreasers reduces emissions from equipment because the solvent is boiled and subsequently condensed rather than allowing vapors to be emitted

. I n general, it is expected to be more difficult to control emissions from cleaning equipmen t in which the solvent is not boiled and condensed ( FR 2003 )

. Both cleaning methods could benefit from the installation of well

- maintained, effective local exhaust ventilation systems as these are the preferred method of solvent emission control.

A summary of 500 personal samples for vapor degreasing by Graul ( 2012 ) reported that

> 87% of the persona l samples were below 25 ppm on an 8

- h ou r TWA basis and approximately 75% of those samples were below 10 ppm on an 8

- h ou r TWA basis.

1

- B romopropane emissions exposure to v apor degreasing workers can be reduce d through changes in equipment and operating pra ctices ( FR 2003
, Hanley and Dunn 2007 ) . For example, additional condensation coils can be installed to prevent vapors from leaving the degreaser. Further, workers can tilt pieces to be cleaned to i ncrease solvent drainage inside the vapor degreaser instead of leaving 1

- bromopropane on the pieces to evaporate outside the degreaser where workers can inhale the vapors. A mechanical hoist operated at a controlled rate is also advantageous so that workers cannot raise the parts basket too quickly
, which may circumvent effective vapor control of the condensing

zone.

Area sample concentrations for 1

- bromopropane for vapor degreasing ranged from 0.02 to 4.42 ppm ( see Appendix B, Table B

- 8 ). These measurements indicate that the highest concentrations are found in areas near degreasers and lower concentrations are in areas away from degreasers.

1.4.6 Cleaning and painting workshops In a study of 33 workers in a cleaning and painting workshop using 1

- bromopropane cleaning solvents in a Japanese factory, Kawai et al. ( 2001 ) reported a geometric mean 1

- bromopropane concentration of 1.42 ppm and a maximum concentration of 27.8 ppm.9/25/13 RoC Monograph on 1

- Bromopropane

12 1.5 Potential for environmental exposure

1.5.1 Release of 1

- bromopropane to the environment Based on the production and use of 1

- bromopropane it may be released to th e environment through various waste streams. 1

- Bromopropane has also been detected in temperate marine macroalgae tissue and is believed to be transported from these algae to the marine environment. ( HSDB 2006 )

.
In a search of t he National Response Center database for the time period of January 1, 1990 to the present
, “1

- bromopropane” identified three chemical spill incidents and “ n

propyl bromide” identified one incident ( NRC 2012 ) . No Toxics Release Inventory (T RI) data for 1

- bromopropane were identified
, since 1

- bromopropane is not included on the TRI list of toxic chemicals ( EPA 2011 )

.

1.5.2 Fate, occurrence, and exposure No data have been identified indicating the measurement of 1

- bromopropane in ambient air, drinking water, surface water, soil, or food. EPA has estimated 1

- bromopropane concentrations in ambient air at a distance of 100 meters from average

- adhesive use mod el facilities via ai r dispersion modeling to be 0.138 mg/m 3 [0. 0 274 ppm] and 1.38 mg/m 3 [ 0. 274 ppm] for high

- adhesive use facilities ( Wolf et al. 2003 )

. EPA also has estimated dai ly uptake from 1

- bromopropane in the environment from inhalation for a person living 100 meters from average

- adhesive use model facilities to be 0.0537 mg/kg

day and 0.537 mg/kg

- day from high

- adhesive use facilities.

I nvestigation of a wastewater tank lea k at a Swiss alkyl halide factory that manufactured 1

- bromopropane at quantities reported as greater than 5 tons/y ea r did not identify any 1

- bromopropane or its alcohol metabolite in groundwater after clean up ( Schwarzenbach et al. 1985 , as cited by N TP 2003a )

.
1.6 Potential for exposure from other sources: consumer products
No 1

- bromopropane concentration measurement data for consumer products have been identified

. Knöppel and Schauenburg ( 1989 ) analyzed VOC emissions of household wax, liquid pastes, and detergents , and 1

- bromopropane was included in the list of analytes; however
, 1

- bromopropane was used as an i nternal standard in that study and the authors did not report it as being present in the consumer products (HSDB 2006)

.
1.7 Exposure levels for people No data for non

- occupational 1

- bromopropane exposure levels for people have been identified.

1.8 Synthesis and summary A significant number of people in the United States are exposed to 1

- bromoproane as a result of widespread us age , high

- production volume, and exposure to high levels of 1

- bromopropane in commercial and industrial settings. The principal uses of 1

- b romopropane are as a solvent cleaner in vapor and immersion degreasing operations to clean optics, electronics
, and metals, as a solvent vehicle in industries that use aerosol

applied adhesives such as foam cushion manufacturing, and as a textile solvent i n theRoC Monograph on 1

- Bromopropane 9/25/13

13 dry

- cleaning industry. In recent years, certain 1

- bromopropane uses have increased because it is an alternative to ozone

- depleting chemicals or suspect carcinogens ; e.g., 1

- bromoprane has been used as an alternative to PERC (listed as reasonably anti cipated to be a human carcinogen in the RoC ) in the dry cleaning industry.
Inhalation is the primary route of human exposure; dermal exposure is also possible. 1

- Bromopropane is a high

- production

- volume chemical with annual production ranging from 1 milli on to 10 million pounds as reported in 1998, 2002, and 2006. Based on occupational exposure data across several industrial sectors, 8

- to 12

- h ou r time

- weighted average ( TWA ) 1

- bromopropane air concentrations ranged from not detected to 380 ppm. 1

- B romoprop ane air concentrations are highest for adhesives use and lowest for vapor degreasing. In extreme cases, vapor degreasing 1

- bromopropane air concentrations may be as much as four orders of magnitude lower than adhesives use concentrations.

No data have been identified indicating measurable levels of 1

- bromopropane in ambient air, drinking water, surface water, soil, or food. However, the EPA has estimated via air dispersion modeling that 1

- bromopropane may be present in ambient air
, and daily intake from exp osure in the environment may occur, particularly for people who live near industrial and commercial users of 1

- bromopropane.9/25/13 RoC Monograph on 1

- Bromopropane

14 This Page Intentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13

15 

## 2 Disposition and Toxicokinetics

This section describes the overall disposition of 1

- bromopropane, i.e., how it can enter the body (absorption), what happens to it once it is in the body (distribution and metabolism), how it leaves the body (excretion), and the extent and/or rates of these processes. Section 2.1 discusses the absorption, distribution, and excretion of 1

- bromopropane for both humans and experimental animals , and m etabolism is discussed in Section 2.2. Toxicokinetics is the mathematical description (toxicokinetic model) of the time course of disposition of a chemical in the body; however, no toxicokinetic models of 1

- bromopropane were identified.

D ata on disposition of 1

- bromopropane are important because they can help identify the various factors that affect the toxicity of the chemical. These factors include routes and rates of absorption, tissue concentrations and their temporal c hanges, reactive metabolites, toxi fi cation and detoxi fi cation reactions, routes of elimination, and species differences in these factors. The mechanistic implications of these data are discussed in Section 5.

2.1 Absorption, distribution, and excretion

2.1.1 Absorption Studies in humans and laboratory animals indicate that 1

- bromopropane can be absorbed following inhalation, ingestion, or dermal contact , and b oth inhalation and dermal exposure are likely to occur in the workplace ( Cheever et al. 2009
, Hanley et al. 2007 )

. O ccupational exposure studies consistently rep orted a correlation between ambient air levels of 1

- bromopropane and levels of 1

- bromopropane or metabolites in urine. (See Section 1 for a description of these exposure studies.) An in vitro study of absorption characteristics of 1

- bromopropane using heat

- separated human epidermal membranes demonstrated that dermal penetration of 1

- bromopropane could be substantial but the actual absorption depended on the type and duration of exposure ( Frasch et al. 2011 )

. The most relevant route of exposure for 1

- bromopropane based on human exposures is inhalation , and m etabolism studies in rats and mice show that 1

- bromopropane is absorbed following inhalation ( Garner et al. 2007
, Garner et al. 2006
, Ishidao et al. 2002 ) or oral exposure ( Jones and Walsh 1979
, Lee et al. 2010a ) . In male Wistar rats exposed to 1

- bromopropane vapor at e ither 700 or 1,500 ppm
, the concentration of 1

- bromopropane in blood decreased linearly with time and was below the detection limit within 0.7 hours following the end of the exposure period ( Ishidao et al. 2002 )

. This study also reported that c oncentrations of bromide ion ( a byproduct of 1

- bromopropane metabolism ) in rat blood decreased much more slowly
, with a half

- life of 4.7 to 15 days, depending on the exposure scenario (concentration and duration of treatment) while t he half

- life of bromide ion excreted in the urine was 5 to 7.5 days.

2.1.2 Distribution No data on distribution of 1

- bromop ropane in humans was identified, and only one study ( Garner et al. 2006 ) was found that reported limited data on distribution of radiolabeled [ 14 C ] 1

- bromopropane in rats and mice after exposure by intravenous (i.v.) injection

.9/25/13 RoC Monograph on 1

- Bromopropane

16 Exhaled air, urine, an d feces were collected at various intervals up to 48 hours
, and blood and tissue (reported as carcass) samples were collected 48 hours post

- exposure. The total radioactivity recovered ranged from 83% to 103% with the largest percentages represented by vola tile organic chemicals ( VOCs ) (25% to 71%), CO 2 (10% to 31%) and urine (13% to 23%). Much smaller amounts were recovered from the total carcass (2% to 6%) and feces (< 1% to 4%). Limited data were reported for radioactivity in liver, and no recovery data w ere reported for other individual tissues that might be potential tumor sites (see Section 4). The liver to blood tissue radioactivity ratios were similar (~3) regardless of dose, and dose

- normalized 1

- bromopropane ng equivalents/g of liver were inversely proportional to dose in both species.

2.1.3 Excretion Once absorbed, the majority of 1

- bromopropane is rapidly cleared from the blood by exhalation of the unchanged compound or as either CO 2 or VOCs, and by urinary excreti on of metabolites of 1

- bromopropane or the unmetabolized molecule. Only limited information is available for the excretion of 1

- bromopropane in humans, but the presence of the unmetabolized molecule in urine has been described in studies of exposed workers ( Ichihar a et al. 2004a
, Kawai et al. 2001 )

. Excretion o f unmetabolized 1

- bromopropane in urine in these studies of exposed workers was significantly correlated with exposure to 1

- bromopropane in air. No studies were identified that reported urinary excretion of unmetabolized 1

- bromopropane in rodents

. Bromide ion is also excreted, but the specificity of this ion as a biomarker for exposure to 1

- bromopropane is limited because of a relatively high background from dietary sources, particularly seafood. As discussed below in the section on metabolism, several merc apturic acid derivatives of 1

- bromopropane have been identified in urine from exposed humans and experimental animals. Many more metabolites or potential metabolites have been identified from experimental animal studies using labeled 1

- bromopropane and the se are discussed below

. Other studies in experimental animals have exposed rats or mice to radiolabeled [ 14 C ] 1

- bromopropane by intraperitoneal (i.p.) injection ( Jones and Walsh 1979 ) or i.v. administration through the tail vein or jugular vein ( Garner et al. 2006 ) . Jones and Walsh reported that 60% of a single dose of 200 mg/kg 1

- bromopropane administered t o rats was exhaled unchanged within 4 hours with only trace amounts detected after that time. Only 1.4% of the total dose was exhaled as CO 2 and about 4 5 % of the metabolized dose was excreted in the urine after 100 hours. A much lower recovery of 3.3% of a n i.p. dose of 200 mg/kg as urinary metabolites was reported by Walsh and Jones ( 1 977 ) after 100 hours.

2.2 Metabolism The metabolites identified in humans are limited to those recovered in the urine of factory workers after exposure to 1

- bromopropane. Several studies have investigated 1

- bromopropane metabolism in experimental animals, a nd the different metabolites identified in studies by different routes of exposure indicate that the metabolism is complex.RoC Monograph on 1

- Bromopropane 9/25/13

17 2.2.1 Metabolites detected in humans Several studies have monitored urine samples from humans occupationally exposed to 1

- bromopropane in order to establish biomarkers of exposure. The predominant metabolite detected in the urine of workers is N

- acetyl

- S

- propylcysteine (AcPrCys), and levels increased with increasing 1

- bromopropane ambient exposure levels ( Hanley and Dunn 2006
, Hanley et al. 2009
, 2010
, Valentine et al. 2007 ) . In addition to AcPrCys, several other urinary mercapturic acid conjugates were identified from 1

- bromopropane

– exposed workers; these included N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine

- S

- oxide, N

- acetyl

- S

- (2

- carboxyethyl)

- L

- cysteine, and N

- acetyl

- S

- (3

- hydroxy

- n

- propyl)

- L

- cysteine ( Cheever et al. 2009
, Hanley et al. 2009 ) . The oxidative metabolites that likely lead to the conjugates have not been reported in human studies, however no publications were identified that actually tested for them. Metabolism has been more extensively studied in experimental animals.

2.2.2 In vivo studies in experimental animals Metabolism studies were conducted in rats and mice exposed by inhalation, oral, subcutaneous ( s.c. ) , i.p., or i.v. administration and in vitro using rat liver microsomes ( Barnsley et al. 1966
, Garner et al. 2007
, Garner et al. 2006
, Jones and Walsh 1979 )

. The four urinary mercapturic acid conj ugates identified in exposed workers were also identified in experimental animals. AcPrCys was identified in the urine of rats, mice, guinea pigs, and rabbits exposed to 1

- bromopropane via s.c. injection. The other metabolites were identified in the urine of rats following oral exposure . Additional urinary metabolites identified from studies in experimental animals are listed in Table 2

- 1 , but the available studies do not agree complete ly with regard to metabolites detected
, which might be due to difference s in route of exposure, species tested, and detection methods

. Overall, t hree major categories of metabolites have been identified: (1) brominated metabolites (Phase I), (2) debrominated metabolites (Phase I), and (3) glucuronide or glutathione conjugated metabolites (Phase II).9/25/13 RoC Monograph on 1

- Bromopropane

18 Table 2

- 1. 1

- Bromopropane metabolites

Metabolite Humans Experimental animals

In vitro Inh. Oral Inj.

N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine (AcPrCys,

n

- propyl mercapturic acid) X a X b,c X d X e,f,g

N

- Acetyl

- 3

- (propylsulfinyl)alanine ( N

- acetyl

S

- ( n

- propyl)

- L

- cysteine

- S

- oxide or n

propylmercapturic acid) X a X b X d X f

N

- Acetyl

- S

- (3

- hydroxypropyl)cysteine X a X d

N

- Acetyl

- S

- (2

- carboxyethyl)cysteine X a X d

1

- Bromo

- 2

- propanol X b

Bromoacetone X b

- Bromohydrin X b Glycidol X h

N

- Acetyl

- S

- (2

- hydroxypropyl)cysteine (2

- hydroxypropyl mercapturic acid) X b X d X f,g

N

- Acetyl

- S

- ( 2

- oxopropyl)cysteine X b

N

- Acetyl

- 3

- [(2

- hydroxypropyl)sulfinyl]alanine X b

N

- Acetyl

- 3

- [(2

- oxopropyl)sulfinyl]alanine X b

N

- Acetyl

- 3

- [(2

- propenol)sulfinyl]alanine X b
2,3

- Dihydroxypropylmercapturic acid X g
1

- Bromo

- 2

- hydroxypropane

- O

- glucuronide X b

3

- Bromopropionic acid X d X g X d Propene X i

n

- Propanol X j
1,2

- Propanediol X i Propionic acid X i

S

- n

- Propylglutathione X i

S

- (2

- Hydroxypropyl)glutathione X i

3

- Hydroxypropionic acid X d

S

- ( 2

- hydroxypropyl)cysteine X d Inh. = inhalation; Inj. = injection

. a Hanley et al. 2009

. b Garner et al. 2006

. c Valentine et al. 2007

. d Jones and Walsh 1979

. e Grenby and Young 1959
, 1960

. f Barnsley et al. 1966

. g Walsh and Jones 1977

. h Ishidao et al. 2002

. i Tachizawa et al. 1982

. j Kaneko et al. 1997

.RoC Monograph on 1

- Bromopropane 9/25/13

19 Garner et al. ( 2006 ) investigated the metabolism of 1

- bromopropane in male F344 rats and B6C3F 1 mice following inhalation or tail vein injection. These routes were selected because they do not involve first

- pass metabolism and the inhalation route, specifically, is more likely to be consistent with occupational or environmental exposures comp ared with the oral and i.p. routes used by Jones and Walsh ( 1979 ) . Much of the administered dose (40% to 70%) was exhaled unchanged. Oxidation and glutathion e conjugation were the primary metabolic pathways (Figure 2

- 1 ). In both rats and mice, hydroxylation at the C 2 position (forming 1

- bromo

- 2

- propanol) was the predominant pathway of oxidation. Although 1

- bromo

- 2

- propanol was not detected in the urine, resona nces associated with unconjugated 1

- bromo

- 2

- propanol were detected in rat liver homogenates
, and more than half of the urinary metabolites were derived from this metabolite . Although b romoacetone was not detected in the urine, its mercapturic acid conjugat e, N

- acetyl

- S

- (2

- oxopropyl)cysteine, was detected in rats at levels approaching that of N

- acetyl

- S

- (2

- hydroxypropyl)cysteine, the mercapturic acid of 1

- bromo

- 2

- propanol. Another possible metabolite detected in rat liver homogenate was

- bromohydrin.

Urinar y metabolites in rats exposed to 1

- bromopropane by i.v. injection were affected by dose ( Garner et al. 2006 ) . At the low dose
, AcPrCys was a relatively minor component compared with earlier eluting peaks that included N

- acetyl

- S

- (2

- hydroxypropyl)cysteine. However, the relative p roportion of AcPrCys increased with dose and accounted for more than 80% of the urinary radioactivity in the high

- dose group. AcPrCys is formed by direct conjugation with glutathione without oxidation (Figure 2

- 1 ). In contrast, in mice injected i.v. with 1

- bromopropane, N

- acetyl

- S

- (2

- hydroxypropyl)cysteine was the single predominant metabolite at all dose levels.
A pathway overlapping in part with that described by Garner et al. ( 2006 ) was reported by Jones and Walsh ( 1979 ) , who investigated the metabolism of 1

- bromopropane in male Sprague

- Dawley rats following five consecutive daily oral doses. Four possible metabolic pathways were identified (Figure 2

- 2). The first pathway involved direct conjugation with glutathione to produce the urinary metabolites AcPrCys and N

- acetyl

- S

- propylcysteine

- S

oxide. The second pathway involved oxidation at C 3 of 1

- bromopropane to 3

- bromo

- 1

- propanol. Pathway 3 was based o n oxidation of C 1 of 1

- bromopropane to CO 2 (hydrolysis
to n

- propanol with rapid oxidation to propionic acid and decarboxylation to CO 2 )

. Pathway 4 is the proposed mechanism for forming N

- acetyl

- S

- (2

- hydroxypropyl)cysteine; however, there was no direct evid ence for this pathway in vivo

. S everal additional metabolites, including 3

- bromopropionic acid and n

- propanol, were identified by Jones and Walsh that were not described by Garner et al. However, as suggested by Garner et al.
, th e difference in the observe d metabolites m ight be explained by the analytical methods used by Jones and Walsh, which included concentration steps that could have amplified several minor metabolites (see Section 2.2.5).9/25/13 RoC Monograph on 1-Bromopropane

20 Figure 2-1 . 1 -Bromopropane metabolism in male F344 rats and B6C3F 1 mice following inhalation exposure Source: Garner et al. 2007
, Garner et al. 2006 . Structure in brackets is a proposed intermediate and was not isolated. FMO = flavin-containing monooxygenase, GSH = glutathione, P450 = cytochrome P450.RoC Monograph on 1-Bromopropane 9/25/13

21 Figure 2-2 . Metabolic pathways of 1-bromopropane in male Sprague-Dawley rats following oral exposure Source: Jones and Walsh 1979 . Compounds enclosed in brackets were not isolated from the urine. Pathway 1: direct conjugation with glutathione; Pathway 2: oxidation at C 3 to 3-bromo-1-propanol; Pathway 3: oxidation at C 1 to n -propanol and then to CO 2 ; Pathway 4: formation of N -acetyl- S

- (2

- hydroxypropyl)cysteine.
Possible reactive metabolites identified in these studies of 1-bromopropane metabolism include glycidol, -bromohydrin, and propylene oxide (1,2-epoxypropane). Glycidol was identified in urine samples but not quantified by Ishidao et al. ( 2002 ) as a metabolite resulting from exposure of rats to 1-bromopropane by inhalation. Walsh and Jones ( 1977 ) did not detect glycidol in rats given an i.p. injection but proposed that it was a likely intermediate in formation of the urinary metabolite 2,3-dihyd roxypropylmercapturic acid. Garner et al. ( 2007 ) identified -bromohydrin as a metabolite. Propylene oxide was proposed as a likely metabolite by Ishidao et al. ( 2002 ) and by Jones and Walsh ( 1979 ), but neither group detected it in their studies. The genotoxicity and potential carcinogenicity of glycidol, -bromohydrin, and propylene oxide are discussed in Section 5.

2.2.3 In vitro studies Several debrominated metabolites of 1-bromopropane were identified only in studies in vitro using rat liver microsomes (see Table 2-1). Three metabolites of 1-bromopropane

– propene, 1,2-propanediol, and propionic acid

– were identified from the in vitro P450- catalyzed metabolism of 1-bromopropane by phenobarbital-induced rat liver microsomes;9/25/13 RoC Monograph on 1

- Bromopropane

22 w hen exogenous glutathione was added to the incubation mixture, S

- (1'

- propyl)glutathione and S

- (2'

- hydroxy

- 1'

- propyl)glutathione were detected ( Tachizawa et al. 1982 ) . In another in vitro metabolism study of 1

- bromopropane by rat liver microsomes reported by Kaneko et al. ( 1997 ) only n

- propyl alcohol was reported as a metabolite, but the authors noted that differe nces between the rate of substrate disappearance and product formation suggested that there might be other metabolic pathways.

Jones and Walsh ( 1979 ) also conducted an in vitro metabolism stud y of 1

- bromopropane. Oxidation of carbons 2 and 3 (C 2 and C 3 ) of 1

- bromopropane was demonstrated in vitro

. Metabolites oxidized at C 3 included 3

- bromopropionate and 3

- hydroxypropionate. Evidence for C 2 oxidation (i.e., formation of 1

- bromo

- 2

- propanol) was provided by the isolation of S

- (2

- hydroxypropyl)cysteine from the reaction mixture after it was reacted with cysteine in sodium hydroxide.

2.2.4 Studies of metabolizing enzymes It is clear from the available studies that mos t of the metabolites of 1

- bromopropane are formed following oxidation reactions and glutathione conjugation. T he proportion of 1

- bromopropane metabolized via oxidation relative to pathways dependent on direct glutathione conjugation was inversely proportio nal to dose in rats but independent of dose in mice ( Garner et al. 2006 ) . Garner et al. concluded that formation of AcPrCys results from release of a bromide ion without oxidation

. Barnsley et al. ( 1966 ) also postulated formation of S

- n

- propylglutathione directly from 1

- bromopropane with subsequent formation of S

- n

- propylcysteine and AcPrCys

.

T he i mportance of the cytochromes P450 ( CYP ) oxidative enzymes in the metabolism of 1

- bromopropane has been confirmed by the severe reduction in formation of metabolites

w hen NADPH was eliminated from the incubation mixture with phenobarbital

- induced rat liver microsomes , effectively inactivating CYP oxidation ( Tachizawa et al. 1982 )

. Pretreatment of rats with 1

- aminobenzotriazole ( ABT )
, a general inhibitor of CYP
, significantly reduced the number of metabolites from 10 to 1 major metabolite
, AcPrCys
, which accounted for more than 90% of the total radioactivity ( Garner et al. 2006 )

. Results f rom a study on the induction of liver CYP isozymes in male and female Sprague

- Dawley rats exposed to 1

- bromopropane indicated that the expression of the CYP2E1 isozyme was enhanced while the signals for the other isozymes (CYP1A/2 and CYP2B1/2) were not, s uggesting that CYP2E1 is possibly responsible for 1

- bromopropane metabolism ( Kim et al. 1999b ) . Further evidence for the specific contribution of CYP2E1 to metabolism of 1

- bromopropane was provided by studies with Cyp2e1 - /

- knockout and wild

- ty pe mice ( Garner et al. 2007 ) . Compared with wild

- type mice exposed to 1

- bromopropane by inhalation for 6 hours, the elimination half

- life was more than twice as long in knockout mi ce (3.2 vs. 1.3 hours) exposed in the same way. In addition, the ratio of glutathione conjugation to 2

- hydroxylation increased 5

- fold, and the urinary concentration of N

- acetyl

- S

- ( 2

- hydroxypropyl)cysteine was reduced by about 50%. These data indicate that CYP2E1 is responsible for much, but not all, of the oxidative metabolism of 1

- bromopropane since hydroxylated metabolites were significantly decreased, but not completely eliminate d, in knockout mice.RoC Monograph on 1

- Bromopropane 9/25/13

23 The role of glutathione conjugation was also investigated using DL

- buthionine (S, R)

- sulfoximine 1

- aminobenzotriazole ( BSO ), an inhibitor of GSH synthesis ( Garner et al. 2006 )

. Pretreatm

ent with BSO did not significantly alter the metabolite profile for 1

- bromopropane, although there was a moderate decrease in the level of AcPrCys with a concomitant increase in other metabolites compared with rats that were exposed to 1

- bromopropane alone . The authors suggested that direct conjugation of 1

- bromopropane

m ight be a relatively minor pathway compared with oxidative metabolism in mammals.

2.2.5 D ifferences in metabolic pathways Differences exist for the metabolites and metabolic pathways identified b y various researchers. Possible explanations for these differences include the route of exposure, the location of the radiolabel, and other potential factors as discussed below.

T he study by Jones and Walsh ( 1979 ) identified two mercapturic acid conjugates derived from metabolites oxidized at the C 3 position (3

- bromo

- 1

- propanol and 3

- bromopropionic acid) that were not detected in other studies. Jones and Wal sh confirmed formation of these molecules using Udenfriend’s reagent (a mixture of iron, citric acid, EDTA, and oxygen) to oxidize 1

- bromopropane in vitro ; these conditions m ight have been too harsh and could reflect more of a chemical reaction than an in vitro metabolism study

. In addition, G arner et al. ( 2006 ) proposed that Jones and Walsh ( 1979 ) might have artificially amplified these metabolites by pool ing, acidifying, and concentrating a large volume of urine prior to analysis. Garner et al. ( 2006 ) also noted differences with the in vitro study of Tachizawa et al. ( 1982 ) (see Section 2.2. 3 ). In vitro metabolism of 1

- bromopropane by hepatic microsomes from phenobarbital

- induced rats produce d propene, 1,2

- propanediol, and propionic acid ; S

- (1'

- propyl)glutathione and S

- (2'

- hydroxy

1'

- propyl)glutathione were detected when glutathione was added to the incubation mixture . However
, none of these metabolites was detected in rat liver homogenate incubations or in experimental animal models . Garner et al. speculated that the use of phenobarbital as an inducer of CYP by Tachizawa et al. might have produced metabolites that are not normally generated by constitutivel y expressed CYP s.

The studies discussed here also reported large differences in the amounts of 1

- bromopropane exhaled as CO 2 . The reason for this apparent discrepancy is unclear but may be attributed to the particular carbon atom that was radiolabeled. Jon es and Walsh ( 1979 ) concluded that oxidation of 1

- bromopropane at the C 1 position with subsequent oxidation to propionate and decarboxylation to CO 2 was insi gnificant in vivo

. However, Garner et al. ( 2007
, 2006 ) concluded that a large portion of the administered dose was converted to CO 2 regardless of the exposure route and that 1

- bromo

- 2

- propanol was the ultimate source of CO 2 (via oxidation to bromoacetone, pyruvaldehyde, and pyruvate). This was supported by a significant drop in exhaled CO 2 in rats pretreated with the CYP inhibitor ABT and by a previous study ( Bond et al. 198 8 ) that reported that about 65% of an analogous molecule, 1

- chloro

- 2

- propanol, administered to rats was excreted as CO 2
. Bond et al. ( 1988 ) demonstrated that about 30% of the CO 2 originated from C 3 and about 35% originated from C 2
.9/25/13 RoC Monograph on 1

- Bromopropane

24 2.3 Synthesis and summary Studies in humans and laboratory animals indicate that 1

- bromopropane can be absor bed following inhalation, ingestion, or dermal exposure. Occupational exposure occurs primarily by inhalation and dermal contact and studies of workers show a good correlation between urinary concentrations of 1

- bromopropane, bromide ion, and N

- a cetyl

- S

- ( n

- propyl)

- L

- cysteine (AcPrCys) with their 1

- bromopropane breathing zone air concentrations. Several studies have monitored urine and blood samples in workers to establish biomarkers of exposure. These studies also indicate that unmetabolized 1

- bromopropane is excreted in the urine in humans but has not been reported in animal studies. The four urinary mercapturic conjugates identified from 1

- bromopropane

– exposed workers have also been reported as urinary metabolites from studies in rodents, incl uding AcPrCys, N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine

- S

- oxide, N

- acetyl

- S

- (2

- carboxyethyl)

- L

- cysteine, and N

- acetyl

- S

- (3

- hydroxy

- n

- propyl)

- L

- cysteine. The oxidative metabolites that likely lead to the conjugates have not been reported in human studies; however, no publications were identified that actually tested for them.
Experimental animal studies have shown that 1

- bromopropane is absorbed, rapidly distributed, and predominantly eliminated by exhalation (approximately 40 % to 70%), but is also excreted in the urine and feces. In rats and mice, most of the 1

- bromopropane administered by i.v. injection was exhaled unchanged or as CO 2 within 4 hours of exposure. Urinary metabolites accounted for 13% to 23% of the administered dose after 48 hours. The available stu dies on 1

- bromopropane metabolism show that CYP

- catalyzed oxidation (primarily via CYP2E1) reactions and glutathione conjugation are the primary metabolic pathways. At least 16 urinary metabolites have been identified in rodent studies (either rats or mice ) , including several reactive intermediate metabolites (bromoacetone, glycidol, and

- bromohydrin).RoC Monograph on 1

- Bromopropane 9/25/13

25 

## 3 Human Cancer Studies

No epidemiological studies or case reports were identified that evaluated the relationship between human cancer and exp osure specific ally to 1

- bromopropane.9/25/13 RoC Monograph on 1

- Bromopropane

26 This Page Intentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13

27 

## 4 Studies of Cancer in Experimental Animals

This section reviews and assesses the carcinogenicity studies in experimental animals exposed to 1

- bromopropane. These studies were identified by searching databases, comprehensive reviews, and citations from studies retrieved from the literature searches as described in Appendix A. Identified citations were reviewed using exclusion and inclusion criteria that limite d selection of the studies to those examining neoplastic lesions, non

- neoplastic or preneoplastic lesions relevant to carcinogenicity, or subchronic studies that provide information on dose selection. Chronic (2

- year) inhalation studies conducted by NTP an d the associated subchronic (90

- day) studies in mice and rats were the only studies identified that examined tissues for neoplastic or preneoplastic endpoints.
The characteristics, methodology, and relevant non

- neoplastic findings from the chronic stud ies by NTP and the associated subchronic studies are reported in S ection 4.1. An assessment of the evidence for carcinogenicity is discussed in Section 4. 2 and the recommendation for the level of evidence is provided in Section 4. 3

. 4.1 Studies in experimen tal animals: characteristics, methodology, and relevant

non - neoplastic findings Both t he subchronic and chronic stud ies in rats and mice were conducted in the same facility using 1

- bromopropane with purity greater than 99% and the same animal husbandry an d testing procedures as in the chronic study under FDA Good Laboratory Practice regulations ( NTP 2011a ) . The subchronic studies in rats and mice were used to determine the exposure groups in the chronic study. B6C3F 1 mice or F344/N rats were administered 1

- bromopropane (99% pure) by whole

- body exposure in inhalation chambers for 6 hours and 10 minutes per day, 5 days a wee k, for either 14 weeks (subchronic studies, 10 ma les and 10 females per exposure group) or 105 weeks (chronic studies, 50 males and 50 females per exposure group) , with controls exposed to filtered air only. (Note: The additional 10 minutes of exposure wer e based on experimental data for the time required to achieve 90% of the target concentration [ T 90 ] after the beginning of vapor generation.) Complete n ecropsies and histopathology were performed on all animals. At necropsy, all organs and tissues were exa mined for grossly visible lesions, and all major tissues were processed and stained for histopathologic examination.

4.1.1 Rats Subchronic study The subchronic study did not identify any neoplastic lesions at the exposure levels tested (0, 62.5, 125, 250, 500, or 1,000 ppm). Male rats exposed to 1,000 ppm had reduced body weight compared with controls ; r ats had evidence of hepatotoxicity at this dose . Sorbitol dehydrogenase activity was increased at 500 ppm (males only) and 1
, 000 ppm (males and females). Liver weight and cytoplasmic vacuolization were increased at 250 ppm or greater exposures in males. In females, liver weight increased at 125 ppm or greater, liver vacuolization at 500 ppm or greater, and hepatocyte degeneratio n was observed at 1,000 ppm. During selection of the maximum level of exposure for the chronic study, liver vacuolization was considered a tolerable toxicity and not life threatening , while hepatocyte degeneration was considered intolerable

.9/25/13 RoC Monograph on 1

- Bromopropane

28 Chronic study
Fischer 344/N rats were exposed to 0, 125, 250, and 500 ppm of 1

- bromopropane based on decreased body weights and increased incidences of liver lesions at 1000 ppm reported in the subchronic study

. During the chronic study, survival in males was significa ntly decreased in the group exposed to 500 ppm, and survival decreased with increas ing level of exposure ( statistically significant negative trend). Survival in females was not significantly decreased in a pa ir

- wise analysis for any exposure level , but the re

was a statistically significant negative trend with the level of exposure . Body weights of exposed males and females were similar to those of controls.
No neoplastic lesions were found in the respiratory tract, but several non

- neoplastic lesions , inclu ding i nflammation, hyperplasia, and metaplasia were found in the upper respiratory tract of both sexes of rats. Hyperplasia of the respiratory epithelium was found at significantly increased incidences in the nasal cavity of females at 125 and 500 ppm and in the trachea of fema les at 500 ppm. Hyperplasia of glands in the nasal cavity
, mostly in level II, was at a significantly increased incidence in both sexes in all exposed groups of rats. Significant increases in the incidences of metaplasia in females we re found in the nasal cavity as olfactory epithelium with morphology of respiratory epithelium at 500 ppm and in the larynx as squamous metaplasia at 500 ppm. Chronic suppurative inflammation of the nasal cavity had a significantly increased incidence in males and females at 500 ppm. Despite the high incidence of chronic active inf l a mmation seen in untreated controls, the incidences of this non

- neoplastic lesion were significant ly increased in the nasal cavity of f emales at all exposure levels, in the larynx of males at 250 ppm and of females at 250 and 500 ppm, as well as in the trachea of females at 500 ppm. Ab s cesses on the tail, Harderian gland, head, and salivary gland of five exposed rats were tested for bacterial growth under anaerobic and aerobic conditions. Pseudomonas aeruginosa was the primary isolate (4 out of 5 sites) in all aerobic cultures and Splendore

- Hoeppli bodies were later observed microscopically in these lesio ns (see discussion in Appendix E
, “ Immunotoxicity ” ). Although inflammation and infections were associated with immunosuppression in rats, it was not noted in the Technical Report (NTP 2011a) whether the ab s cesses were directly associated with tumors. No evidence of suppurative inflammation was reported in the mouse study, although mice were also immunosuppressed after subchronic 1

- bromopropane exposure.

4.1.2 M

i ce Subchronic study The NTP subchronic study did not identify any neoplas tic lesions at the exposure levels tested (0, 62.5, 125, 250 , 500 ppm). S urvival (number surviving/num ber at study start) was decreased in the high

- dose female (5/10) and male (6/10) groups and one death at 250 ppm in males (9/10). There was an increase in kidney, liver, and lung weights in the 500

- ppm female group
, an d the kidney weights of the 500

- ppm male group were decreased.

C hronic study
Based o n mortality at the highest exposure concentration, changes in organ weights, and the incidences of various non

- neoplastic lesions i n the subchronic study, 1

- bromo propaneRoC Monograph on 1

- Bromopropane 9/25/13

29 exposure concentrations selected for the chronic inhalation study in mice were 62.5, 1 25, and 250 ppm. During the chronic study, survival and body weight s of both sexes in exposed groups were similar to those in control groups.

4.2 Assessment of neoplastic findings The chronic inhalation stud ies in B6C3F 1 mice and Fischer 344/N rats conducted by NTP

w ere of sufficient duration to adequately assess the carcinogenic potential of 1

- bromopropane. Factors considered in study design were the number of animals per exposure group, exposure period, dose selection, monitoring of animal health, and complete necropsies of all animals and histopathologic examination of all major tissues. This study is considered a high quality study and provides strong evidence to support the
cancer assessment. Details of study quality criteria and assessment are found in Appendix C

. Important factors taken into account in data assessment are the significance of the effect as compared with the concurrent control (pairwise comparison), whether there is a change in the effect with dose (trend analysis), and the rarity of the event (historical control range). In the NTP assessments of experimental animal data in this report, a P oly

- 3 trend ana lysis is employed
, which is similar to the Cochran

- Armi tage trend test but is survival adjusted

. In rats, there was a significantly increased incidence with a positive trend for benign tumors ( adenoma) of the large intestine (colon or rectum) in females, b ut the incidence did not reach significance for male rats (Table 4

- 1). However, these are rare tumors and the tumor incidence exceeded the historical control range for male and female rats for inhalation studies and studies by all exposure routes and are c on s id e red to be of biological significance

. (A n adenomatous polyp was listed for a male rat exposed to 125

- ppm 1

- bromopropane [ see Appendix Table A1 of th e NTP Technical Report 564 , NTP 2011a] but was not included in the data analysis conducted by the authors

. Addition of this tumor increases the total number of benign tumors of the large intestine in all 1

- bromopropane

– exposed male rats from 3 to 4 tumors, which provides addi tional support for an exposure

- related effect

. ) The ti me to first incidence of tumors of the colon or
rectum was lower with increasing dos e in male rats ( 729 days at 250 ppm and 682 days at 500 ppm ) ; but no clear trend was seen with increasing dose for female rats ( 730 days at 125 ppm, 607 days at 250 ppm, and 719 days at 500 ppm)

. Spontaneous adenoma of the large intestine is rare in male and female rats, occurri ng at a rate of less than 0.2%. Increased incidences of adenocarcinoma of the large intestine were observed in both male and female rats after oral treatme nt with brominated methanes (bromodichloromethane or tribromomethane ( NTP 1987
, 1989 ) and in male rats after tre atment with glycidol ( NTP 1990 ) , a metabo lite of 1

- bromopropane

. Therefore, the findings of intestinal tumors after 1

- bromopropane exposure are considered to be exposure related

. Although no carcinomas of the large intestine were observed in male or female rats in the current study, adenoma of th e large intestine can progress to carcinoma ( NTP 2011a )

.9/25/13 RoC Monograph on 1

- Bromopropane

30 Table 4

- 1

. Large intestine tumors observed in Fischer 344/N rats exposed to 1

- bromopropane by inhalation for 2 years

Sex Conc. (ppm) Number of rats

surviving to study termination Large intestine tumor (adenoma) (% incidence)

Colon Rectum Colon or rectum combined

Male 0

125 250 500 trend + 23

26 18 13 *
P = 0.009 d 0 /50 (0)

0 /50 (0) 0 /50 (0) 1 /50 (2) NR 0 /50 (0)

0 /50 (0) c
2 /50 (4) 0 /50 (0) NR 0 /50 (0.0) a ,b

0 /50 (0.0) 2 /50 (5.3 ) 1 /50 (2.8)
P = 0.197
Female 0

125 250 500 trend + 34

33 30 24
P = 0.028 d 0 /50 (0)

1 /50 (2) 1 /50 (2) 1 /50 (2) NR 0 /50 (0)

0 /50 (0) 1 /50 (2) 4 /50 (8) NR 0 /50 (0.0) a ,b

1 /50 (2.3) 2 /50 (4.7) 5 /50 (13.3)*
P = 0.004 Source: NTP 2011a

. NR = not reported

. * P ≤ 0.05 ( c ompared with concurrent controls by Poly

- 3 test for tumor incidence or life

- table pairwise comparisons for survival ).

+ Determined by P oly

- 3 trend test

. a Number of animals with tumors; (Poly

- 3 estimated tumor incidence percent after adjustment for intercurrent mortality ).
b Historical control range : 0% for inhalation studies and 0 %

– 2 % for studies by all routes.

c Appendix Table A1 of the NTP Technical Report (TR 564 ) indicated that an adenomatous polyp was observed at this treatment dose, but the polyp was not included in the data analysis (see TR 569 [NTP 2011a]
, Table 9 )

. d Survival analysis performed by lif e

- table trend test.
Male rats had a significant increase in the incidence of malignant or benign skin tumors (keratoacanthoma ; keratoacanthoma or squamous

- cell carcinoma combined ; and keratoacanth oma, squamous

- cell carcinoma, basal

- cell adenoma, or basal

- cell carcinoma combined) as well as significant positive trends for these three groups of skin tumors (Table 4

- 2 ) . These effects are also considered to be exposure related. Female rats had a signif icant positive trend for keratoacanthoma, squamous

- cell papilloma , basal

- cell adenoma, or basal

- cell carcinoma combined
, with the high

- dose group (500 ppm) outside of the historical control range for inhalation studies and studies by all exposure routes, s o these combined skin tumors may be exposure related

. Keratoacanthomas also occurred in females, but the incidences were not increased compared with the concurrent or historical controls. Keratoacanthomas can progress to squamous

- cell carcinoma, a malignan t tumor; however, no squamous cell

- carcinomas were identified in female rats.RoC Monograph on 1

- Bromopropane 9/25/13

31 Table 4

- 2

. Skin tumors observed in Fischer 344/N rats exposed to 1

- bromopropane by inhalation for 2 years

Sex Conc.

(ppm) Number of

rats surviving to study termination Skin tumors ( % i ncidence ) a

KA KA or SCC

combined KA, SCC ,

BCA or BCC combined KA, SCP,

BCA, or BCC combined

Male 0

125 250 500 trend + 23

26 18 13 *
P = 0.009 d 0 /50 (0.0) b

3 /50 (7.4) 6 /50 (15.4)* 6 /50 (16.2)**
P = 0.008 1 /50 (2.4) b

4 /50 (9.8) 6 /50 (15.4)* 8 /50 (21.4)**
P =0.006 1 /50 (2.4) c

7 /50 (17 .0 )* 9 /50 (22.6)** 10 /50 (26.7)**
P = 0.003 NR

Female 0

125 250 500 trend + 34

33 30 24
P = 0.028 d 1/50 (2) e , g

0/50 (0) 1/50 (2) 1/50 (2) NR 1/50 (2) g

0/50 (0) 1/50 (2) 1/50 (2) NR 1/50 (2) f
, g 1/50 (2) 1/50 (2) 3/50 (6) NR 1 /50 (2.2) f

1 /50 (2.3) 1 /50 (2.4) 4 /50 (10.6)
P = 0.05 Source: NTP 2011a

. BCA = basal

- cell adenoma, BCC = basal

- cell carcinoma, KA = keratoac anthoma, NR = not reported, NS = not significant, SCA = squamous

- cell papilloma, SCC = squamous

- cell carcinoma

. * P ≤ 0.05, ** P ≤ 0.01 (compared with concurrent controls by Poly

- 3 test).

+ Determined by P oly

- 3 trend test

. a Number of animals with tumors (Poly

- 3 estimated tumor incidence percent after adjustment for intercurrent mortality ).
b Historical contro l range: 0%

– 8 % for inhalation studies and 0 %

– 1 6 % for studies by all routes.

c Historical control range : 0%

– 10 % for inhalation studies and 0 %

– 20 % for studies by all routes.
d Survival analysis performed by life table trend test.

e Historical control range : 0%

– 2 % for inhalation studies and 0 %

– 4 % for studies by all routes.
f Historical control range : 0%

– 2 % for inhalation studies and 0 %

– 6 % for studies by all routes

. g Percent incidence is overall rate (non

- P oly

- 3 adjusted).

Male rats had a significant positive trend of malignant mesothelioma ( tunica vaginalis of the epididymis) with a significant increase in tumor incidence at the high dose that was slightly greater ( 10. 8%) than the historical control range (0 % to 6%) for inhalation studies and studies by all exposure routes (Table 4

- 3 )

. Therefore, these results may be exposure related. A significant increase was also observed in the incidence of mali gnant or benign pancreatic islet

- cell tumors (adenoma and adenoma or carcinoma combined) for all exposure groups for adenoma and for 125 ppm and 250 ppm for adenoma and carcinoma combined in male rats; the incidence of adenoma and carcinoma was increased ( but not statistically significant) at the highest exposure level (500 ppm)

. Although the tumor incidences were within the historical control range for inhalation studies and studies by all exposure routes
, t here was a significant positive trend for benign pancreatic islet

- cell tumors (adenoma) suggesting that the tumors may have been caused by 1

- bromopropane exposure

. No exposure

- relat ed response of pancreatic islet

- cell tumors was observed in female rats.9/25/13 RoC Monograph on 1

- Bromopropane

32 Table 4

- 3

. Malignant mesotheliomas and p ancreatic islet

- cell tumors observed in Fischer 344/N rats exposed to 1

- bromopropane by inhalation for 2 years

Sex Conc.

(ppm) Number of

rats surviving to study termination Malignant

mesothelioma (% incidence ) a , b Pancreatic islet cell tumor (% incidence) b

Adenoma Carcinoma Adenoma

or carcinoma combined

Male 0

125 250 500 trend + 23

26 18 13 *
P = 0.009 g 0 /50 (0.0) c

2 /50 (4.9) 2 /50 (5.2)
4 /50 (10.8 ) *
P = 0.031 0 /50 (0.0) d

5 /50 (12.2) * 4 /50 (10.4) * 5 /50 (13.9 ) *
P = 0.043 3 /50 (7.2) e

7 /50 (17.0) 5 /50 (13.0) 3 /50 (8.3)
P = 0.0516N 3 /50 (7.2) f

10 /50 (24.2) * 9 /50 (23.1) * 8 /50 (22.2)
P = 0.093

Female 0

125 250 500 trend + 34

33 30 24
P = 0.028 g NR 0 /50 (0) h
, i
2 /50 (4) 1 /50 (2) 0 /50 (0) NR 1 /50 (2) g , h

1 /50 (2) 1 /50 (2) 0 /50 (0) NR 1 /50 (2.2) f

3 /50 (6.9) 2 /50 (4.7) 0 /50 (0.0)
P = 0.537N Source: NTP 2011a

. N = n egative trend, N R = not reported

. * P ≤ 0.05 (compared with concurrent contro ls by Poly

- 3 test).

+ Determined by Poly

- 3 trend test.

a Epididymis in all affected animals with other tissues variably affected.
b Percentage reported as the adjusted rate, which takes into account the survival rate and is calculated during the Poly

- 3 test a nalysis.

c Historical control range s for inhalation studies and studies by all routes are 0 %

– 6%

. d Historical control range : 0%

– 12% for inhalation studies and 0 %

– 14% for studies by all routes.

e Historical control range : 2 %

– 10% for inhalation studies and 0 %

– 10% for studies by all routes.
f Historical control range : 6 %

– 18% for inhalation studies and 0 %

– 18% for studies by all routes

. g Survival analysis performed by life table trend test.
h Historical contro l range: not reported for inhalation studies and studies by all routes.
i Percentage reported as the overall incidence rate (non

- P oly

- 3 adjusted).

In female mice, t here were significantly increased incidences of benign and malignant lung tumors (alveolar/bronchiolar adenoma, alveolar/bronchiolar carcinoma, and combined) with positive dose

- re s ponse trends for benign lung tumors (alveolar/bronchiolar adenoma) and combined groups. Some females in the 250

- ppm group had multiple adenomas and some females in all of the exposed groups had multiple carcinomas. Based on positive pairwise comparisons, positive trend data for adenoma and highly significant trend data for combined, and tumor incidences outside of historical control ranges , these results are considered to be exposure related. There was no evidence of neoplastic lesions in male mice (Table 4

- 4)

.RoC Monograph on 1

- Bromopropane 9/25/13

33 Table 4

- 4

. Lung tumors observed in B6C3F 1 mice exposed to 1

- bromopropane by inhalation for 2 years

Sex Conc. (ppm) Number of mice surviving to study termination Lung tumors (% incidence ) a

Alveolar/ bronchiolar adenoma Alveolar/

bronchiolar carcinoma Combined

Male 0

62.5 125 250 trend + 37

33 32 36
P = 0.934 d 6 /50 (1 3.3 ) c

5 /50 (1 1.5 ) 4 /49 ( 9.0 ) 5 /49 (1 1.9 ) b

P = 0.476N 8 /50 (1 7.8 ) c

7 /50 (1 5.9 ) b
10 /49 (2 2.0 ) b
10 /49 (2 4.3 ) b

P = 0.209 13 /50 (2 8.3 ) c

12 /50 (2 7.3 ) 14 /49 ( 30.8 ) 15 /49 (3 5.7 )
P = 0.225
Female 0

62.5 125 250 trend + 36

40 37 42
P = 0.363N d 1 /50 (2 .2 ) e

6 /50 (12 .8 ) 4 /50 (8 .9 ) 10 /50 (20 .8 )**
P = 0.0 07 0 /50 (0) f

7 /50 (14 .9 )** 5 /50 (1 1.1 )* 4 /50 (8 .5 )
P = 0.277 1 /50 (2 .2 ) g

9 /50 (1 9.2 )** 8 /50 (1 7.8 )* 14 /50 (2 9.2 )***
P < 0.001 Source: NTP 2011a

. N = n egative trend.

* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 (compared with concurrent controls by Poly

- 3 test).

+ Trend of tumor incidence compared with the overall change in exposure levels by Poly

- 3 trend test

. a Number of animals with tumors ( includes multiple) (Poly

- 3 estimated neoplasm incidence percentage after adjustment for intercurrent mortality ).
b Incid en ce of mice with multiple lung tumors

- adenoma: 0/50, 0/50, 0/50, 2/49 and carcinoma: 0/50, 2/50, 1/50, 1/50

. c Historical contro l range: not reported for inhalation studies and studies by all routes.
d Survival analysis per formed by life table trend test.

e Historical control range : 2%

– 12% for inhalation studies and 0 %

– 1 2 % for studies by all routes.
f Historical control range : 0%

– 6 % for inhalation studies and 0 %

– 1 2 % for studies by all routes.

g Historical control range : 2%

– 1 2 % for inhalation studies and 2%

– 18% for studies by all routes

. As mentioned in Section 4.1.1, an inflammatory response was observed in rats, which could potentially be related to tumor development; however, the i nflammatory response did not cor

relate with tumorigenicity. Chronic active and chronic suppurative inflammation were observed in the respiratory tract of both sexes of rats; however, incidences of lung and nasal tumors were not increased. In contrast, 1

- brom o propane did

c a use lung tumors in male mic e , but no chronic suppurative or chronic active inflammation of the respiratory tract was reported for either male or female mice.

4.3 NTP level of evidence conclusion These data meet the Report on Carcinogens criteria for sufficient evidence of carcinog enicity in experimental animals based on an increased incidence of tumors in rats and mice
, at multiple tissue sites , and the occurrence of rare tumors . This conclusion is based on exposure

- related neoplastic lesions in the skin of male rats, large intesti nes of male and fe male rats, and lung of female mice

.9/25/13 RoC Monograph on 1

- Bromopropane

34 This Page Intentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13

35 

## 5 Mechanistic Data and Other Relevant Effects

Th e purpose of this section is to review data that are relevant for identifying and evaluating the potential mechanisms of action for the carcinogenic effects discussed in Section 4 . Data reviewed in this section include the following: (1) genetic and related effects (Section 5.1 with data tables in Appendix D ) , (2) relevant toxicological effects ( S ection 5.2 and A

ppendix E )
, (3) mechanistic considerations (Section 5.3) , and (4) carcinogenic effects of metabolites and analogues ( S ect i on 5.4)

.
5.1 Genetic and related effects
1

- Bromopropane has been tested in several short

- term assays to evaluate potential induction of mutagenic or other genotoxic effects. The database of genotoxicity studies include s DNA and protein a dducts (Section 5.1.1 ) in vitro studies in bacteria (Section 5 .1. 2 ) and in mammalian cells (Section 5 .1. 3 ), and in vivo studies in rodents (Section 5 .1. 4 ) and in 1

- bromopropane

– exposed workers (Section 5 .1. 5 ). Genotoxicity studies are also available on some metabolites of 1

- bromopropane (Section 5 .1. 6 ). An overall assessment of the genotoxicity of 1

- bromopropane is presented in the final section (Section 5 .1. 7 ). Data tables for genotoxicity studies discussed in Section 5.1 are provided in Appendix D

.

5.1.1 DNA and protein adducts N o published data were identified for 1

- bromopropane DNA adducts. However, DNA adducts are formed by some 1

- bromopropane metabolites (see Se ction 5.1. 5), and the N 7

- guanine DNA adduct was formed when 2

- bromopropane was incubated with 2'

- deoxyguanosine ( Zhao et al. 2002 ) (see Section 5.4.2).
Although no in vivo studies of 1

- bromopropane DNA adducts were identified
, 1

- bromopropane can form covalent adducts with protein in vivo (binding to sulfhydryl groups). One study measured S

- propylcysteine (PrCys) adducts with globin and neurofilaments in rats after inhalation exposure ( Valentine et al. 2007 )

. Rats exposed to 1

- bromopropane for two weeks at 0 to 800 ppm had a statistically significant linear dose response for PrCys globin and neurofilament adducts; exposure to 50 ppm for 8 hours/day, 5 days/week for 4 weeks produced a linear accumulation of PrCys globin adducts . Although there are v ery few data, DNA and protein adducts could be involved in 1

- bromopropane

– induced toxicity and carcinogenicity (see Section 5.3 ).

Valentine et al. ( 2007 ) measured S

- propylcysteine globin adducts in 26 female factory workers in China who were exposed to 1

- bromopropane by inhalation and possibly by skin contact. Controls were age

- matched workers from a Chinese beer factory. Exposure to 1

- bromopropane was assessed via individual “ passive ” (diffusion) samplers
, and exposure levels ranged from 0.34 to 49.2 ppm for the workers who gave blood samples and 0 to 170.54 ppm for the workers who g ave urine samples. There was a si gnificant increase in the S

- propylcysteine adducts measured in the globin of exposed workers (1.52 pmol/mg globin) over controls (0.11 pmol/mg globin). The level of urinary N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine (AcPrCys) increased with increasing exposure concentrations

.9/25/13 RoC Monograph on 1

- Bromopropane

36 5.1.2 In vitro studies in bacteria 1

- Bromopropane has been tested in vitro to evaluate mutagenic effects in bacterial strains of Salmonella typhimurium and Escherichia coli. Results of the mutagenicity studies of 1

- bromopropane in bacteria are summarized in Appe n dix D, Table D

- 1

.
1

- Bromopropane was reported to be mutagenic in a dose

- dependent manner in two tester strains: TA100 and TA1535, when the S. typhimurium assay was modified by using a closed chamber specifically designed for testing volatile substances ( Barber et al. 1981 )

. In this study, the authors compared the mutagenic potency of 10 volatile halogenate d alkane solvents in the standard assay versus a closed

- chamber assay. They reported that while only 2 of the solvents were positive in the standard assay (1

- bromopropane was negative), 7 of the 10 substances, including 1

- bromopropane, were positive in the closed system. In the closed

- system assay, re sults were similar both in the absence and presence of metabolic activation (S9), indicating that 1

- bromopropane is a direct

- acting mutagen.
In standard test assays, in two independent laboratories, 1

- bromopropane was reported to be no n

- mutagenic at doses tested up to 3
, 333 μg/plate ; higher doses (to 10,000 μg/plate) were tested but were too toxic to evaluate ( NTP 2011a ) . In addition, there were no mutagenic effects with S9 ( prepared from Aroclor 1254

- induced livers of rat or hamster ) metabolic activation added to the culture at 10% or 30%. These studies were conducted in an open system, so the volatility of 1

- bromopropane could have lowered the amount that the bacteria were exposed to. The observation of toxicity at high treatment doses indicated that exposure to 1

- bromopropane did, in fact, occur
, but it is unclear what the actual exposure levels were to the bacteria. T he Barber study reported mutagenicity at lower doses us ing a modified closed system protocol ; the treatment concentration was determined by using gas chromatography to measure 1

- bromopropane in water placed in the chamber rather than by the amount of chemical added to the culture plate

. This study also reporte d mutagenic effects for several other volatile substances that were previously reported as non

- mutagenic when tested in the standard protocol bacterial assay. 1

- Bromopropane was not mutagenic in S. typhimurium in several strains, both with and without S9, in two unpublished studies reviewed in NTP 2003 ( Elf Atochem 1994
, Kim et al. 1998 )

. The NTP description of the Elf Atochem study noted that the cultures were incubated in closed stainless steel chambers but other important details, such as protocol modifications for sample preparation and treatment with a volatile substance, were not specifi ed. In addition, other specific d etails were not provided in the NTP review of these stud ies (e.g., numbers of revertant colo nies in either study , as well as cytotoxicity observations, solvent specification, and incubation condi tions in the Kim et al. study ), which makes it difficult to evaluate the discrepancy between these and the Barber et al. study results.

In summary, the data indicate that 1

- bromopropane is a direct

- acting mutagen in S. typhimurium, because similar findings were observed both with and without the addition of metabolic activation, in the only reported study that used appropriate methodology ( treatment and incubation in a closed chamber) for testing a volatile substance.RoC Monograph on 1

- Bromopropane 9/25/13

37 5.1.3 In vitro studies in mammalian cells Available in vitro studies suggest that 1

- bromopropane induces mutations and DNA damage in mammalian cells. Two studies were identified that utilized mammalian cells in vitro to assess DNA damage of 1

- bromopropane in human leukocytes and mutagenicity in mouse lymphoma cells ( see Appendix D, Table D

- 2 ) . The comet assay showed that in vitro exposure to the highest dose of 1

- bromopropane in human leukocytes induced an increase in DNA damage as measured by comet tail moment but no increase was observed for lower doses ( Toraason et al. 2006 ) . In th e same study , the temporal response
t o high

- dose 1

- bromopropane treatment was assessed using the comet assay
, and DNA damage was significantly increased after both 4

- and 8

- hour exposures; DNA damage was higher after 8 hour s compared with 4 hour s . Toraason et al. also reported a dose

dependent increase in the percentage of apoptotic cells in 1

- brom o propane

– treated human leukocytes. 1

- Bromopropane induced mutations at the thymidine kinase locus in the L5178Y mouse lymphoma cell assay, both with and without t he addition of S9 metabolic activation (Elf Atochem 1996 as cited in NTP 2003a ).

5.1.4 In vivo studies in rodents The micronucleus assay was used to evaluate the potential effects of a th ree

- month exposure of up to 500

- ppm 1

- bromopropane in male and female B6C3F 1 mice by inhalation ( NTP 2011a ) . No increases in the frequencies of micronucleated normochromatic erythrocytes were reported for either sex of mice. In addition, two unpublished studies, reviewed by NTP ( 2003a ) , also reported that micronuclei were not increased in mice treated by i.p. injection or in rats exposed by inhalation to 1

- bromopropane (Kim et al. 1998 and Elf Atochem 1995 , both cited in NTP 2003a ). (See Appendix D, Table D

- 3 for findings from in vivo studies in rodents.)

D ominant lethal mutation assay s were negative in ICR mice ( Yu et al. 2008 ) and in Sprague

- Dawley rats ( Saito

- Suzuki et al. 1982 ) as shown in Appendix D, Table D

- 3

. Male ICR mice were administered 1

- bromopropane by i.p. injection while male Sprague

Dawley rats were given five consecutive daily doses in olive oil by oral gavage prior to mating with untreated fe males. The dominant lethal mutation assay identifies germ

- cell mutagens by measuring a chemical ’s ability to penetrate gonadal tissue and produce embryonic death via chromosomal breakage in parent germ cells. Limitations for evaluating genotoxicity using t his assay are that it does not detect somatic mutations and, because the spontaneous mutation frequency is high, the assay may have limited sensitivity for detection of small increases in induced mutation frequency ( Singer et al. 2006 ) . The study in rats also tested four other structurally related halogenated 3

- carbon compounds that have a similar structure to a known mutagen
, 1,2

- dibromo

- 3

- chloropropane (DBCP). Only 1,2,3

- tribromopropan e and DBCP induced dominant lethal mutations; the authors suggested that in order for pro panes to induce dominant lethal mutatio ns, they should have bromine or chlorine on each carbon atom and 2 of the 3 halogen atoms should be bromine.

5.1.5 Studies in exposed workers The comet assay was used to assess DNA damage (strand breaks) in peripheral blood leukocytes from 64 workers (18 males and 46 females) exposed occupati onally to9/25/13 RoC Monograph on 1

- Bromopropane

38 1

- bromopropane ( Toraason et al. 2006 ) at two facilities ( designated as A and B) that utilized spray adhesives containing 1

- bromopropane. There was no unexposed population so the workers were divided into high er

- exposure (sprayer) and lower

- exposure groups (non

- s prayers ) ( see Appendix D, Table D

- 4 ).
In analysis by facility (A and B) and job type ( sprayer and non

- sprayer) , no clear exposure

- response patterns were observed. DNA damage (as measured by tail moment) in leukocytes from sprayers were numerically higher for both start

- and end

- of

- work week samples than non

- sprayers but none of the increases were statistically significant and spraye rs at Facility B (lower

- exposure facility) had higher measures of DNA damage than sprayers at Facility A (higher

- exposure facility) at the start, but not at the end, of the work week . No exposure

- response patterns were observed for DNA damage as assessed by tail moment dispersion coefficient

.

M ultivariate analyses were also performed that evaluated the association between DN A damage (start

- of

- work week and end

- of

- work week comet tail moment and dispersion

c oefficients ) and three 1

- bromopropane exposure indices

– 1

- bromopropane TWA levels, and serum and urinary bromide concentrations

– in models that controlled for gender, age, smoking s tatus, facility
, and two DNA polymorphisms (GSTM1 and GSTT1). For each of the three exposure indices, both linear regression models using log

- transformed exposure indices and exposure quartiles analyses were performed. Both start

- of

work week and end

- of

- wor k week comet tail moments in leukocytes were significantly associated with serum bromide quartiles ; end

- of

- work week values were also significantly associated with 1

- bromopropane TWA quartiles. Although not statistically significant, all of the other associa tions between 1

- bromopropane exposure indices and DNA damage were positive, with the exception of the end

- of

- work week urinary bromide. The strengths of this study are that the assessment of exposure to workers was at the individual level and that these wor kers were exposed to a wi de range of levels of 1

- bromopropane, which allowed for the evaluation of exposure

- response relationships . Multivariate analyses w ere considered to be more informative than the analysis by job and facility . Limitations to this study include s mall numbers of exposed workers , no unexposed controls, and multiple comparisons.
These results provided limited evidence that 1

- bromopropane causes DNA damage in vivo

.

5.1.6 Genotoxic effects of 1

- bromopropane metabolites The genotoxic effects o f several known or postulated metabolites of 1

- bromopropane have been evaluated in numerous in vitro and in vivo studies. Two reviews by the International Agency for Research on Cancer (IARC) provided most of the information for glycidol ( IARC 2000 ) and propylene oxide ( IARC 1994 ) and primary studies were used to update or supplement this information ( see Appendix D, Ta ble D

- 5 )

. Both glycidol (known metabolite in rats) and propylene oxide (postulated metabolite) are mutagenic in bacteria, yeast, Drosophila , and mammalian cells; they are direct

- acting mutagens, as the addition of metabolic activation did not change the response. Both metabolites have been shown to form DNA adducts, and both induce DNA damage andRoC Monograph on 1

- Bromopropane 9/25/13

39 chromosomal damage in vitro in rodent and human cells. Available in vivo test results for glycidol indic ate that it induces micronucleus formation but not chromosomal aberrations (CA) in the mouse. Studies of propylene oxide for chromosomal damage reported positive responses in mouse bone marrow for micronucle us induction and chromosomal aberration tests, as well as DNA damage in the sister chromatid exchange (SCE) assay, but results with monkey lymphocytes for both CA and SCE were negative. In occupationally exposed propylene oxide workers, DNA damage was induced in the SCE assay, and both DNA and hemoglobin (protein) adducts were formed. Propylene oxide has also been shown to bind to DNA in rodents and to hemoglobin in rodents, dogs, and monkeys. Other 1

- bromopropane metabolit es have been shown to be direct

- acting mutagens and to induce DNA damage in bacteri a.

- Bromohydrin and 3

- bromo

- 1

- propanol were mutagenic in the S. typhimurium reversion assay, and 3

- bromo

- 1

- propanol and 1

- bromo

- 2

- propanol induced DNA damage in E. coli

.

5.1.7 Synthesis of results Studies in vivo show that 1

- bromopropane can covalently bind to protein in exposed rats and occupationally exposed workers. The available data provide some support that 1

- bromopropane is genotoxic as it induced mutations in bacterial and mammalian cells and DNA damage in human cells . There is limited evidence that DNA damage was induced in leukocytes from 1

- bromopropane

– exposed workers. 1

- Bromopropane did not induce chromosomal damage in exposed rodents ( micronucleus induction assay) or gene

cell mutations ( dominant letha l mutation assay )

.

Table 5

- 1 . Summary of 1

- bromopropane genotoxicity information

Effect In vitro In vivo

Rodents Humans

Mutation Bacteria Mammalian cells ± a

+ NT NT
DNA damage + NT + Micronuclei induction NT

– NT
Dominant lethal mutation NT

– NT + = positive, ± = both positive and negative,

– = negative. NT = not tested.

a Positive in the only study whose design was appropriate for testing volatile chemicals.
Several known or postulated metabolites of 1

- bromopropane have been iden tified as mutagens and two, glycidol and propylene oxide (proposed), were shown to cause chromosomal and DNA damage in cultured mammalian cells . Both metabolites caused chromosomal damage in cells from rodents exposed in vivo , and propylene oxide induced D NA damage in cells from exposed workers (Table 5

- 2)

. Three other 1

- bromopropane metabolites (

- bromohydrin, 3

- bromo

- 1

- propanol, and 1

- bromo

- 2

- propanol) were mutagenic or caused DNA damage in bacteria (Table 5

- 2).9/25/13 RoC Monograph on 1

- Bromopropane

40 Table 5

- 2 . S ummary of genotoxicity data for 1

- bromopropane metabolites a

Effect Metabolite In vitro (cell type b ) In vivo (mammals) Humans (Epidemiology studies)

DNA adducts Glycidol Propylene oxide + (mammal)

+ (bacteria, mammal) NT + (rodents, dogs) NT

+ Mutation Glycidol Propylene oxide

- Bromohydrin 3

- Bromo

- 1

- propanol 1

- Bromo

- 2

- propanol + c

+ c

+ (bacteria)

+ (bacteria) NT NT

– (germ cell) NT NT NT NT NT NT NT NT DNA damage Glycidol Propylene oxide

- Bromohydrin 3

- Bromo

- 1

- propanol 1

- Bromo

- 2

- propanol + d

+ d
NT

+ ( bacteria)

+ (bacteria) NT NT NT NT NT NT

+ NT NT NT Chromosomal damage Glycidol Propylene oxide + (mammal, human) + (mammal, human) ± (rodents)

+ (rodents);

– (monkeys) NT Inc NT = not tested; Inc = inconclusive, + = positive,

– = negative, ± = pos i tive and negative results.

a Does not include findings from insect studies or gene conversion studies in yeast.
b Positive in bacteria, yeast, mammalian cells, and human cells.

c Positive in bacteria, yea st, and mammalian cells. d Positive in bacteria, mammalian cells, and human cells.

5.2 Relevant toxicological effects
1

- Bromopropane has caused neurological, developmental, reproductive, immunological, and hepatotoxic effects in roden ts and neurological effec ts in humans ( Lee et al. 2007a
, Lee et al. 2010a
, Lee et al. 2010b
, NTP 2003a
, 2011a )

. S tudies on t oxic effects were reviewed (see Appendix E ) to determine whether they could inform potential mechanisms of carcinogen icity. Several studies indicate that metabolic activation and glutathione depletion are important factors for many of the toxic effects observed in rodents. Appendix E provides a brief review of the toxic effects that have been linked to metabolic activation and/or glutathione depletion and oxidative stress and other alterations, and provide s background information for Section 5.3, which discus s es t hese mechanisms as they relate to carcinogenicity.

5.3 Mechanistic considerations
T he biological ev ents associated with chemically induced cancer are not completely understood even for chemicals that have been extensively studied and are known to cause cancer in humans (e.g., benzene and arsenic) ( Guyton et al. 2009 )

. It is important to recognize that chemicals can act through multiple toxicity pathways and mechanisms to induce cancer or other health effects, and the relative importance of the various pathways may vary with life stage, genetic background, and dose. Thus, it is unlikely that for anyRoC Monograph on 1

- Bromopropane 9/25/13

41 chemical a single mechanism or mode of action will fully explain the multiple biological alterations and toxicity pathways that can cause normal cells to tr ansform and ultimately form a tumor.
Although no studies were identified that were specifically designed to investigate possible modes of action for 1

- bromopropane

– induced carcinogenesis, the available data indicate that metabolic activation , genetic damage, and oxidative stress from glutathione depletion are important factors. As discussed in the previous section, these factors were linked to several of the primary non

- neoplastic toxic effects of 1

- bromopropane, including immunosuppression , neurotoxic ity, reproductive toxicity, and hepatotoxicity

. Other factors that have been associated with carcinogenesis and may be relevant for 1

- bromopropane are discussed and include immune

- response modulation, altered cell signaling and gene expression, inflammation, and cytotoxicity and compensatory cell proliferation.

5.3.1 Metabolic activation and genotoxicity As mentioned above
, there is some evid e nce that 1

- b romopropane and its metabolites are mutagenic and genotoxic (see Section 5.1). Metabolism of many halogenated hydrocarbons results in the formation of highly reactive oxidative intermediates that can alkylate proteins and nucleic acids ( Morgan et al. 2011 ) . Reactive metabolites of 1

- bromopropane include bromoacetone (1

- bromo

- 2

- propanone) , glycidol, propylene oxide ( p roposed ), and

- bromohydrin (see Section 5.1.6)

. Bro moacetone and other

- bromoketones have been shown to disrupt enzymatic processes by alkylating trypsin at histidine residues or glutathione

- S

- transferases at cysteine residues ( Beeley and Neurath 1968
, Mitchell et al. 1998 )

. Garner et al. ( 2006 ) reported that rats pretreated with ABT, a potent inhibitor of CYP , had a 10

- f old reduction in hepatic radiochemical content (4.1 to 0.46 g equivalents per gram of tissue) suggesting that oxidati ve metabolism leads to more reactive species.

5.3.2 Oxidative stress O xidative stress due to cellular glutathione depletion could contribute to t he carcinogenicity of 1

- bromopropane ( Morgan et al. 2011 )

. Although no studies were identified that directly investigated the possible role of glutathione levels and oxidative stress in 1

- bromopropane

– induced carcinogenicity , s everal studies have shown evidence that exposure to 1

- bromopropane causes toxic effects in the liver and in the r eproductive and nervous systems of mice and rats that are associated with glutathione depletion and oxidative stress ( Huang et al . 2011, Lee et al. 2007a
, Lee et al. 2005a
, Lee et al. 2005b
, Lee et al. 2010a
, Lee et al. 2007b
, Lee et al. 2010b
, Liu et al. 2009
, Liu et al. 2010
, Subramanian et al . 2012 )

. A dose

- dependent depletion of glutathione by 1

- bromopropa ne was reported in mice (Lee et al. 2007 a, b ), and a role for Cyp2e1 metabolism in this effect was indicated by a greater depletion of glutathione in wild

- type mice than in Cyp2e1 knockout mice (Garner et al. 2007). Oxidative stress in rodents exposed to 1

- bromopropane is consistent with dose

- dependent increases in oxidative stress markers (ROS, RNS) in rat cerebellum (Subramanian et al. 2012), increased lipid peroxidation in male mice (Liu et al. 2010), and altered expression of oxidative stress genes (NQO 1 and HO

- 1) in mice (L iu et al. 2009, Liu et al. 2010) (for more information, see Appendix E )

.9/25/13 RoC Monograph on 1

- Bromopropane

42 Glutathione conjugation is generally regarded as a detoxification mechanism ( Morgan et al. 2011 ) . Most of the urinary metabolites of 1

- bromopropane are derived from glutathione conjugates, thus, chronic exposure could produce levels of metabolites that exceed the amount of glutathione available for conjugation. Glutathione levels also may be depleted by oxidative metabolites that inhibit enzymes required for glutathione synthesis. Liu et al. ( 2009 ) also reported lower hepatocellular glutathione

- S

- transferase (GST) activity in susceptible mouse strains exposed to 1

- bromop ropane. Lower GST activity could reduce glutathione conjugation and increase toxicity. Huang et al. ( 2011 ) reported differential expression of several proteins in the hippocampus of rats exposed to 1

- bromopropane that support the hypothesis that oxidative stress plays a role in 1

- bromopropane

– induced damage. These proteins included HSP60, GRP78, DJ

- 1, GSTA3, a nd GSTP1. The proteins HSP60, GRP78, GSTA3, and GSTP1 were up

regulated after 1

- bromopropane exposure. HSP60 is a mitochondrial matrix protein induced by various kinds of stresses and GRP78 is an endoplasmic reticulum

- resident molecular chaperone that supp resses oxidative stress

. GSTA3 and GSTP1 belong to a family of detoxification enzymes that also protect against oxidative stress. DJ

- 1 has been shown to prevent oxidative stress in age

- related neurodegeneration and was down

regulated after 1 week of exposu re. Thus down

- regulation of DJ

- 1 could result in increased oxidative stress.

5.3.3 Immunosuppression and other factors
Immune

- response modulation, cell signaling, altered gene expression, inflammation, and cytotoxicity and compensatory cell proliferation are ot her key events that have been associated with carcinogenesis. Recent studies have shown that 1

- bromopropane causes immunosuppression in rodents ( Anderson et al. 2010
, Lee et al. 2007a
, Lee et al. 2007b )

. In particular, deleterious effects on T

- cell numbers and subpop ulations were reported. Since T

- cells play an impor tant role in detecting and eliminating tumor cells
, a compromised immune system could facilitate tumor progression ( Töpfer et al. 2011 )

. Anderson and Rice ( 1987 ) demonstrated that athymic nude mice that do not have T

- cells were more sensitive to skin tumorigenesis that euthymic mice. In addition, d ata from genetic, disease, and drug

- induced immunosuppressi on in humans have consistently shown that immunosuppression is associated with an increased risk of skin tumors and certain other cancers ( DePry et al. 2011
, Kuschal et al. 2012
, Weaver 2012 ) . However, a possible role of immunosuppression in 1

- bromopropane

– induced skin cancer in rodents has not been described.

Chronic inflammation w as one of the key events associated with various carcinogenic modes of action ( Guyton et al. 2009 )

. In a series of studies, Han et al. ( 2008
, 2012 ) investigated the effect of 1

- bromopropane on nitric oxide and proinflammatory cytokine production and the role of NF

- B in 1

- bromopropane

– mediated inducible nitric oxide synthases (iNOS) and proinflammatory cytokine expression in mouse mac rophages. iNOS catalyzes the formation of nitric oxide and may be an important mediator of carcinogenesis in some circumstances . Overexpression of iNOS has been described in human cancer
, and tumor

- associated production of nitric oxide by iNOS may elevate tumor progression. 1

- Bromopropane caused pro inflammatory changes in mouse macrophages including upregulation of iNOS and cytokines ( IL

- 1 , IL

- 6, and TNF

- ),RoC Monograph on 1

- Bromopropane 9/25/13

43 enhanced the production of prostaglandin E 2 ( PGE 2 )
, and dose

- dependently increased cyclooxygenase

- 2 ( COX

- 2 ) protein and mRNA levels. Increased PGE 2 production may contribute to the tumorigenic process through effects on cell proliferation, apoptosis, and vascular growth. Thus, 1

- bromopropane exposure induced a variety of effects, includi ng increased levels of proinflammatory cytokines, increased macrophage activation, and over expression of COX

- 2, that collectively support the assertion that 1

- bromopropane induces inflammation

. Exposure

- related increased incidences of chronic respiratory tract inflammation (nasal cavity, larynx, and trachea) occurred in rats, and increased incidences of cytoplasmic vacuolization in the nasal cavity, larynx, trachea, and bronchiolar epithelium occurred in mice ( NTP 2011a ) . Bronchiole regeneration also was significantly increased in exposed male and female mice. These lesions are indicative of local irritant effects, but there was no apparent association with carcinogenic effec ts because lung tumors occurred only in female mice
, and upper respiratory tract tumors were not increased in mice or rats.
There is also some evidence from neurotoxicity studies in rodents that 1

- bromopropane causes hyperexcitability of the hippocampus du e to dysfunction of

- aminobutyric acid (GABA) feedback inhibition ( Fueta et al. 2004
, Fueta et al. 2002a
, Mohideen et al. 2009 ) (s ee Appendix E )

. Although a primary role of GABA is as an inhibitory neurotransmitter in the adult mammali an nervous system, there is substantial evidence that it is involved in the proliferation, differentiation, and migration of several cell types, including cancer cells ( Watanabe et al. 2006 )

. Young and Bordey ( 2009 ) reported that GABAergic signaling and its control over proliferation is widespread through peripheral organs containing adult stem cells (e.g., liver, pancreas, kidney, intestine, prostate, testis, and ovary). GABA is a strong inhibitor of cell proliferation; however, it is possible that altered GABAergic signaling in tumors cells leads to abnormal proliferation. Tatsuta et al. ( 1990 ) demonstrated that GA BA or a GABA B receptor agonist inhibited N

- methyl

- N'

- nitro

- N

- nitrosoguanidine

- induced gastric carcinogenesis in Wistar rats. Maemura et al. ( 2003 ) examined the expression of GABA in human intramucosal colonic tumors. Tissue samples included 56 protruded

- type colonic tumors that were classified as adenocarcinoma, adenoma with severe atypia, or adenoma with mild to moderate atypia. The level of GABA expression was proportional to the degree o f atypia in colonic neoplasms and was proposed as a possible tumor marker. Schuller et al. ( 2008 ) reported that GABA may have tumor suppressor function in small airway epithelia and that downregulation of GABA by nicotine

- derived carcinogens may contribute to lung cancer in smokers.

5.3.4 Sex differences in chemical carcinogenesis Sex differences were observed for 1

- bromopropane

– induced tumors in both rats and mice in the NTP experimental animal studies, as described in detail in Section 4. While both sexes of rats developed large intestinal tu mors, t he incidence was higher in females; skin tumors were induced in male rats, but the findings were only equivocal in females. In mice, lung tumors were observed in females but not in males.
In a recent survey of 278 chemicals identified as carcinogen ic in rats in the NTP 2

- year bioassay, 201 exhibited statistically significant sex differences ( P < 0.05) in at least one9/25/13 RoC Monograph on 1

- Bromopropane

44 non

- reproductive organ (Kadekar et al. 2012) with males showing a dominance: t umors were induced in non

- reproductive organs in male ra ts for 130 chemicals and in females for 59

. Induction of both s kin tumor s and tumors of the large intestine were significantly greater in male rats ( P < 0.05) , which is consistent for the skin tumors but not the large intestinal tumor findings for 1

- bromop ropane. However, this general pattern of increased incidence in males is based on a review of a large database of multiple chemicals, which may induce tumors via more than one mechanism. G reater male susceptibility to cancer has also been noted in surveys of human cancers (Cook et al. 2009, E d gren et al. 2012); however, no clear explanation for the male dominance in rats or humans was apparent.

As discuss ed in Section 2.2.4 and Appendix E , CYP2E1 and glutathione S

- transferase (GST) are important in 1

- bromopropane metabolism and toxicity and thus probably play a role in carcinogenicity . There is some evidence that there are sex differences in enzymatic activity in 1

- bromopropane

– exposed rats. p

- Nitrophenol hydroxylase ( p NPH )
, a ssociated with CYP2E1 expression
, and NADPH b 5 reductase levels increased in a dose

dependent fashion and were consistently higher in male than female rats for the control treatment and all doses tested

. GST and lipid peroxide (LPO) levels also increased w ith increasing dose; in general, GST levels were higher in males, however LPO levels were higher in females (Kim et al. 1999b). It is unclear how these sex differences in enzymatic activity translate to sex differences in tumor incidence in 1

- bromopropane

– exposed rats; some of the differences would suggest a potential increase in reactive oxygen species or oxidative damage (CYP2E1 in males), while others suggest a decrease (e.g., LPO*). It is also not known if sex differences occur similarly at other tissue sites.

In mice, an evaluation of the NTP 2

- year bioassay historical control database indicates that there is a sex difference in the spontaneous incidence of lung tumors: 32% of males had tumors, compared with 8% of females (see NTP database http://ntp.niehs.nih.gov/go/datasearch ). No studies looking at gender differences specific for 1

- bromopropane exposure in mice were identified; however, normal CYP2E1 expression measured in mice was found to vary by tissue type as well as by sex (Chanas et al. 2003). Expression was significantly greater in the kidneys of males and slightly higher (non

- significant) in lungs of females, but no sex difference was observed in the liver.

Overall, 1

- bromopropane caused tumors at different sites in male and female rats and mice, and some data from the NTP database for chemical carcinogenesis were consistent with the observed pattern; however, there is limited information on sex differences in 1

- bromopropane metabolism or other mechanistic data.

5.4 Carcinogenicity of 1

- bromopropane metabolites and analogues While 1

- bromopropane and other halogenated hydrocarbons are generally stable compounds, they can undergo metabolism or bioactivation that results in toxic effects, usually subsequent to dehalogenation, i.e., their toxicity is generally associated with the reactive, electrophilic metabolites formed from the carbon skeleton rather than with the halide ion released from the molecule ( Anders 1983 )

.RoC Monograph on 1

- Bromopropane 9/25/13

45 5.4.1 Metabolites Glycidol i s the only urinary metabolite of 1

- bromopropane that has been tested for carcinogenicity ; it is currently listed as reasonably anticipated to be a human carcinogen by the NTP ( 2011b ) . Propylene oxide, a proposed intermediate metabolite of 1

- bromopropane, also is currently listed as reasonably anticipated to be a human carcinogen by the NTP ( 2011c )

. - Bromohydrin is another re active metabolite of 1

- bromopropane, but it has not been tested for carcinogenicity.
Oral administration of glycidol caused benign and malignant tumors at multiple tissue sites in rats and mice ( NTP 1990 ) . Organs and tissues affected in rats included the oral mucosa, forestomach, glandular stoma ch, intestines, mammary glands, skin, tunica vaginalis , clitoral gland, thyroid gland, brain, and Zymbal gland. Tissues affected in mice included the mammary glands, forestomach, Harderian gland, lung, liver, skin, uterus, and urinary bladder. The tumor pr ofile for glycidol was more varied than that for 1

- bromopropane but there were some similarities. In particular, glycidol and 1

- bromopropane induced mesothelioma in the tunica vaginalis covering the epididymis and testes, benign but rare intestinal tumors, and skin tumors in rats. Glycidol also induced lung tumors in male mice, while 1

- bromopropane induced lung tumors in female mice. Glycidol also has induced immunosuppressive effects in mice ( Guo et al. 2000 )

. Propylene oxide caused benign and malignant tumors in rats and mice at several tissue sites when administered by inhalation, stomach tube, or s.c. injection ( IA RC 1994 ) . Rats developed nasal cavity, adrenal gland, forestomach, abdominal cavity, and mammary tumors. Mice devel oped nasal

- cavity and injection

- site tumors.

5.4.2 Analogues 1

- Bromopropane is one member of the large class of halogenated alkane s, and chemic al characteristics shared by these related molecules could be informative for the carcinogenicity of 1

- bromopropane. In general, the presence of a halogen substituent on a carbon atom has an electron

- withdrawing effect making the carbon atom more electroph ilic, which increases the reactivity of the carbon atom ( van Hylckama Vlieg and Janssen 2001 ) . Among the halogens, bromine is recognized as a better leaving group than the smaller, more electr onegative chlorine and fluorine atoms. Thus, halogenated, and particularly brominated, alkanes would be expected to more readily form activated intermediates that could covalently modify biological molecules. Activated intermediates may result from bioacti vation by CYP . These bioactive (electrophilic) compounds can also be conjugated by the nucleophile, glutathione
, a reaction catalyzed by glutathione

- S

transferases (GSTs) ( Anders 1982
, 2001 ) . Exposure of mice to 1

- bromopropane causes hepatotoxicity and may be related to glutathione depletion associated with conjugate formation and subsequent formation of reactive oxygen species (see Section 5.2.3)

. Since glutathione is an important cellular defense mechanism against reactive oxygen species, reduced levels of glutathione can lead to oxidative stress, enhanced toxicity, and possibly carcinogenicity.
The nearest structural analogue for 1

- bromopropane is 2

- bromopropane, an isomer that has not been tested for carcinogenicity. However, 2

- bromopropane has been studied in a number of genotoxicity assays. Similar to 1

- bromopropane, 2

- bromopropane caused9/25/13 RoC Monograph on 1

- Bromopropane

46 base

- pair mutations in Salmonella strains TA100 and TA1535 ( NTP 2003b ) and DNA damage in cultures of rat Leydig c ells ( Wu et al. 2002 ) , but did not induce chromosomal aberrations in Chinese hamster lung cells . In rodents, it induced micronucleus formation in embryos from pregnant mice exposed to 2

- bromopropane by i.p. injection but did not

cause micronuclei in bone marrow of adult rats exposed by i.p. injection

. 2

- Bromo propane also formed N 7

- isopropyl guanine adducts ( Zhao et al. 2002 ) and caused massive depurination ( Sherchan et al. 2009a
, Sherchan et al. 2009b ) . Unrepaired apurinic sites lead to lethality or base substitution errors. Although 2

- bromoprop ane causes similar types of toxicities ( neurological [ Yu et al. 2001 ] , hematological [ Kim et al. 1999a ]
, immunological [ Anderson et al. 2010 ]
, and reproductive [ NTP 2003b ] ), the primary me tabolic products are different from those of 1

- bromopropane.
Other analogues for 1

- bromopropane are monobrominated, short

- chain alkanes, such as bromomethane, bromoethane , 1

- bromobutane, and 2

- bromobutane. Bromomethane (methyl bromide) is classified by NIOSH as a potential occupational carcinogen ( CDC 2010 ) and by IARC as Group 3, not classifiable as to its carcinoge nicity in humans , but neither it nor the bromobutane isomers have been tested in 2

- year bioassays by the NTP or reviewed for the Report on Carcinogens. Bromoethane has been tested in a 2

- year bioassay by the NTP, and it is listed by IARC as Group 3; it has not been reviewed by NTP for the Report on Carcinogens. Bromoethane is classified by the American Conference of Governmental Industrial Hygienists as A3, confirmed animal carcinogen with unknown relevance to humans.
While the examination of the potential carcinogenicity of all members of the large class of halogenated alkanes is beyond the scope of this document, several halogenated alkanes (bromodichloromethane, carbon tetrachloride, chloroform, 1,2

- dibromo

- 3

- chloropropane, 1,2

- dibromoethane (ethylene dib romide), 1,2

- dichloroethane, dichloromethane, hexachloroethane, and 1,2,3

- trichloropropane) are listed in the NTP Report on Carcinogens as reasonably anticipated to be a human carcinogen and classified by IARC as possible or probable carcinogens. In additi on to the analogues described above, more than a dozen other halogenated alkanes have been reviewed by IARC and listed as Group 3. No mechanistic data were identified to suggest that these molecules would act by a common mechanism with 1

- bromopropane and t hey are not discussed further here.

A search of the IARC website ( www.iarc.fr ) identified 1 2 additional halogenated alkanes that had been reviewed by IARC and placed in Group 3, i.e., not classifiable as to their

car cinogenicity in humans. The majority of these molecules ( bromoform [ tribromomethane ] , chlorodibromomethane, chloroethane, chlorofluoromethane, 2

- chloro

- 1,1,1,

- trifluoroethane, 1,2

- dichloropropane, methyl iodide, pentachloroethane, and 1,1,2

- trichloroetha ne ) were reported to have no epidemiological data relevant to their carcinogenicity and limited data in experimental animals. One other molecule (chlorodifluoromethane) also had limited data in experimental animals and data in humans were considered inadequa te ; the last two molecules (methyl chloride and 1,1,1

- trichloroethane) had inadequate data in both humans and experimental animals. Two halogenated alkanes (1,1,1,2

- tetrachloroethane and 1,1,2,2

- tetrachloroethane) have been recently listed by IARC as Group 2B, possibly carcinogenic to humans, and are pending publication in Volume 106.RoC Monograph on 1

- Bromopropane 9/25/13

47 

## 6 Overall Cancer Evaluation

– Synthesis of Animal, Human, and Mechanistic Data

This section synthesizes the information from the animal and mechanistic studies and applies the R oC listing criteria to that body of knowledge to reach a preliminary listing recommendation. No epidemiological studies were identified that evaluated the relationship between human cancer and exposure specifically to 1

- bromopropane. As stated in Section 4 , cancer studies in experimental animals identified 1

- bromopropane

– induced tumor s in the intestine, skin, and lung s that met the RoC criteria for sufficient evidence of carcinogenicity in experimental animals. That assessment did not consider data on mecha nis ms of carcinogenesis . This section (1) briefly summarizes the assessment of the cancer studies in experimental animals (as reported in Section 4) and (2) discusses the data on mechanis ms of carcinogenesis and metabolism of 1

- bromopropane reported in Sections 2 and 5, including a synthesis of the information available from studies in humans. The RoC listing recommend ation for 1

- bromopropane follows the discussion.

6.1 Cancer studies in experimental animals Inhalation exposure to 1

- bromopropane increase d the incidence s of skin tumors (keratoacanthoma ; keratoacanthoma and squamous

- cell carcinoma combined ; and keratoacanthoma, squamous

- cell carcinoma, basal

- cell adenoma, and basal

- cell carcinoma combined) in male rats, large

- intestine tumors (aden oma of the colon and rectum) in rats of both sexes , and lung tumors (alveolar/bronchiolar adenoma and carcinoma) in female mice. Increase d incidences of skin tumors in male rats, intestinal tumors in female rats, and lung tumors in female mice were statist ically significant and dose

- related. The increased incidence of intestinal tumors in male rats, although not statistically significant, was considered to be of biological significance because of the rarity of this type of tumor (incidence of less than 0.2% in historical controls). The incidence of adenocarcinoma of the large intestine was increased in rats of both sexes after oral exposure to brominated methanes (bromodichloromethane or tribromomethane) and in male rats after exposure to glycidol, a metabol ite of 1

- bromopropane. Additional tumors that may have been related to 1

- bromopropane exposure included malignant mesothelioma of the abdominal cavity and pancreatic islet tumors (adenoma) in male rats and skin tumors (keratoacanthoma, basal

- cell adenoma, and basal

- cell carcinoma combined) in female rats.

6.2 Mechanistic and other relevant data No studies were found that evaluat ed mechanisms of carcinogenicity of 1

- bromopropane
at the tumor sites found in experimental animals ( skin, large intestine, and lung )

. However, 1

- bromopropane, either directly or via reactive metabolites, causes molecular alterations related to carcinogen icity , including genotoxicity, oxidative stress, glutathione depletion, immunosuppression, and inflammation (see Section 5.3 for details ). These alterations, observed mainly in vitro and in toxicity studies in rodents, are relevant to possible mechanisms of carcinogenicity in human s and support the relevance of the cancer studies in experimental animals to cancer in human s

.9/25/13 RoC Monograph on 1

- Bromopropane

48 The available studies suggest that both direct effects and metabolic activation are important in 1

- bromopropane

– induced carcinogenesis. There is some evidence that 1

- bromopropane is directly genotoxic. It has been shown to bind to macromolecules
, forming S

- propylcystein e globin adducts in exposed animals and humans . It also caused mutations in bacteria (in the only reported study whose design was appropriate for testing a highly volatile chemical) and cultured mammalian cells with or without exogenous mammalian metabolic activation and DNA damage in cultured human cells without exogenous metabolic activation. In rodent s exposed to 1

- bromopropane in vivo

, negative results were reported for the only two end points measured
, micronucleus formation (in bone marrow or peripher al blood erythrocytes) and dominant lethal mutation . However, the dominant lethal mutation assay detects only germ

- cell mutations and is generally regarded as relatively insensitive for the detection of mutagenic agents

. There is evidence suggesting that metabolic activation plays a role in the genotoxicity and toxicity of 1

- bromopropane. S everal potential reactive metabolites or proposed reactive intermediates have been identified in rodents , including glycidol and

- bromohydrin , and propylene oxide has b een proposed as a metabolite (see Section 2.2). These compounds cause gen otoxic effects in vitro ( including DNA adduct formation
, mutations, and DNA or chromosome damage). Glycidol and propylene oxide cause chromosome damage in vivo and are carcinogenic in experimental animals. Both chemicals are listed in the Report on Carcinogens as reasonably anticipated to be human carcinogens . These reactive and genotoxic metabolites may be responsible for at least some of the carcinogenic effects of 1

- bromopropane. As with 1

- bromopropane
, oral exposure to glycidol caused rare tumors of the large intestine in rats, as did oral exposure
to two halogenated alkane analogues of 1

- bromopropan e, tribromomethane and bromodichloromethane.
Chronic exposure to 1

- bromopropane may produce levels of o xidative metabolites that exceed the capacity for glutathione conjugation or may inhibit enzymes required for glutathione synthesis. T he resulting reduction in glutathione levels can lead to oxidative
stress , increased toxicity, and carc inogenesis. Numerous studies on mechanisms of toxicity in rodents have show n that 1

- bromopropane causes oxidative stress and glutathione depletion. Moreover, studies with Cyp2e1 -/- knockout mice
, cytochrome P450 inhibitors, or a glutathione synthesis inhib itor showed that this pathway (metabolic activation leading to oxidative stress from glutathione depletion) is involved in 1

- bromopropane

- induced toxicity (see Appendix E for details). Although no studies have evaluated the rol e of oxidative stress in 1

- bromopropane

- induced carcinogenicity, oxidative stress is a relevant mechanism for carcinogenicity in humans

.
Other effects associated with 1

- bromopropane that could be relevant to carcinogenesis include immunosuppression and inf lammation. Recent studies in rodents have shown that 1

- bromopropane causes immunosuppression
, increased levels of proinflammatory cytokines, increased macrophage activation, and over production of cyclooxygenase 2 . In addition, there is some evidence from n eurotoxicity studies in rodents that 1

- bromopropane causes reduced GABAergic feedback inhibition. Although GABA ’s primary role is as an inhibitory neurotransmitter in the adult mammalian nervous system,RoC Monograph on 1

- Bromopropane 9/25/13

49 there is substantial evidence that it is involved in the proliferation, differentiation, and migration of several cell types, including cancer cells.
Although the available data on 1

- bromopropane metabol ism , genotoxicity , and mechanis ms of action in humans are limited, they provide some support for the relev ance of the findings in experimental animals to humans. Data on human metabolism of 1

- bromopropane suggest that metabolic pathways are similar in humans and experimental animals. Urinary mercapturic conjugates identified from workers exposed to 1

- bromoprop ane were also reported as urinary metabolites in rodents
, and CYP2E1, the major cytochrome P450 enzyme involved in 1

- bromopropane metabolism, is produced in human lung and other tissues. Although it is likely that humans metabolize 1

- bromopropane to reacti ve metabolites, no studies in humans have explored potential pathways leading to additional metabolites or likely intermediates identified from rodent

or in vitro studies
, such as propylene oxide, glycidol, and

- bromohydrin. Studies of 1

- bromopropane

- exposed workers have found S

- propylcysteine adducts in globin and limited evidence of DNA damage in leukocytes. Case reports and epidemiological studies suggest that 1

- bromopropane causes neurological effects, and studies in experimental anima l s have shown that glutathione depletion and oxidative stress play a role in this toxicity.

6.3 NTP listing recommendation
1

- Bromopropane is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experi mental animals

. These studies found that exposure to 1

- bromoproane caused tumors at several tissue sites in rats and mice. 1

- Bromopropane, either directly or via reactive metabolites, causes molecular alterations that typically are associated with carcinog enesis, including genotoxicity, oxidative stress, and glutathione depletion. These alterations, observed mainly in vitro and in toxicity studies in rodents, are relevant to possible mechanisms of human carcinogenicity and support the relevance of the cance r studies in experimental animals to cancer in human s

.9/25/13 RoC Monograph on 1

- Bromopropane

50 This Page Intentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13

51 

## References

1. Anders MW. 1982. Mechanisms of haloalkane and haloalkene biotransformation. Trends Pharm Sci 3(C): 356

- 357. (Support not reported. Author affiliated with University of Minnesota, MN.)

2. Anders MW. 1983. Bioactivation of halogenated hydrocarbons. J Toxicol Cl in Toxicol 19(6

- 7): 1982

- 1983. (Supported by NIEHS. Author affiliated with University of Minnesota, MN; University of Rochester, NY.)

3. Anders MW. 2001. Formation and fate of reactive intermediates of haloalkanes, haloalkenes, and alpha

- haloacids. Adv Exp Me d Biol 500: 113

- 120. (Supported by NIEHS. Author affiliated with University of Rochester Medical Center, NY.)

4. Anderson LM, Rice JM. 1987. Tumorigenesis in athymic nude mouse skin by chemical carcinogens and ultraviolet light. J Natl Cancer Inst 78(1): 125

- 134. (Supported by the National Cancer Institute. Authors affiliated with NCI

Frederick Cancer Research Facility, MD.)

5. Anderson SE, Munson AE, Butterworth LF, Germolec D, Morgan DL, Roycroft JA, Dill J, Meade BJ. 2010. Whole

- body inhalation exposure to 1

- bromopropane suppresses the IgM response to sheep red blood cells in female B6C3F1 mice and Fisher 344/N rats. Inhal Toxicol 22(2): 125

- 132. (Supported by NIH, the National Institute of Environmental Health Sciences and the National Institute of Occupation al Safety and Health. Authors affiliated with National Institute of Occupational Safety and Health, WV; NIEHS, NC; Batelle, WA.)

6. Barber ED, Donish WH, Mueller KR. 1981. A procedure for the quantitative measurement of the mutagenicity of volatile liquids in the Ames salmonella/microsome assay. Mutat Res 90(1): 31

- 48. (Support not reported. Authors affiliated with Eastman Kodak Company, NY.)

7. Barnsley EA, Grenby TH, Young L. 1966. Biochemical studies of toxic agents. The metabolism of 1

- and 2

- bromopropane in rats. Biochem J 100(1): 282

- 288. (Supported by St. Thomas's Hospital. Authors affiliated wit h St Thomas 's Hospital Medical School, UK.)

8. Beeley JG, Neurath H. 1968. The reaction of trypsin with bromoacetone. Biochemistry 7(3): 1239

- 1251. (Supported by the National Institutes of Health, the National Science Foundation, and the American Cancer Society. Authors affiliated with University of Washington, WA; University of Glasgow, Scotland.)

9. Blando JD, Schill DP, De La Cruz MP , Zhang L, Zhang J. 2010. Preliminary study of propyl bromide exposure among New Jersey dry cleaners as a result of a pending ban on perchloroethylene. J Air Waste Manag Assoc 60(9): 1049

-9/25/13 RoC Monograph on 1

- Bromopropane

52 1056. (Supported by NIOSH. Authors affiliated with New Jersey Depart ment of Health and Senior Services, NJ; University of Medicine and Dentistry of New Jersey, NJ.)

10. Bond JA, Birnbaum LS, Dahl AR, Medinsky MA, Sabourin PJ, Henderson RF. 1988. Disposition of inhaled 1

- chloro

- 2

- propanol in F344/N rats. Toxicol Appl Pharmacol 95(3): 444

- 455. (Supported by the U.S. Department of Energy and NIEHS. Authors affiliated with Lovelace Biomedical and Environmental Research Institute, NM; NIEHS, NC.)

11. CDC. 2008. 1

- BP: A Potential Occupational Hazard . Centers for Disease Control and Preve ntion. http://blogs.cdc.gov/niosh

- science

- blog/2008/12/1bp/

. Accessed on 2/8/12.

12. CDC. 2010. Pocket Guide: Methyl bromide . Centers for Disease Control and Prevention. Updated on 11/18/10. http://ww w.cdc.gov/niosh/npg/npgd0400.html . A ccessed on 12/6/12.

13. Chanas B, Wang H, Ghanayem BI. 2003. Differential metabolism of acrylonitrile to cyanide is responsible for the greater sensitivity of male vs female mice: role of CYP2E1 and epoxide hydrolases. Toxi col Appl Pharmacol 193(2): 293

- 302. (Support not reported. Authors affiliated with NIEHS, NC; University of North Carolina, NC.)

14. Cheever KL, Marlow KL, B'Hymer C, Hanley KW, Lynch DW. 2009. Development of an HPLC

- MS procedure for the quantification of N

- acetyl

- S

- (n

propyl)

- L

- cysteine, the major urinary metabolite of 1

- bromopropane in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 877(8

- 9): 827

- 832. (Support not reported. Authors affiliated with NIOSH, OH.)

15. Chovanec M, Cedervall B, Kolman A. 2001. DNA damage induced by gamma

radiation in combination with ethylene oxide or propylene oxide in human fibroblasts. Chem Biol Interact 137(3): 259

- 268. (Supported by the Swedish Radiation Protection Institute and the Slovak Grant Agency for Science. Au thors affiliated with Cancer Research Institute, Slovakia; Karolinska Institute, Sweden; Stockholm Uniersity, Sweden.)

16. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, Devesa SS, McGlynn KA. 2009. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 18(4): 1174

- 1182. (Supported by NIH. Authors affiliated with National Cancer Institute, MD.)

17. Couch R, Ehrenberg L, Magnusson AL, Nilsson R, de la Rosa ME, Törnqvist M. 1996. In vivo dosimetry of ethylene oxi de and propylene oxide in the cynomolgus monkey. Mutat Res 357(1

- 2): 17

- 23. (Supported by the Swedish Environmental Protection Agency and from the National Swedish Chemicals Inspectorate. Authors affiliated with Coulston Foundation, NM; Stockholm Universit y, Sweden; Universidad National Autonoma de Mexico, Mexico.)RoC Monograph on 1

- Bromopropane 9/25/13

53 18. Craft TD. 2013. Letter to R. Linn [ sic ] , National Toxicology Program, Research Triangle Park, NC from T.D. Craft, Albemarle Corporation, Baton Rouge, LA, March 7, 2013.

19. Czene K, Osterman

- Golkar S , Yun X, Li G, Zhao F, Pérez HL, Li M, Natarajan AT, Segerbäck D. 2002. Analysis of DNA and hemoglobin adducts and sister chromatid exchanges in a human population occupationally exposed to propylene oxide: a pilot study. Cancer Epidemiol Biomarkers Prev 1 1(3): 315

- 318. (Support not reported. Authors affiliated with Karolinska Institute, Sweden; Stockholm University, Sweden; Leiden University Medical Centre, Netherlands; Liaoning Institute of Occupational Health, China; Huludao Chemicals Plant, China; Hulud ao Institute of Occupational Health, China.)

20. DePry JL, Reed KB, Cook

- Norris RH, Brewer JD. 2011. Iatrogenic immunosuppression and cutaneous malignancy. Clin Dermatol 29(6): 602

- 613. (Support not reported. Authors affiliated with Kansas City University of M edicine, KS; Mayo Clinic, MN.)

21. Dröge W, Schulze

- Osthoff K, Mihm S, Galter D, Schenk H, Eck HP, Roth S, Gmünder H. 1994. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J 8(14): 1131

- 1138. (Support not reported. A uthors affiliated with Deutsches Krebsforschungszentrum, Germany.)

22. Dröge W, Breitkreutz R. 2000. Glutathione and immune function. Proc Nutr Soc 59(4): 595

- 600. (Support not reported. Authors affiliated with Deutsches Krebsforschungszentrum, Germany.)

23. Edgre n G, Liang L, Adami HO, Chang ET. 2012. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol 27(3): 187

- 196. (Supported by the Svenska Sällskapet för Medicinsk Forskning (SSMF). Authors affiliated with Karolinska Institutet, Sweden; Harvard Schoo l of Public Health, MA; Cancer Prevention Institute of California, CA; Stanford University School of Medicine, CT.)

24. Eisenberg J, Ramsey J. 2010. Evaluation of 1

- Bromopropane Use in Four New Jersey Commercial Dry Cleaning Facilities . Health Hazard Evaluatio n Report HETA 2008

- 0175

- 3111. National Institute for Occupational Safety and Health. 28 pp.

25. El Ramy R, Ould Elhkim M, Lezmi S, Poul JM. 2007. Evaluation of the genotoxic potential of 3

- monochloropropane

- 1,2

- diol (3

- MCPD) and its metabolites, glycidol and β

- chlorolactic acid, using the single cell gel/comet assay. Food Chem Toxicol 45(1): 41

- 48. (Supported by the French Food Safety Agency and Afssa. Authors affiliated with Agence Française de Sécurité Sanitaire des Aliments, France; Aventis Pharma, France.)9/25/13 RoC Monograph on 1

- Bromopropane

54 26. Elf Atochem. 1994. Ames Test

-- Reverse Mutation Assay on Salmonella typhimurium. n

- Propyl Bromide . HIS1005/1005A. Study performed by Sanofi Recherche. Service de Toxicologie (as cited in NTP 2003a)

.
27. Elf Atochem. 1995. Acute Dermal Toxicity in Rats. N

- propy l bromide . Study No. 13113 Tar. Miserey, France: Study Director, Stephane de Jouffrey. Centre International de Toxicologie (as cited in NTP 2003a)

.
28. Elf Atochem. 1996. In vitro mammalian cell gene mutation test in L5178Y TK+/

- mouse lymphoma cells of n

- prop yl bromide . Study No. 13293. Miserey, France: Study Director, B. Molinier. Centre International de Toxicologie (as cited in NTP 2003a)

.
29. EPA. 2007 . Protection of stratospheric ozone: listing of substitutes for ozone

depleting substances n

- propyl bromide in solvent cleaning Fed Reg 72(103): 30142

- 30167.

30. EPA. 2011. List of Lists: Consolidated List of Chemicals Subject to the Emergency Planning and Co mmunity Right

- To

- Know Act (EPCRA), Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) and Section 112(r) of the Clean Air Act . EPA 550

- B

- 10

- 001. U.S. Environmental Protection Agency. 98 pp.

31. EPA. 2012. Non

- confidential IUR Produc tion Volume Information . U.S. Environmental Protection Agency. http://cfpub.epa.gov/iursearch/index.cfm and search by CAS no.

32. ESIS. 2012. 2012 ACGIH TLV Updates: March 2012 Newsletter . Cromwell, CT: ESIS Environmental Health Lab.

33. Fabiani R, Rosignoli P, De Bartolomeo A, Fuccelli R, Morozzi G. 2012. Genotoxicity of alkene epoxides in human peripheral blood mononuclear cells and HL60 leukaemia cells evaluated with the comet assay. Mutat Res 747(1): 1

- 6. (Support not reported. Authors affiliated with Università di Perugia, Italy.)

34. FR. 2003. Protection of stratospheric ozone; Listing of substitutes for ozone

depleting substances

- n

- propyl bromide. Fed Reg 68(106): 33284

- 33316.

35. FR. 2007. Protection of s tratospheric ozone: Listing of substitutes for ozone

depleting substances

- n

- propyl bromide in adhesives, coatings and aerosols. Fed Reg 72(103): 30168

- 30207.

36. Frasch HF, Dotson GS, Barbero AM. 2011. In vitro human epidermal penetration of 1

- bromopropane. J Toxicol Environ Health A 74(19): 1249

- 1260. (Support not reported. Authors affiliated with NIOSH, WV and OH.)

37. Fueta Y, Fukunaga K, Ishidao T, Hori H. 2002a. Hyperexcitability and changes in activities of Ca 2+ /calmodulin

- dependent kinase II and mitogen

- a ctivatedRoC Monograph on 1

- Bromopropane 9/25/13

55 protein kinase in the hippocampus of rats exposed to 1

- bromopropane. Life Sci 72(4

- 5): 521

- 529. (Supported by the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Labor for Occupational Health Studies. Authors af

filiated with University of Occupational and Environmental Health, Japan; Kumamoto University, Japan.)

38. Fueta Y, Ishidao T, Arashidani K, Endo Y, Hori H. 2002b. Hyperexcitability of the hippocampal CA1 and the dentate gyrus in rats subchronically exposed to a substitute for chlorofluorocarbons, 1

- bromopropane vapor. J Occup Health 44(3): 156

- 165. (Supported by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Labor for Occupational Health Studies. Authors affiliated with University of Occupational and Environmental Health, Japan.)

39. Fueta Y, Fukuda T, Ishidao T, Hori H. 2004. Electrophysiology and immunohist ochemistry in the hippocampal CA 1 and the dentate gyrus of rats chronically exposed to 1

- bromopropane, a substitute for specific chlorofluorocarbons. Neuroscience 124(3): 593

- 603. (Supported by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Labor for Occupational Health Studies. Authors affiliated with University of Occupational and Environmental Health, Japan; Kyushu University, Japan.)

40. Fueta Y, Ishidao T, Ueno S, Yosh ida Y, Kunugita N, Hori H. 2007 . New approach to risk assessment of central neurotoxicity induced by 1

- bromopropane using animal models. Neurotoxicology 28(2): 270

- 273. (Supported by the Ministry of Health, Labour and Welfare of Japan, the Japan Society for the Promotion of Science and the University of Occupational and Environmental Health. Authors affiliated with University of Occupational and Environmental Health, Jap an.)

41. Garner CE, Sumner SC, Davis JG, Burgess JP, Yueh Y, Demeter J, Zhan Q, Valentine J, Jeffcoat AR, Burka LT, Mathews JM. 2006. Metabolism and disposition of 1

- bromopropane in rats and mice following inhalation or intravenous administration. Toxicol Appl Pharmacol 215(1): 23

- 36. (Supported by NIEHS. Authors affiliated with RTI International, NC; National Institute of Environmental Health Sciences, NC.)

42. Garner CE, Sloan C, Sumner SC, Burgess J, Davis J, Etheridge A, Parham A, Ghanayem BI. 2007. CYP2E1

- catalyzed oxidation contributes to the sperm toxicity of 1

- bromopropane in mice. Biol Reprod 76(3): 496

- 505. (Supported by the National Institutes of Health /National Institute of Environmental Health Sciences. Authors affiliated with RTI International, NC; National Institute of Environmental Health Sciences, NC.)

43. Ghanayem BI, Hoffler U. 2007. Investigation of xenobiotics metabolism, genotoxicity, and carcinogenicity using Cyp2e1(

- /

- ) mice. Curr Drug Metab 8(7): 728

- 749. (Supported by the NIH, National Institute of Environmental9/25/13 RoC Monograph on 1

- Bromopropane

56 Health Sciences. Authors affiliated w ith National Institute of Environmental Health Sciences, NC.)

44. Golomb BA. 1999. Chapter 10: Does accumulation of the Bro mide from PB Produce Bromism? In A Review of the Scientific Literature as it Pertains to Gulf War Illness . vol 2. Pyridostigmine Bromide. National Defense Research Institute. http://www.gulflink.osd.mil/library/randrep/pb_paper/mr1018.2.chap10.html

. (Support and author affiliation not reported .)

45. Graul F. 2012

. Summary of Data on Workplace Exposure to n

- Propyl Bromide. Attachment sent with public comment. 8 pp.

46. Grenby TH, Young L. 1959. Isolation of n

- propylmercapturic acid from the urine of animals dosed with 1

- bromopropane. Biochem J 71: P25. (Support not reported. Authors affiliated with St Thomas's Hospital Medical School, UK.)

47. Grenby TH, Young L. 1960. Biochemical studies on toxic agents. 12. The biosynthesis of n

- propylmercapturic acid from n

- propyl halides. Biochem J 75: 28

- 33. (Supported by St. T homas's Hospital. Authors affiliated with St. Thomas's Hospital Medical School, UK.)

48. Guo TL, McCay JA, Brown RD, Musgrove DL, Butterworth L, Munson AE, Germolec DR, White KL, Jr. 2000. Glycidol modulation of the immune responses in female B6C3F1 mice. Drug Chem Toxicol 23(3): 433

- 457. (Supported by NIEHS. Authors affiliated with Virginia Commonwealth University, VA; NIEHS, NC.)

49. Guyton KZ, Kyle AD, Aubrecht J, Cogliano VJ, Eastmond DA, Jackson M, Keshava N, Sandy MS, Sonawane B, Zhang L, Waters MD, Smith MT. 2009. Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res 681(2

- 3): 230

- 240. (Supported by the U.S. EPA, Integrated Laboratory Systems (ILS), Inc., Pfizer, Inc. and NIEHS. Au thors affiliated with U.S. Environmental Protection Agency, Washington, D.C.; University of California

- Berkeley, CA; Pfizer Global Research and Development, CT; International Agency for Research on Cancer, France; University of California

- Riverside, CA ; Integrated Laboratory Systems (ILS), Inc., NC; California Environmental Protection Agency, CA.)

50. Han EH, Hwang YP, Lee KJ, Jeong TC, Jeong HG. 2008. 1

- Bromopropane induces macrophage activation via extracellular signal

- regulated kinase 1/2 MAPK and NF

- κB pathways. Cancer Lett 262(1): 28

- 36. (Supported by the National Institute of Toxicological Research. Authors affiliated with Chosun University, Republic of Korea; Yeungnam University, Republic of Korea.)

51. Han EH, Yang JH, Kim HK, Choi JH, Khanal T, Do MT, C hung YC, Lee KY, Jeong TC, Jeong HG. 2012. 1

- Bromopropane up

- regulates cyclooxygenase

- 2 expression via NF

- κB and C/EBP activation in murine macrophages. FoodRoC Monograph on 1

- Bromopropane 9/25/13

57 Chem Toxicol (In press). (Supported by the National Research Foundation of Korea. Authors affiliat ed with Chungnam National University, South Korea; Korea International University, South Korea; Chonnam National University, South Korea; Yeungnam University, South Korea.)

52. Hanley K, Curwin B, Sanderson W, Johnson B. 2005. Workers’ Exposures to n

Propyl Br omide in Two Foam Fabricating Plants Manufacturing Furniture Polyurethane Seat Cushions in North Carolina . IWSB 232.10. National Institute for Occupational Safety and Health. 22 pp.

53. Hanley KW, Dunn K. 2006. Workers’ Exposures to n

- Propyl Bromide at a Helicopter Transmission Factory . IWSB 232.11. National Institute for Occupational Safety and Health. 21 pp.

54. Hanley KW, Petersen M, Curwin BD, Sanderson WT. 2006a. Urinary bromide and breathing zone concentrations of 1

- bromopropane from workers exposed to flexible foam spray adhesives. Ann Occup Hyg 50(6): 599

- 607. (Supported by the National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS) and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC). Authors affiliated with NIOSH, OH; University of Iowa, IA.)

55. Hanley KW, Dunn K, Sollberger R. 2006b. Workers’ Exposures to n

- Propyl Bromide at an Aerospace Components Manufacturer . IWSB 232.12. National Institute for O ccupational Safety and Health. 26 pp.

56. Hanley KW, Dunn KL. 2007. Workers’ Exposures to n

- Propyl Bromide at an Optical Prism and Optical Assemblies Manufacturer . IWSB 232.15. National Institute for Occupational Safety and Health. 23 pp.

57. Hanley KW, Dunn KL, Johnson B. 2007. Workers’ Exposures to n

- Propyl Bromide at an Adhesives and Coatings Manufacturer . IWSB 232.16. National Institute for Occupational Safety and Health. 24 pp.

58. Hanley KW, Johnson B. 2007a. Workers’ Exposures to n

- Propyl Bromide at a Printed Electronics Circuit Assembly Manufacturer . IWSB 232.14. National Institute for Occupational Safety and Health. 23 pp.

59. Hanley KW, Johnson B. 2007b. Workers’ Exposures to n

- Propyl Bromide at a Hydraulic Power Control Component Manufacturer . IWSB 232.13. Na tional Institute for Occupational Safety and Health. 26 pp.

60. Hanley KW, Petersen MR, Cheever KL, Luo L. 2009. N

- acetyl

- S

- ( n

- propyl)

- l

cysteine in urine from workers exposed to 1

- bromopropane in foam cushion spray adhesives. Ann Occup Hyg 53(7): 759

- 769. (S upported by the NTP, National Institute of Environmental Health Sciences (NIEHS), and the NIOSH Centers for Disease Control and Prevention (CDC). Authors affiliated with NIOSH, OH; Constella Group, OH.)9/25/13 RoC Monograph on 1

- Bromopropane

58 61. Hanley KW, Petersen MR, Cheever KL, Luo L. 2010. Brom ide and N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine in urine from workers exposed to 1

- bromopropane solvents from vapor degreasing or adhesive manufacturing. Int Arch Occup Environ Health 83(5): 571

- 584. (Supported by NTO

- NIEHS and NIOSH. Authors affiliated with NIOS H, OH.)

62. Harney JM, Hess J, Reh CM, Trout D. 2002. NIOSH Health Hazard Evaluation Report. STN Cushion Company, Thomasville, NC . HETA 2000

- 0410

- 2891. Cincinnati, OH: National Institute for Occupational Safety and Health. 54 pp.

63. Harney JM, Nemhauser JB, Reh CM, Trout D. 2003. NIOSH Health Hazard Evaluation Report. Marx Industries, Inc., Sawmills, NC . HETA 99

- 0260

- 2906. Cincinnati, OH: National Institute for Occupational Safety and Health. 64 pp.

64. HSDB. 2006. Hazardous Substances Data Bank . National Library of Medicine. Updated on 4/20/06. http://toxnet.nlm.nih.gov/cgi

- bin/sis/htmlgen?HSDB and search on CAS number or compound name. Last accessed 2/7/12.

65. Huang Z, Ichihara S, Oikawa S, Chang J, Z hang L, Takahashi M, Subramanian K, Mohideen SS, Wang Y, Ichihara G. 2011. Proteomic analysis of hippocampal proteins of F344 rats exposed to 1

- bromopropane. Toxicol Appl Pharmacol 257(1): 93

- 101. (Supported by the Japanese Society for the Promotion of Sci ence. Authors affiliated with Nagoya University Graduate School of Medicine, Japan; Guangdong Prevention and Treatment Center for Occupational Diseases, China; Mie University, Japan.)

66. Hyman J, Leifer Z, Rosenkranz HS. 1980. The E. coli Pol A

- 1 assay: a qua ntitative procedure for diffusible and non

- diffusible chemicals. Mutat Res 74(2): 107

- 111. (Supported by the National Cancer Institute. Authors affiliated with New York Medical College, NY.)

67. IARC. 1994. Propylene o xide. In Some Industrial Chemicals . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 60. Lyon, France: International Agency for Research on Cancer. pp. 181

- 213.

68. IARC. 2000. Glycidol. In Some Industrial Chemicals . IARC Monographs on the Evaluation of Carcinogenic Risks to H umans, vol. 77. Lyon, France: International Agency for Research on Cancer. pp. 469

- 486.

69. Ichihara G, Miller JK, Ziolkowska A, Itohara S, Takeuch i Y. 2002 . Neurological disorders in three workers exposed to 1

- bromopropane. J Occup Health 44(1): 1

- 7. (Support not reported. Authors affiliated with Nagoya University Graduate School of Medicine, Japan; Johnson Neurological Clinic, NC; High Point Regional Hospital, NC.)

70. Ichihara G, Li W, Ding X, Peng S, Yu X, Shibata E, Yamada T, Wang H, Itoha ra S, Kanno S, Sakai K, Ito H, Kanefusa K, Takeuchi Y. 2004a. A survey on exposure level, health status, and biomarkers in workers exposed to 1

-RoC Monograph on 1

- Bromopropane 9/25/13

59 bromopropane. Am J Ind Med 45(1): 63

- 75. (Support not reported. Authors affiliated with Nagoya University, Japan ; WHO Collaborating Center for Research Reproduction, China; Yixing Anti

- epidemic and Health Station, China; National Institute of Industrial Health, Japan; Nagoya City Public Health Research Institute, Japan; Aichi Human Service Center, Japan. )

71. Ichihara G, Li W, Shibata E, Ding X, Wang H, Liang Y, Peng S, Itohara S, Kamijima M, Fan Q, Zhang Y, Zhong E, Wu X, Valentine WM, Takeuchi Y. 2004b. Neurologic abnormalities in workers of a 1

- bromopropane factory. Environ Health Perspect 112(13): 1319

- 1325. (Suppor ted by the Japan Society for the Promotion of Science. Authors affiliated with Nagoya University, Japan; Shanghai Institute of Planned Parenthood Research, China; Aichi Medical University, Japan; Johns Hopkins University School of Medicine, MD; Yixing Anti

- Epidemic and Health Station, China; Vanderbilt University Medical Center, TN.)

72. Ichihara G, Li W, Shibata E, Ding X, Wang H, Li J, Huang F, Peng S, Gu B, Ichihara S, Takeuchi Y. 2006. Exposure to 1

- bromopropane adversely affects vibration sense and nerve c onduction velocity of lower limbs and central nervous system in workers. Clin Toxicol 44(5): 668. (Support not reported. Authors affiliated with Nagoya University Graduate School of Medicine, Japan; Shanghai Institute of Planned Parenthood Research, China; Aichi Medical University, Japan; Yixing Center for Disease Control and Prevention, China; Mie University Functional Genomics Institute, Japan.)

73. Ichihara G, Kitoh J, Li W, Ding X, Ichihara S, Takeuchi Y. 2011. Neurotoxicity of 1

- bromopropane: Evidence from animal experiments and human studies. J Adv Res (In press). (Support not reported. Authors affiliated with Nagoya University, Japan; Shanghai Institute of Planned Parenthood Research, China; Mie University, Japan.)

74. Ishidao T, Kunugita N, Fueta Y, Arashidan i K, Hori H. 2002. Effects of inhaled 1

- bromopropane vapor on rat metabolism. Toxicol Lett 134(1

- 3): 237

- 243. (Support not reported. Authors affiliated with University of Occupational and Environmental Health, Japan.)

75. Johnson CW, Williams WC, Copeland CB, DeVito MJ, Smialowicz RJ. 2000. Sensitivity of the SRBC PFC assay versus ELISA for detection of immunosuppression by TCDD and TCDD

- like congeners. Toxicology 156(1): 1

- 11. (Supported by a Cooperative Research and Development Agreement with E.I. DuPont de N emours & Company and the Dow Chemical Company and NHEERL/ORD/EPA and the U.S. EPA/UNC Research Training Agreement. Authors affiliated with University of North Carolina, NC; U.S. EPA, NC.)

76. Jones AR, Walsh DA. 1979. The oxidative metabolism of 1

- bromopropan e in the rat. Xenobiotica 9(12): 763

- 772. (Support not reported. Authors affiliated9/25/13 RoC Monograph on 1

- Bromopropane

60 with The University of Sydney, Australia; Camperdown Children’s Hospital, Australia.)

77. Kadekar S, Peddada S, Silins I, French JE, Högberg J, Stenius U. 2012. Gender differen ces in chemical carcinogenesis in National Toxicology Program 2

- year bioassays. Toxicol Pathol 40(8): 1160

- 1168. (Supported by the Swedish Research Council for the Environment, Agricultural Sciences and Spatial Planning (FORMAS) and by the Intramural Resea rch Program of the National Institutes of Health, National Institute of Environmental Health Sciences. Authors affiliated with Karolinska Institutet, Sweden; NIEHS, NC.)

78. Kaneko T, Kim HY, Wang PY, Sato A. 1997. Partition coefficients and hepatic metabolism in vitro of 1

- and 2

- b romopropanes. J Occup Health 39(4): 341

- 342. (Support not reported. Authors affiliated with Medical University of Yamanashi, Korea; Research Institute of Industrial Health, Korea.)

79. Kawai T, Takeuchi A, Miyama Y, Sakamto K, Zhang ZW, Higashikawa K, Ikeda M. 2001. Biological monitori ng of occupational exposure to 1

- bromoprop ane by means of urinalysis for 1

- bromopropane and bromide ion. Biomarkers 6(5): 303

- 312. (Support not reported. Authors affiliated with Osaka Occupational Health Service Center, Japan; Kyoto Women’s University, Japan; Kyoto Industrial Health Association, Japan.)

80. Kim H, Chung J, Chung Y, et al . 1998. Toxicological Studies on Inh alation of 1

- Bromopropane Using Rats . Report submitted to the Industrial Health Research Institute

– Korea Industrial Safety Corporation (as cited by NTP 2003a)

.
81. Kim KW, Kim HY, Park SS, Jeong HS, Park SH, Lee JY, Jeong JH, Moon YH. 1999b. Gender differenc es in activity and induction of hepatic microsomal cytochrome P

- 450 by 1

- bromopropane in Sprague

- Dawley rats. J Biochem Mol Biol 32(3): 232

- 238. (Support not reported. Authors affiliated with Industrial Heahh Research Institute, Korea; University of Tokyo, Japan.)

82. Kim Y, Park J, Moon Y. 1999a. Hematopoietic and reproductive toxicity of 2

- bromopropane, a recently introduced substitute for chlorofluorocarbons. Toxicol Lett 108(2

- 3): 309

- 313. (Support not reported. Authors affiliated with Industrial Health Res earch Institute, Korea.)

83. Knöppel H, Schauenburg H. 1989. Sceening of household product for the emission of volatile organic compounds. Environ Int 15: 413

- 418. (Support not reported. Authors affiliated with Commission of the European Communities, Italy.)

84. K olman A, Spivak I, Näslund M, Dušinská M, Cedervall B. 1997. Propylene oxide and epichlorohydrin induce DNA strand breaks in human diploid fibroblasts. Environ Mol Mutagen 30(1): 40

- 46. (Supported by the Swedish Fund for Research Without Animal Experiments , the Swedish Radiation Protection Institute, the Slovak Grant Agency, the European Commission, theRoC Monograph on 1

- Bromopropane 9/25/13

61 Stockholm Cancer Society, the Fund of Karolinska Institute and the Swedish Institute. Authors affiliated with Stockholm University, Sweden; Russian Academy of Sciences, Russia; Institute of Preventive and Clinical Medicine, Slovak Republic; Karolinska Institute, Sweden.)

85. Kuschal C, Thoms KM, Schubert S, Schafer A, Boeckmann L, Schon MP, Emmert S. 2012. Skin cancer in organ transplant recipients: effects of im munosuppressive medications on DNA repair. Exp Dermatol 21(1): 2

- 6. (Supported by the Deutsche Forschungsgemeinschaft DFG, the the Deutsche Krebshilfe, Georg

- August

- University Goettingen and the Niedersächsische Krebsgesellschaft. Authors affiliated with G eorg

- August

- University, Germany.)

86. Lee SK, Jin CH, Hyun SH, Lee DW, Kim GH, Jeon TW, Lee J, Kim DH, Jeong HG, Lee ES, Jeong TC. 2005a. Identification of glutathione conjugates and mercapturic acids of 1,2

- dibromopropane in female BALB/c mice by liquid chrom atography

- electrospray ionization tandem mass spectrometry. Xenobiotica 35(1): 97

- 105. (Supported by KOSEF, Korea. A uthors affiliated with Yeungnam University, Korea; Korea Institute of Science and Technology, Korea; Chosun University, Korea.)

87. Lee SK, Jo SW, Jeon TW, Jun IH, Jin CH, Kim GH, Lee DJ, Kim TO, Lee ES, Jeong TC. 2005b. Hepatotoxic effect of 1

- bromopropane and its conjugation with glutathione in male ICR mice. Arch Pharm Res 28(10): 1177

- 1182. (Supported by Yeungnam University. Authors affiliate d with Yeungnam University, Korea; Kumoh National Institute of Technology, Korea.)

88. Lee SK, Jeon TW, Kim YB, Lee ES, Jeong HG, Jeong TC. 2007a. Role of glutathione conjugation in the hepatotoxicity and immunotoxicity induced by 1

- bromopropane in female BALB /c mice. J Appl Toxicol 27(4): 358

- 367. (Supported by the National Institute of Toxicological Research, KFDA, and from Korea Science and Engineering Foundation. Authors affiliated with Yeungnam University, South Korea; Korea Institute of Toxicology, South Korea; Chosun University, South Korea.)

89. Lee SK, Lee DJ, Jeong H, Bista SR, Kang MJ, Lee ES, Son JK, Nam DH, Chang HW, Lee SH, Jahng Y, Jeong TC. 2007b. Hepatotoxic and immunotoxic effects produced by 1,3

- dibromopropane and its conjugation with glutathione in female BALB/c mice. J Toxicol Environ Health A 70(15

- 16): 1381

- 1390. (Supported by the National Institute of Toxicological Research. Authors affiliated with Yeungnam University, Korea.)

90. Lee SK, Kang MJ, Jeon TW, Ha HW, Yoo JW, Ko GS, Kang W, Jeong HG, L yoo WS, Jeong TC. 2010a. Role of metabolism in 1

- bromopropane

- induced hepatotoxicity in mice. J Toxicol Environ Health A 73(21

- 22): 1431

- 1440. (Supported by the Korea Research Foundation and the Regional Technology Innovation Program of the Ministry of Kno wledge & Economy. Authors9/25/13 RoC Monograph on 1

- Bromopropane

62 affiliated with Yeungnam University, Korea; Chungnam National University, Korea.)

91. Lee SK, Lee DJ, Ko GS, Yoo SH, Ha HW, Kang MJ, Jeong TC. 2010b. Role of glutathione conjugation in 1

- bromobutane

- induced hepatotoxicity in mice. Foo d Chem Toxicol 48(10): 2707

- 2711. (Supported by the National Institute of Food and Drug Safety Evaluation and the Regional Technology Innovation Program of the Ministry of Knowledge & Economy (MKE), Korea. Authors affiliated with Yeungnam University, South Korea.)

92. Li W, Shibata E, Zhou Z, Ichihara S, Wang H, Wang Q, Li J, Zhang L, Wakai K, Takeu chi Y, Ding X, Ichihara G. 2010b . Dose

- dependent neurologic abnormalities in workers exposed to 1

- bromopropane. J Occup Environ Med 52(8): 769

- 777. (Supported by the Japan Society for the Promotion of Science. Authors affiliated with Fudan University, China; Shanghai Institute of Planned Parenthood Research, China; Aichi Medical University, Japan; Mie University Graduate School of Regional Innovation Studies, Japan; N agoya University, Japan.)

93. Li WH, Zhou ZJ, Wang QY, Ichihara G, Takeuchi Y, Ding XC. 2010a. [Effects of 1

- bromopropane on neurological and hematological changes of female exposed workers]. Chin J Ind Hyg Occup Dis 28(5): 339

- 344. (Support unknown due to for eign language. Authors affiliated with Fudan University, China.)

94. Liu F, Ichihara S, Mohideen SS, Sai U, Kitoh J, Ichihara G. 2009. Comparative study on susceptibility to 1

- bromopropane in three mice strains. Toxicol Sci 112(1): 100

- 110. (Supported by the J apanese Society for the Promotion of Science. Authors affiliated with Nagoya University, Japan; Mie University, Japan.)

95. Liu F, Ichihara S, Valentine WM, Itoh K, Yamamoto M, Sheik Mohideen S, Kitoh J, Ichihara G. 2010. Increased susceptibility of Nrf2

- null mice to 1

- bromopropane

- induced hepatotoxicity. Toxicol Sci 115(2): 596

- 606. (Supported by the Japanese Society for the Promotion of Science. Authors affiliated with Nagoya University, Japan; Mie University, Japan; Vanderbilt University Medical Center, TN; Hirosaki University Graduate School of Medicine, Japan; Tohoku University, Japan.)

96. Maemura K, Yamauchi H, Hayasaki H, Kanbara K, Tamayama T, Hirata I, Watanabe M. 2003. γ

- Amino

- butyric acid immunoreactivity in intramucosal colonic tumors. J Gastroenterol H epatol 18(9): 1089

- 1094. (Supported by the Osaka Medical Research Foundation for Incurable Disease and the Ministry of Education, Sports, Culture, Science and Technology of Japan. Authors affiliated with Osaka Medical College, Japan.)RoC Monograph on 1

- Bromopropane 9/25/13

63 97. Majersik JJ, Caravati EM, Steffens JD. 2007. Severe neurotoxicity associated with exposure to the solvent 1

- bromopropane (n

- propyl bromide). Clin Toxicol (Phila) 45(3): 270

- 276. (Support not reported. Authors affiliated with University of Michigan, MI; Uta h Poison Control, UT; University of Utah, UT.)

98. Mathias PI, Cheever KL, Hanley KW, Marlow KL, Johnson BC, B'Hymer C. 2012. Comparison and evaluation of urinary biomarkers for occupational exposure to spray adhesives containing 1

- bromopropane. Toxicol Mech Methods 22(7): 526

- 532. (Support not reported. Authors affiliated with NIOSH, OH.)

99. Mazon G, Philippin G, Cadet J, Gasparutto D, Fuchs RP. 2009. The alkyltransferase

- like ybaZ gene product enhances nucleotide excision repair of O(6)

- alkylguanine adducts in E. coli

. DNA Repair (Amst) 8(6): 697

- 703. (Supported by the The Olefins Panel Ethylene/Propylene Work Group of the American Chemistry Council, The Propylene Oxide and Glycols Sector Group of Cefic, The Ethylene Oxide and Derivatives Sector Group of Cefic a nd The Lower Olefins Sector Group of Cefic. Authors affiliated with CNRS, France; INAC/SCIB, France.)

100. Meyer

- Baron M, Kim EA, Nuwayhid I, Ichihara G, Kang SK. 2012. Occupational exposure to neurotoxic substances in Asian countries

- Challenges and approache s. Neurotoxicology (In press). (Supported by the Ministry of Education, Science, Sports and Culture, Japan and the Japan Society for the Promotion of Science. Authors affiliated with Leibniz Research Centre for Working Environment and Human Factors, German y; Occupational Safety and Health Research Institute, Korea; American University of Beirut, Lebanon; Nagoya University, Japan.)

101. Mirza T, Gérin M, Bégin D, Drolet D. 2000. A study on the substitution of trichloroethylene as a spot remover in the textile ind ustry. AIHAJ 61(3): 431

- 438. (Supported by IRSST. Authors affiliated with Université de Montréal, Canada; IRRST, Canada.)

102. Mitchell AE, Zheng J, Hammock BD, Lo Bello M, Jones AD. 1998. Structural and functional consequences of haloenol lactone inactivation of murine and human glutathione S

- transferase. Biochemistry 37(19): 6752

- 6759. (Supported by the National Institute of Environmental Health Sciences, NIH, with funding provided by EPA and the NIEHS Center for Environmental Health Sciences at the University of California

- Davis. Authors affiliated with University of California

- Davis, CA; University of Rome “Tor Vergata”, Italy; Pennsylvania State University, PA.)

103. MMWR. 2008. Neurologic illness associated with occupational exposure to the solvent 1

- bromopr opane

- New Jersey and Pennsylvania, 2007

- 2008. MMWR 57(48): 1300

- 1302. (Support and author affiliations not reported.)9/25/13 RoC Monograph on 1

- Bromopropane

64 104. Mohideen SS, Ichihara S, Banu S, Liu F, Kitoh J, Ichihara G. 2009. Changes in neurotransmitter receptor expression levels in rat brain a fter 4

- week exposure to 1

- bromopropane. Neurotoxicology 30(6): 1078

- 1083. (Supported by the Japan Society for the Promotion of Science. Authors affiliated with Nagoya University, Japan; Mie University, Japan; National University Hospital, Singapore.)

105. Mohid een SS, Ichihara G, Ichihara S, Nakamura S. 2011. Exposure to 1

- bromopropane causes degeneration of noradrenergic axons in the rat brain. Toxicology 285(1

- 2): 67

- 71. (Supported by the Japan Society for the Promotion of Science. Authors affiliated with Nago ya University, Japan; Mie University, Japan; Yamaguchi University, Japan.)

106. Morgan DL, Nyska A, Harbo SJ, Grumbein SL, Dill JA, Roycroft JH, Kissling GE, Cesta MF. 2011. Multisite carcinogenicity and respiratory toxicity of inhaled 1

- bromopropane in rats an d mice. Toxicol Pathol 39(6): 938

- 948. (Supported by NIH, National Institute of Environmental Health Sciences. Authors affiliated with National Institute of Environmental Health Sciences, NC; Tel Aviv University, Israel; Battelle Toxicology Northwest, WA.)

107. Nivard MJ, Czene K, Segerbäck D, Vogel EW. 2003. Mutagenic activity of ethylene oxide and propylene oxide under XPG proficient and deficient conditions in relation to N

- 7

- (2

- hydroxyalkyl)guanine levels in Drosophila. Mutat Res 529(1

- 2): 95

- 107. (Supported by the Programme ‘INCO

- Copernicus’ of the European Commission. Authors affiliated with Leiden University Medical Centre, Netherlands; Karolinska Institute, Sweden.)

108. NRC. 2012. National Response Center Database . United States Coast Guard. http://www.nrc.uscg.mil/foia.html

. Last accessed 5/14/12.

109. NTP. 1987. Toxicology and Carcinogenesis Studies of Bromodichloromethane (CAS No. 75

- 27

- 4) in F344/N Rats and B6C3F 1 Mice (Gavage Studies) . NTP TR 321, NIH Publication No. 88

- 2537. Research Triangle Park, NC: National Toxicolgy Program. 185 pp.

110. NTP. 1989

. Toxicology and Carcinogenesis Studies of Tribromomethane (Bromoform) (CAS No. 75

- 25

- 2) in F344/N Rats and B6C3F 1 Mice (Gavage Studies) . N TP TR 350, NIH Publication No. 89

- 2805. Research Triangle Park, NC: National Toxicolgy Program. 198 pp.

111. NTP. 1990. Toxicology and Carcinogenesis Studies of Glycidol (CAS No. 556

- 52

- 5) in F344/N Rats and B6C3F 1 Mice (Gavage Studies) . NTP TR 374, NIH Public ation No. 90

- 2829. Research Triangle Park, NC: National Toxicolgy Program. 231 pp.

112. NTP. 2003a. NTP

- CERHR Monograph on the Potential Human Reproductive and Developmental Effects of 1

- Bromopropane . Research Triangle Park, NC:RoC Monograph on 1

- Bromopropane 9/25/13

65 National Toxicology Program, Ce nter for the Evaluation of Risks to Human Reproduction. 88 pp.

113. NTP. 2003b. NTP

- CERHR Monograph on the Potential Human Reproductive and Developmental Effects of 2

- Bromopropane (2

- BP) . NIH Publication No. 04

- 4480. Research Triangle Park, NC: National Toxico logy Program. 11 pp.

114. NTP. 2011a. NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1

- Bromopropane (CAS No. 106

- 94

- 5) in F344/N Rats and B6C3F1 Mice (Inhalation Studies) . NTP TR 564, NIH Publication No. 11

- 5906. Research Triangle Park, N C: National Toxicology Program. 195 pp.

115. NTP. 2011b. Glycidol. In Report on Carcinogens . 12th ed. Research Triangle Park, NC: National Toxicology Program. p p . 215

- 216.

116. NTP. 2011c. Propylene oxide. In Report on Carcinogens . 12th ed. Research Triangle Park, NC: National Toxicology Program. p p . 367

- 368.

117. OSHA. 2011. Chemical Exposure Health data . Occupational Safety and Health Administratio n. http://www.osha.gov/opengov/healthsamples.html

. Accesse d on 4/17/13.

118. Plna K, Nilsson R, Koskinen M, Segerback D. 1999. 32 P

- postlabelling of propylene oxide 1

- and N 6

- substituted adenine and 3

- substituted cytosine/uracil: formation and persistence in vitro and in vivo

. Carcinogenesis 20(10): 2025

- 2032. (Supported by the American Chemical Manufacturer's Association. Authors affiliated with Karolinska Institute, Sweden; Stockholm University, Sweden.)

119. Raymond LW, Ford MD. 2007. Severe illness in furniture makers using a new glue: 1

- bromo propane toxicity confounded by arsenic. J Occup Environ Med 49(9): 1009

- 1019. (Support not reported. Authors affiliated with Carolinas Medical Center, NC; University of North Carolina, NC.)

120. Reh CM, Nemhauser JB. 2001. NIOSH Health Hazard Evaluation Report. Trilithic, Inc., Indianapolis, IN . HETA 2000

- 0233

- 2845. Cincinnati, OH: National Institute for Occupational Safety and Health. 16 pp.

121. Reh CM, Mortimer V, Nemhauser JB, Trout D. 2002. NIOSH Health Hazard Evaluation Report. Custom Products, Inc. Mooresvill e, NC . HETA 98

- 0153

- 2883. Cincinnati, OH: National Institute for Occupational Safety and Health. 46 pp.

122. Ríos

- Blanco MN, Faller TH, Nakamura J, Kessler W, Kreuzer PE, Ranasinghe A, Filser JG, Swenberg JA. 2000. Quantitation of DNA and hemoglobin adducts

an d apurinic/apyrimidinic sites in tissues of F344 rats exposed to propylene oxide by inhalation. Carcinogenesis 21(11): 2011

- 2018. (Supported by the Chemical Manufacturers Association, the European Chemical Industry Council9/25/13 RoC Monograph on 1

- Bromopropane

66 and Novartis. Authors affiliated with University of North Carolina, NC; GSF National Research Center for Environment and Health, Germany.)

123. Ríos

- Blanco MN, Ranasinghe A, Lee MS, Faller T, Filser JG, Swenberg JA. 2003. Molecular dosimetry of N7

- (2

- hydroxypropyl)guanine in tissues of F344

ra ts after inhalation exposure to propylene oxide. Carcinogenesis 24(7): 1233

- 1238. (Supported by the Propylene Oxide/Propylene Glycol Panel and the Olefins Panel of the American Chemistry Council, the Propylene Oxide and Derivatives Sector Group of the Euro pean Chemical Industry Association (CEFIC) and NIH. Authors affiliated with University of North Carolina, NC; GSF National Research Center for Environment and Health, Germany.)

124. Saito

- Suzuki R, Teramoto S, Shirasu Y. 1982. Dominant lethal studies in rats with 1,2

- dibromo

- 3

- chloropropane and its structurally related compounds. Mutat Res 101(4): 321

- 327. (Support not reported. Authors affiliated with Institute of Environmental Toxicology, Japan.)

125. Schuller HM, Al

- Wadei HA, Majidi M. 2008. Gamma

- aminobutyric acid, a potential tumor suppressor for small airway

- derived lung adenocarcinoma. Carcinogenesis 29(10): 1979

- 1985. (Supported by the National Cancer Institute. Authors affiliated with University of Tennessee, TN; Sana’a University, Yemen.)

126. Schwarzenbach RP, Giger W, Schaffner C, Wanner O. 1985. Groundwater contamination by volatile halogenated alkanes: abiotic formation of volatile sulfur compounds under anaerobic conditions. Environ Sci Technol 1 9(4): 322

- 327. (Support not reported. Authors affiliated with Swiss Federal Institute for Water Resources and Water Pollution Control, Switzerland.)

127. Segerbäck D, Plná K, Faller T, Kreuzer PE, Håkansson K, Filser JG, Nilsson R. 1998. Tissue distribution of DNA adducts in male Fischer rats exposed to 500 ppm of propylene oxide: quantitative analysis of 7

- (2

- hydroxypropyl)guanine by 32 P

- postlabelling. Chem Biol Interact 115(3): 229

- 246. (Supported by the American Chemical Manufacturers Association. Authors aff iliated with Karolinska Institute, Sweden; GSF National Research Center for En6ironment and Health, Germany; Stockholm University, Sweden.)

128. Sherchan J, Choi H, Lee E

- S. 2009a. Depurination of nucleosides and calf thymus DNA induced by 2

- bromopropane at the physiological condition. Bull Korean Chem Soc 30(10): 2309

- 2317. (Supported by Yeungnam University. Authors affiliated with Yeungnam University, Korea.)

129. Sherchan J, Yun M, Lee E

- S. 2009b. Deadenylation of adenine based

nucleosides and calf thymus DNA indu ced by halogenated alkanes at the physiological condition. Bull Korean Chem Soc 30(10): 2318

- 2328. (Supported by Yeungnam University. Author s affiliated with Yeungnam University, Korea.)RoC Monograph on 1

- Bromopropane 9/25/13

67 130. Singer TM, Lambert IB, Williams A, Douglas GR, Yauk CL. 2006. Detecti on of induced male germline mutation: correlations and comparisons between traditional germline mutation assays, transgenic rodent assays and expanded simple tandem repeat instability assays. Mutat Res 598(1

- 2): 164

- 193. (Support not reported. Authors affi liated with Health Canada, Canada; Carleton University, Canada.)

131. SMARTe.org. 201 2. Understanding Units of Measurement . SMARTe.org. Updated on 10/08. http://www.smarte.org

. A ccessed on 9/19/12.

132. Snow ET, Singh J, Koenig KL, Solomon JJ. 1994. Propylene oxide mutagenesis at template cytosine residues. Environ Mol Mutagen 23(4): 274

- 280. (Supported by the Center for Indoor Air Research and NIH. Authors affiliated with New York University Medical Cent er, NY.)

133. SRI. 2012. Directory of Chemical Producers . Menlo Park, CA: SRI Consulting. Database edition. Accessed on 2/13/12.

134. Stolzenberg SJ, Hine CH. 1979. Mutagenicity of halogenated and oxygenated three

- carbon compounds. J Toxicol Environ Health 5(6): 11 49

- 1158. (Supported by the Shell Oil Company. Authors affiliated with University of California

- San Francisco, CA.)

135. Stolzenberg SJ, Hine CH. 1980. Mutagenicity of 2

- and 3

- carbon halogenated compounds in the Salmonella/mammalian

- microsome test. Environ Mu tagen 2(1): 59

- 66. (Supported by the Shell Oil Company. Authors affiliated with University of California

- San Francisco, CA.)

136. Subramanian K, Mohideen SS, Suzumura A, Asai N, Murakumo Y, Takahashi M, Jin S, Zhang L, Huang Z, Ichihara S, Kitoh J, Ichihara G . 2012. Exposure to 1

- bromopropane induces microglial changes and oxidative stress in the rat cerebellum. Toxicology 302(1): 18

- 24. (Supported by the Japan Society for the Promotion of Science. Authors affiliated with Nagoya University, Japan; Kitasato Uni versity School of Medicine, Japan; Mie University, Japan.)

137. Tachizawa H, MacDonald TL, Neal RA. 1982. Rat liver microsomal metabolism of propyl halides. Mol Pharmacol 22(3): 745

- 751. (Supported by the United States Public Health Service. Authors affiliated with Vanderbilt University, TN; Daiichi Seiyaku Company, Japan; Chemical Industry Institute of Toxicology, NC.)

138. Tatsuta M, Iishi H, Baba M, Nakaizumi A, Ichii M, Taniguchi H. 1990. Inhibition by γ

- amino

- n

- butyric acid and baclofen of gastric carcinogenesis induced by N

- methyl

- N '

- nitro

- N

- nitrosoguanidine in Wistar rats. Cancer Res 50(16): 4931

- 4934. (Support not reported. Authors affiliated with Center for Adult Diseases, Japan.)9/25/13 RoC Monograph on 1

- Bromopropane

68 139. Temple L, Kawabata TT, Munson AE, White KL, Jr. 1993. Comparison of ELISA and p laque

- forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo[a]pyrene or cyclophosphamide. Fundam Appl Toxicol 21(4): 412

- 419. (Supported by Proctor & Gamble Company, NIEHS and NIH. Authors affiliated with Virginia Commonwealth University, VA; Proctor and Gamble Co., OH.)

140. Töpfer K, Kempe S, Müller N, Schmitz M, Bachmann M, Cartellieri M, Schackert G, Temme A. 2011. Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011: 918471. (Supported by the D eutsche Krebshilfe e.V. and the Dr. Robert Pfleger

- Stiftung. Authors affiliated with University Hospital Carl Gustav Carus, Germany; Medical Faculty Carl Gustav Carus, Germany.)

141. Toraason M, Lynch DW, DeBord DG, Singh N, Krieg E, Butler MA, Toennis CA, Nem hauser JB. 2006. DNA damage in leukocytes of workers occupationally exposed to 1

- bromopropane. Mutat Res 603(1): 1

- 14. (Support not reported. Authors affiliated with National Institute for Occupational Safety and Health OH; University of Washington, WA; Na tional Center for Environmental Health/Agency for Toxic Substances and Disease Registry, GA.)

142. Ueno S, Yoshida Y, Fueta Y, Ishidao T, Liu J, Kunugita N, Yanagihara N, Hori H. 2007. Changes in the function of the inhibitory neurotransmitter system in the
rat brain following subchronic inhalation exposure to 1

- bromopropane. Neurotoxicology 28(2): 415

- 420. (Supported by the Japan Society for the Promotion of Science and the University of Occupational and Environmental Health. Authors affiliated with University of Occupational and Environmental Health, Japan.)

143. UNEP. 2001. Montreal Protocol on Substances that Deplete the Ozone Layer. Report of the Technology and Economic Assessment Panel . Nairobi, Kenya: United Nations Environment Programme. 228 pp.

144. USITC. 2012. USITC Interactive Tariff and Trade Dataweb . United States International Trade Commission. http://dataweb.usitc.gov/scripts/user_set.asp and search on HTS no. 2903391550. Accessed on 10/11/12.

145. Valentine H, Amarnath K, Amarnath V, Li W, Ding X, Valentine WM, Ichihara G. 2007. Globin S

- propyl cysteine and urinary N

- acetyl

- S

- propylcysteine as internal biomarkers of 1

- bromopropane exposure. Toxicol Sci 98(2): 427

- 435. (Supported by the National Inst itute of Environmental Health Sciences, the Center of Molecular Toxicology, and the Japan Society for the Promotion of Science. Authors affiliated with Vanderbilt University Medical Center, TN; WHO Collaborating Center for Research Reproduction, China; Nag oya University Graduate School of Medicine, Japan.)RoC Monograph on 1

- Bromopropane 9/25/13

69 146. van Hylckama Vlieg JE, Janssen DB. 2001. Formation and detoxification of reactive intermediates in the metabolism of chlorinated ethenes. J Biotechnol 85(2): 81

- 102. (Supported by the EU Environment and C limate Programme. Authors affiliated with University of Groningen, Netherlands; NIZO Food Research, Netherlands.)

147. Vogel EW, Nivard MJ. 1997. The response of germ cells to ethylene oxide, propylene oxide, propylene imine and methyl methanesulfonate is a mat ter of cell stage

- related DNA repair. Environ Mol Mutagen 29(2): 124

- 135. (Supported by the Programme ‘‘Environment’’ of the European Commission. Authors affiliated with Leiden University, Netherlands.)

148. Walsh DA, Jones AR. 1977. Metabolism of bromopropane in the rat. Proc Aust Biochem Soc 10: 49

- 49. (Support not reported. Authors affiliated with University of Sydney, Australia.)

149. Wang H, Ichihara G, Ito H, Kato K, Kitoh J, Yamada T, Yu X, Tsuboi S, Moriyama Y, Sakatani R, Shibata E, Kamijima M, Itohara S, Ta keuchi Y. 2002. Biochemical changes in the central nervous system of rats exposed to 1

- bromopropane for seven days. Toxicol Sci 67(1): 114

- 120. (Support not reported. Authors affiliated with Nagoya University, Japan; Aichi Human Service Center, Japan; Okay ama University, Japan.)

150. Wang H, Ichihara G, Ito H, Kato K, Kitoh J, Yamada T, Yu X, Tsuboi S, Moriyama Y, Takeuchi Y. 2003. Dose

- dependent biochemical changes in rat central nervous system after 12

- week exposure to 1

- bromopropane. Neurotoxicology 24(2): 19 9

- 206. (Support not re ported. Authors affiliated with Nagoya University, Japan; Aichi Human Service Center, Japan; Okayama University, Japan, National Institute of Radiological Sciences, Japan.)

151. Watanabe M, Maemura K, Oki K, Shiraishi N, Shibayama Y, Katsu K. 2006. Gamma

- aminobutyric acid (GABA) and cell proliferation: focus on cancer cells. Histol Histopathol 21(10): 1135

- 1141. (Supported by the Osaka Medical Research Foundation for Incurable Disease, and the Ministry of Education, Sports, Culture, Science and Technology of Japan. Authors affiliated with Osaka Medical College, Japan.)

152. Weaver JL. 2012. Establishing the carcinogenic risk of immunomodulatory drugs. Toxicol Pathol 40(2): 267

- 271. (Support not reported. Author affiliated with U.S. FDA, MD.)

153. Wolf K, Morris M, Swanson MB, Geibig JR, Kelly KE. 2003. Alternative Adhesive Technologies: Foam Furniture and Bedding Industries . U.S. Environmental Protection Agency. 260 pp.

154. Wu X, Faqi AS, Yang J, Pang BP, Ding X, Jiang X, Chahoud I. 2002. 2

- Bromopropa ne induces DNA damage, impairs functional antioxidant cellular defenses, and enhances the lipid peroxidation process in primary cultures of rat9/25/13 RoC Monograph on 1

- Bromopropane

70 Leydig cells. Reprod Toxicol 16(4): 379

- 384. (Support not reported. Authors affiliated with Freie Universität Be rlin, Germany; National Evaluation Center for the Toxicology of Fertility Regulating Drugs, China; IIT Research Institute, IL; Thomas Jefferson University, PA.)

155. Young SZ, Bordey A. 2009. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology 24: 171

- 185. (Supported by NIH. Authors affiliated with Yale University, CT.)

156. Yu WJ, Kim JC, Chung MK. 2008. Lack of dominant lethality in mice following 1

- bromopropane treatment. Mutat Res 652(1): 81

- 87. (Support not repo rted. Authors affiliated with Korea Institute of Toxicology, Korea; Chonnam National University, Korea.)

157. Yu X, Ichihara G, Kitoh J, Xie Z, Shibata E, Kamijima M, Takeuchi Y. 2001

. Neurotoxicity of 2

- bromopropane and 1

- bromopropane, alternative solvents for chlorofluorocarbons. Environ Res 85(1): 48

- 52. (Supported by the Japanese Ministry of Education, Science, Sports, and Culture, and the Daiko Foundation Japan. Authors affiliated with Nagoya University, Japan; National Institute of Industrial Health, Japan .)

158. Zhao LX, Kim EK, Lim HT, Moon YS, Kim NH, Kim TH, Choi H, Chae W, Jeong TC, Lee ES. 2002. Synthesis, characterization and in vtro identification of N 7

- guanine adduct of 2

- bromopropane. Arch Pharm Res 25(1): 39

- 44. (Supported by the Korea Science and Engineering Foundation. Authors affiliated with Yeungnam University, Korea; Catholic University of Daegu, Korea; Dong Kook Pharm. Co., Korea.)RoC Monograph on 1

- Bromopropane 9/25/13

71 

## Abbreviations

1

- BP: 1

- bromopropane

3

- BPA: 3

- bromopropio nic acid

ABT: 1

- aminobenzotriazole

ACGIH: American Conference of Governmental Industrial Hygienists
AcPrCys: N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine

ADD: average daily dose

ALT: serum alanine aminotransferase, alanine aminotransferase

ANOVA: analysis of variance

AST: serum aspartate aminotransferase, aspartate aminotransferase

atm: atmosphere

BSO: DL

- buthionine (S,R)

- sulfoximine

CDC: Centers for Disease Control and Prevention

CERHR: Center for the Evaluation of Risks to Human Reproduction

cm 2 : square centimeter

COX

- 2: cyclooxygenase

- 2

DBCP: 1,2

- dibromo

- 3

- chloropropane

DLMI: dominant lethal mutation index

DLMR: dominant lethal mutation rate

EQ: exposure quartiles model

FDA: Food and Drug Administration

FR: Federal Register

f t : fee t

GC/MS: gas chromatography/mass spectrometry9/25/13 RoC Monograph on 1

- Bromopropane

72 GSH: glutathione

GSSH: oxidized glutathione

GST: glutathione

- S

- transferase

HHE: Health Hazard Evaluation

HHS: Department of Health and Human Services

HIC: highest ineffective concentration

HID: highest ineffective dose

HO

- 1: heme oxygenase

- 1

hr: hour

in : inch

i.s.: internal standard

iNOS: inducible nitric oxide synthases

L: liter

LEC: lowest effective concentration

LED: lowest effective dose

m 3 : cubic meter

mg: milligram

MMWR: Morbidity and Mortality Weekly Report

MN: micronuclei

mol: mole

NCE: normochromatic erythrocyte

NCTR: National Center for Toxicological Research

ND: not done

NIC: Notices of Intended Changes

NIEHS: National Institute of Environmental Health SciencesRoC Monograph on 1

- Bromopropane 9/25/13

73 NIH: National Institutes of Health

NIOSH: National Institute for Occupational Safety and Health

nPB: normal propyl bromide

NQO1: NAD(P)H:quinone oxidoreductase

NR: not reported

NS: non

- sprayer

NTP: National Toxicology Program

OHAT: Office of Health Assessment and Translation

OSHA: Occupational Sa fety and Health Administration

PBZ: personal breathing zone

PCE: polychromatic erythrocyte

PEL: permissible exposure limit

PERC: tetrachloroethylene (perchloroethylene)

PGE 2 : prostaglandin E 2

ppm: parts per million
PrCys: S

- propylcysteine

r: correlation c oefficient

RoC: Report on Carcinogens

RTG: relative total growth

s.c.: subcutaneous

SD: standard deviation

SNAP: Significant New Alternatives Policy

Solv.: aerosol solvents use

SP: sprayer

TBARS: thiobarbituric acid

- reactive substance9/25/13 RoC Monograph on 1

- Bromopropane

74 TLV: threshold limit value

TM: tail moment

TMD: tail moment dispersion coefficient

TWA: time weighted average

VOC: volatile organic compound

μg: microgramRoC Monograph on 1

- Bromopropane 9/25/13

75 

## Glossary

Aerosol solvent : A cleaning agent stored in a metal container (i.e., a hand

- held can) under pressure and then released through a push

- button valve or nozzle as a suspension of particles in air.
Apoptosis : Cell deletion by fragmentation into membrane

- bound particles
, which are phagocytosed by other cells.

Aroclor 1254

- induced liver : Liver tissue treated with the po lychlorinated biphenyl mixture Aroclor 1254 used as a source of S9 fraction for mutagenic and genotoxic effects testing.

Assembly worker : A foam seat cushion manufacturing facility employee who sprays adhesive on foam pieces and presses them together by ha nd to form the cushion. Assembly department workers are either sprayers or assemblers.

Ataxia : Loss of the ability to coordinate muscular movement.

Axial exhaust f

an : An air

- moving device in which the air flow is parallel (or axial) to the shaft on which the propeller is mounted; also called a propeller fan.
Boiling point: The boiling point of the anhydrous substance at atmospheric pressure (101.3 kPa) unless a different pressure is stated. If the substance decomposes below or at the boiling point, this is noted (dec). The temperature is rounded off to the nearest °C.

Cauda e pididymis : The tail of the epididymis; part of the reservoir for spermatozoa.

CD8 + T

- cell blast : An immature, undifferentiated lymphocyte that expresses the CD8 transmembrane glycoprot ein.
Chemical Data Reporting Rule : Chemical Data Reporting (CDR) is the new name for Inventory Update Reporting (IUR). The purpose of Chemical Data Reporting is to collect quality screening

- level, exposure

- related information on chemical substances and to make that information available for use by the U.S. Environmental Protection Agency (EPA) and, to the extent possible, to the public. The IUR/CDR data are used to support risk screening, assessment, priority setting and management activities and constitute the most comprehensive source of basic screening

- level, exposure

- related information on chemicals available to EPA. The required frequency of reporting currently is once every four years.
Comet assay : A genotoxicological technique for measuring DNA damag e in an individual cell using single

- cell gel electrophoresis. Cell DNA fragments assume a "comet with tail" formation on electrophoresis and are detected with an image analysis system. Alkaline assay conditions facilitate sensitive detection of single

- str and damage.

Conversion factor : A numerical factor used to multiply or divide a quantity when converting from one system of units to another.9/25/13 RoC Monograph on 1

- Bromopropane

76 Cooking : In dry cleaning, boiling the solvent cleaner to remove impurities.

Cover worker : A foam seat cushion manufacturing facility employee who places covers around the assembled cushions and seals the cover around the cushion with adhesive. All workers in the Covers department are sprayers.
Dehydrodehalogenation : An elimination reaction in which a halogen is re moved from one carbon and a hydrogen is removed from an adjacent carbon.
Disposition : The description of absorption, distribution, metabolism, and excretion of a chemical in the body.
Distal latency : The interval between the stimulation of a compound musc le and the observed response. Normal nerve conduction velocity is above 40 m/sec in the lower extremities and above 50 m/sec in the upper extremities, but age, muscle disease, temperature, and other factors can influence the velocity.

Dominant lethal mutat ion assay : The dominant lethal assay identifies germ cell mutagens by measuring the ability of a chemical to penetrate gonadal tissue and produce embryonic death due to chromosomal breakage in parent germ cells.
ELISA assay : Enzyme

- linked immunosorbent ass ay; a sensitive immunoassay that uses an enzyme linked to an antibody or antigen as a marker for the detection of a specific protein, especially an antigen or antibody.

EPA SNAP p rogram : The U.S. Environmental Protection Agency Significant New Alternative s Policy program reviews alternatives to ozone depleting substances and approves the use of alternatives that do not present substantially greater risk to the public health and environment than the substance they replace or other substitutes available.

F 0 generation : F 0 generation is the initial parent generation in a multi

- generation reproduction study.

F 1 and F 2 offspring : F 1 offspring is the first filial generation, which comprise s offspring resulting from a cross between strains of distinct genotypes. The F 1 generation is the generation resulting immediately from a cross of the first set of parents (parental generation, i.e., F 0 generation). F 2 offspring is the second filial genera tion, which comprise s offspring resulting from a cross of the members of F 1 generation. The F 2 generation is the result of a cross between two F 1 individuals (from F 1 generation).
FDA Good Laboratory Practice Regulations : A quality system codified by the U .S. Food and Drug Administration that prescribes operating procedures for conducting nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administr ation.

Heat

- separated human epidermal membrane : A skin sample used for dermal absorption testing. The method of preparation of epidermal membranes varies acrossRoC Monograph on 1

- Bromopropane 9/25/13

77 species due to the inherent differences in skin morphology and follicle depth. Commonly, heat separation (60°C for one to two minutes ) is used for human and pig skin; the epidermal membrane is peeled from the dermis using forceps.

Helminthes : Eukaryotic animals with worm

- like appearance (i.e., small animals with long, slender bod ies and without app endages) and mostly parasitic.
Henry’s Law constant at 25°C : The ratio of the aqueous

- phase concentration of a chemical to its equilibrium partial pressure in the gas phase. The larger the Henry’s law constant the less soluble it is (greater tendency for v apor phase).
Immersion cleaning: A process in which a tank containing cleaning solvent at a temperature below its boiling point is used for metal parts cleaning. To use the vapor degreaser, the operator places the parts to be cleaned in a metal wire basket , removes the cover, and lowers the basket of parts by hand into the cleaning solvent. After a brief period of time, the operator raises the basket and allows the parts to drip

- dry inside the degreaser.

Karmen unit : A formerly used enzyme unit for aminotr ansferase activity; a change of 0.001 in the absorbance of reduced nicotinamide adenine dinucleotide (NADH) per minute.
Lymphokine

- activated killer cell : Killer cell lymphocytes activated in the presence of interleukin

- 2 (IL

- 2). Lymphokine

- activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins. LAK s exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage.
Melting point : The melting point of the substance at atmospheric pressure (101.3 kPa). When there is a significant difference between the melting point and the freezing point, a range is given. In case of hydrated substances (i.e., those with crystal water), the apparent melting point is given. If the substance decomposes at or below its melting point, this is noted (dec). The temperature is rounded off to the nearest °C.

Molecular chaperone : Any of a di verse group of proteins that oversee the correct intracellular folding and assembly of polypeptides without being components of the final
structure.
Molecular weight : The molecular weight of a substance is the weight in atomic mass units of all the atoms i n a given formula. The value is rounded to the nearest tenth.

Natural killer cells : A type of white blood cell that contains granules with enzymes that can kill tumor cells or microbial cells. Also called large granular lymphocytes.
Octanol/water partition coefficient (log K ow ) : A measure of the equilibrium concentration of a compound between octanol and water.9/25/13 RoC Monograph on 1

- Bromopropane

78 Ozone

- depleting substance : A family of man

- made compounds that includes, but are not limited to, chlorofluorocarbons (CFCs), bromofluorocarbons (ha lons), methyl chloroform, carbon tetrachloride, methyl bromide, and hydrochlorofluorocarbons (HCFCs). These compounds have been shown to deplete stratospheric ozone.
Personal breathing zone : A sampling area as close as practical to an employee’s nose and m outh, (i.e., in a hemisphere forward of the shoulders within a radius of approximately nine inches) so that it does not interfere with work performance or safety of the employee.

Phase I metabolism : metabolism of drugs or other xenobiotic molecules, usually by oxidation or hydrolysis and involving a cytochrome P450 monooxygenase.

Phase II metabolism : a conjugation reaction that forms a covalent linkage between a functional group on a xenobiotic mole cule and glucuronic acid, sulfate, glutathione, amino acid, or acetate.

Pla q ue a ssay : An assay for antibody production by single lymphocytes using cells isolated from the spleen or lymph nodes of animals injected with sheep red blood cells as an antigen. I ncubation of the antibody

- forming cells together with sheep red cells in an agar layer with exposure to guinea pig serum as complement results in formation of microscopic plaques (i.e., circular areas of hemolytic clearance around a lymphoid cell) due to r elease of hemolysin.
Plate incorporation : A commonly used procedure for performing a bacterial reverse mutation test. Suspensions of bacterial cells are exposed to the test substance in the presence and in the absence of an exogenous metabolic activation s ystem. In the plate

incorporation method, these suspensions are mixed with an overlay agar and plated immediately onto minimal medium. After two or three days of incubation, revertant colonies are counted and compared with the number of spontaneous reverta nt colonies on solvent control plates.

Poly

- 3 test : A survival

- adjusted statistical test that takes survival differences into account by modifying the denominator in the numerical (quantal) estimate of lesion incidence to reflect more closely the total num ber of animal years at risk.
Pyknotic shrinkage : A thickening, especially the degeneration of a cell in which the nucleus shrinks in size and the chromatin condenses to a solid, structureless mass or

masses.

S9 metabolic activation : Addition of the superna tant fraction obtained from an organ (usually liver) homogenate by centrifuging at 9000 g

- force for 20 minutes in a suitable medium to a biological assay (e.g., genetic toxicology) to provide metabolic enzymes

.
Saw worker : A foam seat cushion manufacturing facility employee who cuts bulk foam with various saws.

SKF

- 525A : An inhibitor of drug metabolism and cytochrome P

- 450 activity.RoC Monograph on 1

- Bromopropane 9/25/13

79 Solubility : The ability of a substance to dissolve in another substance and form a solution.
Specific gravity : The ratio of th e density of a material to the density of a standard material, such as water at a specific temperature; when two temperatures are specified, the first is the temperature of the material and the second is the temperature of water.
Sperm motility : Movement c haracteristics of spermatozoa in a fresh specimen. It is measured as the percentage of sperms that are moving, and as the percentage of sperms with productive flagellar motion such as rapid, linear, and forward progression.
Spinnerette : A small, thimble

- shaped, metal nozzle having fine holes through which a spinning solution is forced to form a filament.
Splendore

- Hoeppli reaction material : Homogeneous, eosinophilic material that coats the grains that are characteristic of the exudate in lesions o f botryomycosis.
Sprayer : Any cushion manufacturing facility employee who works directly with adhesive formulations via spray application using a compressed air spray gun.

Static diffusion cell : A diffusion cell consists of a donor chamber and a receptor

c hamber between which the skin is positioned. The cell should provide a good seal around the skin, enable easy sampling and good mixing of the receptor solution in contact with the underside of the skin, and provide good temperature control of the cell and its contents. In a static diffusion cell, the receptor fluid is sampled at intervals and replaced with equal volumes of fresh receptor fluid.
Temperate marine macroalgae : Algae growing in the ocean in large seaweed form, generally visible to the naked eye (e.g., kelp), in regions where the climate undergoes seasonal change in temperature and moisture. Temperate regions of the earth lie primarily between 30 and 60 degrees latitude in both hemispheres.

Time

- weighted average : The average exposure concentratio n of a chemical measured over a period of time (not an instantaneous concentration).

Toxicokinetics : The mathematical description (toxicokinetic models) of the time course of disposition of a chemical in the body.
Vapor degreasing : A type of cleaning proce dure using a refrigerated cooling coil around the top of the interior of a vapor chamber to condense solvent vapor into liquid droplets on the surface of parts to remove surface impurities. Excess solvent drips back into the solvent sump and is recycled as the parts ascend from the vapor to condensing zones.

Vapor density, relative : A value that indicates how many times a gas (or vapor) is heavier than air at the same temperature. If the substance is a liquid or solid, the value applies only to the vapor f ormed from the boiling liquid.9/25/13 RoC Monograph on 1

- Bromopropane

80 Vapor pressure : The pressure of the vapor over a liquid (and some solids) at equilibrium, usually expressed as mm Hg at a specific temperature (°C).Appendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 1 

## Appendix A : Literature Search Strategy

This document identifies the data sources, search terms, and search strategies that were used to identify literature for the monograph on 1

- bromopropane ( CASRN 106

- 94

- 5 ). The literature search strategy used for 1

- bromopropane involved several approaches designed to identify potentially useful information for the broad range of topics covered by a Report on Carcinogens (RoC) monograph , as listed below.

Properties and Human Exposure (focusing on the U.S. population) Disposition (ADME) and Toxicokinetics Human Cancer Studies (if available) Cancer Studies in Experimental Animals Mechanisms and Other Relevant Effects

o Genotoxicity

o Toxicity as It Relates to Mechanisms

o Mechanisms of Ca rcinogenicity
The methods for identifying the relevant literature for the 1

- bromopropane monograph including (1) the search strategy, (2) updating the literature search, and (3) review of citations using web

- based systematic review software are illustrated in Figure A

- 1 and discussed below.
Click here to return to text citing Appendix A

.9/25/13 RoC Monograph on 1-Bromopropane Appendix A

A-2 Figure A-1. Literature search strategy and reviewAppendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 3 Search strategies

Relevant literature is identified using search terms, data sources, and strategies as discussed below.

1. General data search: This search covers a broad range of general data sources (see Table A

- 1) for information relevant to many or all of the wide range of monogra ph topics pertaining to 1

- bromopropane.

2. Exposure

- related data s earch : Th is search covers a broad range of potential sources (see Table A

- 2) for exposure

- related information and physical

- chemical properties.

3. Database searches in PubMed, Scopus, and Web of Science: The majority of the primary literature used to draft the 1

- bromopropane monograph was identified from searches of these three extensive databases available through the NIEHS Library. Synonyms, metabolites (both Phase I and Phase II) , and the chem ical class for 1

- bromopropane were identified from the sources listed in Table A

- 3 and the search terms are listed in Table A

- 4. Information on metabolites and structurally related chemicals may be important for evaluating potential mechanisms of carcinoge nicity. Initial literature searches were conducted to obtain all literature (not restricted to topic) on 1

- bromopropane, its metabolites and chemical class. The searches for the four debrominated Phase I metabolites of 1

- bromopropane and the relevant chemi cal class brought up several thousand references and thus subsequent topic

- specific searches were conducted to focus the search on identifying mechanistic information for these chemicals. See Table A

- 4 for details on this approach and Table A

- 5 for topic

- specific search terms

. Searches for human cancer studies are somewhat unique because they involve the identification of search terms for exposure scenarios that might result in exposure of people to 1

- bromopropane. The major uses of 1

- bromopropane are as a cleaner/degreaser, as an adhesive for manufacture of foam cushions, and as a solvent in dry cleaning. The use of 1

- bromopropane in dry cleaning is more recent, since 2006. Because the expansion in the use of 1

- bromopropane has been fairly recent, epidemiologic studies of workers may not be able to evaluate potential risks for cancer, whic h is associated with long latency periods. Formal searches were not conducted for epidemiologic studies of dry cleaners because these workers would most likely hav e been exposed to other solvents such as tetrachloroethylene. Literature searches conducted using search terms for spray adhesive and degreaser industries were combined with search terms for cancer epidemiologic studies (see Tables A

- 4 and A

- 5).

4. QUOSA li brary of occupational case

- control studies: A search of the QUOSA

based library of approximately 6,000 occupational case

- control studies, approximately 60% of which are currently available as searchable full

- text PDF s, was conducted using the synonyms “1

- b romopropane,” “propyl bromide,” and the CASRN number ( 106

- 94

- 5 ).9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 4 5. Special topic

- focused search: One of the key questions in the concept document on 1

- bromopropane was whether the reported alterations in immune surveillance in rodents lead to an increased i ncidence of tumors. An additional literature search of the three databases was conducted to identify information on immunosuppression and chemically induced cancer using the following search terms: (can cer OR tumor OR neoplasm) AND (immune suppression OR i mmunosuppression ) AND (skin OR dermal) AND (chemically induced). The review of these citations was limited to review articles.

6. Secondary sources: Citations identified from authoritative reviews or from primary references located by literature search , toge ther with publications citing key papers identified using the Web of Science “Cited Reference Search,” were also added.
Updating the literature search

The literature search was updated prior to submitting the draft monograph for peer review and was updat ed prior to finalizing the monograph. Monthly search alerts for 1

- bromopropane synonyms, metabolites, chemical class, exposure scenarios (human cancer), and topic

- focused searches were created in PubMed, Scopus, and Web of Science, and the results of these s earches from the closing date of the initial search were downloaded for review.
Review of citations using web

- based systematic review software

Citations retrieved from literature searches were uploaded to web

- based systematic review software and screened u sing inclusion and exclusion criteria. Multi

- level reviews of the literature we re conducted, with initial reviews (Level 1) based on titles and abstracts only to identify citations that could be excluded and to assign the included literature to one or more monograph topics; subsequent reviews (Level 2) for literature assigned to the various monograph topics were based on full

- text (i.e., PDFs) of the papers and were carried out by the writer and scientific reviewer for each monograph section

. Two reviewers, at least one of whom is a member of the ORoC at NIEHS, participated at each level of review.
Inclusion/exclusion questions for literature

Level 1:
1. Should we obtain a PDF of this article?  Yes  No

1. If yes, for which sections of the monograph does this article contain useful information? Check all that apply.  Properties and Human Exposure  Toxicokinetics (also includes ADME, i.e., absorption, distribution, metabolism, and excretion)  Human Cancer Studies  Studies of Cancer in Experimental Anima ls  Mechanisms

- Genetic ToxicologyAppendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 5  Mechanisms

- Toxicity  Mechanisms of Carcinogenicity

2. If no, check the reason that applies below or enter a reason in the textbox for “Other.”  It does not contain relevant information on 1

- bromopropane or any related substance (metabolite or structural analogues).  It is related to 1

- bromopropane but does not contain information relevant to any topic covered by the monograph.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropane, “useful” or “relevant” information as it applies to primary screening can include any of the following: The article specifically mentions 1

- bromopropane, a metabolite, or struct ural analogue and reports information on one of the topics included in a cancer evaluation (see Question #1 above for a list of topics) The article does not specifically mention 1

- bromopropane, or any related substance, but it does one of the following:

o It reports information on one of the topics included in a cancer evaluation with potential for exposure to 1

- bromopropane and should be included until full

text review, which would provide more information if the study is specific for exposure to 1

- bromoprop ane or a related substance.

o It reports information on an exposure scenario that could include exposure to the 1

- bromopropane.

o It reports information on methodology that is potentially informative for evaluating cancer or mechanistic studies on exposure to 1

- bromopropane.

o It reports information on a potential mode of action that may be informative for 1

- bromopropane.

Level 2

- Exposure: 1. Does this paper contain information that could be useful in answering the key questions about exposure?  Yes  No

2. I f the answer to Question #1 is “No” select the reason below for excluding i t from review.  It does not contain relevant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or one of its metabolites or analogues), but the paper does not contain information that will help answer the key questions about exposure.  Other9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 6 Note: In the context of the systematic review of literature u sed for 1

- bromopropane, “useful” or “relevant” information as it applies to screening for the exposure section can include information, from either primary research papers, review articles, databases, or other published sources, on any of the following top ics: occupational exposure, environmental occurrence, occurrence in consumer products, food, cigarette smoke, or other sources, biological indices of exposure, and Federal regulations or guidelines to reduce exposure.

Toxicokinetics: 1. Does this paper co ntain information that could be useful in answering the key questions about toxicokinetics?  Yes  No

2. If the answer to Question #1 is “No” select the reason below for excluding i t from review.  It does not contain relevant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or one of its metabolites or analogues), but the paper does not contain information that will help an swer the key questions about toxicokinetics.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropane, “useful” or “relevant” information as it applies to screening for the toxicokinetics (and ADME) section can include (but is not limited to) information from primary research papers or review articles on any of the following topics: absorption, distribution, metabolism, excretion (ADME), toxicokinetics, and physiologically based pharmacoki netic models (PBPK).

Human Cancer: 1. Does this paper contain information that could be useful in answering the key questions about human cancer?  Yes  No

2. If the answer to Question #1 is “No” select the reason below for excluding i t from review.Appendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 7  It does not contain relevant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or one of its metabolites or analogues), but the paper does not contain information that will help an swer the key questions about human cancer.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropane, “useful” or “relevant” information as it applies to screening for the human cancer section can include, but is not l imited to, epidemiologic studies, descriptive studies, pooled analyses, meta

- analyses, case reports, reviews, letters to editors, exposure

assessment studies (for use in epidemiologic studies) and information on co

- exposures or potential confounders and ot her special topics of relevance to the evaluation.

Animal Tumors: 1. Does this paper contain information that could be useful in answering the key questions about animal tumors?  Yes  No

2. If the answer to Question #1 is “No” select the reason below for excluding i t from review.  It does not contain relevant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or one of its metabolites or analogues), but the paper does not contai n information that will help answer the key questions about animal tumors.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropa ne, “useful information” as it applies to screening for the animal tumors section can include, but is not limited to, information from primary research papers or review articles on (1) chronic studies (ideally for lifetime of the animal) in experimental an imals that are assessing neoplastic endpoints, non

- cancer data important for cancer assessment, such as preneoplastic lesions that are considered part of a morphologic continuum to neoplasia, or (2) subchronic studies in experimental animals that provide i nformation on preneo plastic lesions, neoplastic les ions, or on dose setting for chronic studies.9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 8 Level 2

- Genetic Toxicology: 1. Does this paper contain information that could be useful in answering the key questions about genetic toxicology?  Yes  No

2. If the answer to Question #1 is “No” select the reason below for excluding if from review.  It does not contain relevant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or on e of its metabolites or analogues), but the paper does not contain information that will help answer the key questions about genetic toxicology.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropane, “useful” or “relevant” information as it applies to screening for the genetic toxicology section can include, information from primary research papers or review articles on
stu dies in experimental systems (both in vitro and in vivo ) and in exposed humans assessing the following endpoints: both direct and indirect DNA or chromosomal damage, events associated with mutagenesis, cellular transformation or other related effects.

Lev el 2

- Toxicity: 1. Does this paper contain information that could be useful in answering the key questions about toxicity?  Yes  No

2. If the answer to Question #1 is “No” select the reason below for excluding if from review.  It does not contain relev ant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or one of its metabolites or analogues), but the paper does not contain information that will help answer the key questions abo ut toxicity.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropane, “useful” or “relevant” information as it applies to screening for the toxicity section can include any of the following: information from primary research papers or review arti clesAppendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 9 on toxicity of 1

- bromopropane to organs or tissues that were identified as tumor sites from studies in experimental animals.

Level 2

- Mechanisms of Action:

1. Does this paper contain information that could be useful in answering the key questions ab out mechanisms of action?  Yes  No

2. If the answer to Question #1 is “No” select the reason below for excluding if from review.  It does not contain relevant information on the candidate substance (or one of its metabolites or analogues).  It is related to the candidate substance (or one of its metabolites or analogues), but the paper does not contain information that will help answer the key questions about mechanisms of action.  Other

Note: In the context of the systematic review of literature used for 1

- bromopropane, “useful” or “relevant” information as it applies to screening for the mechanism data section can include information from primary research papers or review articles on data rel ated to molecular alterations associated with carcinogenicity or potential modes of action, such as genotoxicity, epigenetics, gene expression, immune

- response modulation, inflammation, cytotoxicity and compensatory cell proliferation, mitogenicity, chroni c metabolic or physiologic overload, nutrient deficiency, and interference with intercellular communication, for 1

- bromopropa ne, its metabolites and analogues.9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 10 Table A

- 1. General sources c hecklist for: 1

- Bromopropane

Source Name of document A) Comprehensive sources or reviews 1) NTP technical reports NTP2011 2) NTP nomination for toxicological evaluation documents NTP1999 3) OHAT (formerly CERHR)

Public comments to CERHR

- 10 listed on NTP website NTP2003a (1BP) NTP 2003b (2BP)

Albemarle2001a Albemarle2001b Atofina2001 BSC2000 BSC2001a BSC2001b Envirotech2001 IRTA2001 EPA2002 Envirotech2002 4) IARC monographs

-- 5 ) ATSDR Toxicological Profile s

-- 6 ) EPA IRIS

-- 7 ) NAS Reports and Publications NAS2007 (Climate Change) NAS2008 (Review of NIOSH HHE Program) 8 ) WHO (IPCS) INCHEM

- related documents (a

- k below)

-- a) CICADS

-- b) EHC

-- c) HSGs

-- d) ICSCs IPCS2004 e) JECFA

-- f) JMPR

-- g) KemI

- Riskline

-- h) PDs

-- i) PIMS

-- j) SIDS

-- k) UKPID

-- 9 ) California EPA Prop 65 hazard identification documents CAEP 2004 CAEPA2008 10 ) Health Canada HealthCanada2009a HealthCanada, 2009b 11) New York State Department of Health

- Health Topics A to Z

--
B) General information sources 1) U.S. National Library of Medicine (NLM)

- TOXNET

-- a) HSDB HSDB 2006 b) CCRIS CCRIS2008

c ) GENETOX

-- d ) ITER

--
e ) LactMed

-- f ) CPD

-- g ) CTD CTD 2012 2) PubChem PubChem 2012 3) Kirk

- Othmer Encyclopedia Wypych2006Appendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 11 Source Name of document Pocius&Campbell2009 Suh2000 4) USGS (Minerals)

--

C ) European Union

– sources to search 1) International Uniform Chemica l Information Database (IUCLID)

-- 2) European Chemicals Agency

-- 3) The International Portal on Food Safety, An imal and Plant Health (IPFSAPH) -- 4) Th e European Food Safety Authority

-- 5 ) European Centre for Disease Prevention and Control (ECDC)

-- 6 ) European Monitoring Centre for Drugs and Drug Addiction

-- 7) International Labour Organization (ILO) ILO 2 005 8) United Nations Environment Programme (UNEP)

--9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 12 Table A

- 2

. Exposure

- related s ources c hecklist for: 1

- Bromopropane

Source Name of document Exposure

- and properties

- specific sources 1) U.S. National Library of Medicine (NLM)

- TOXNET

-- a) ChemIDplus ChemIDplus2012 b) Haz

- Map Haz

- Map 2012 c) HPD

-- d) TOXMAP

-- 2) Akron database Akron2012 3) SRI Directory of Chemical Producers SRI2012 4) Chem Sources Suppliers ChemSources2012 5) National Health and Nutrition Examination Survey (NHANES) data studies -- 6) National Occupational Exp osure Survey (NOES) (1981

- 1983)

-- 7) National Institute for Occupational Safety and Health (NIOSH)

- Health Hazard Evaluations 5 HHE: Eisenberg2010 Harney2002 Harney2003 Reh2001 Reh2002 8 ) National Response Center (NRC) Database NRC2012a NRC2012b 9 ) U.S. Interna tional Trade Commission (USITC)

- Import/Export data USITC2012 10 ) EPA Toxics Release Inventory (TRI)

-- 11 ) Environmental Protection Agency (EPA) AP

- 42, Compilation of Air Pollutant Emission Factors -- 12 ) EPA EJView Database

-- 13 ) EPA High Production Volume Chemicals (HPV Challenge Program Chemical List) -- 14 ) EPA Inventory Update Rule (IUR) EPA2012
15 ) EPA Locating and Estimating (L&E) documents

-- 16 ) EPA/Office of Pesticide Programs (OPP) Chemical Ingredients Database -- 17 ) Food and Drug Administration (FDA) Pesticide Monitoring Database -- 18) FDA Orange Book

-- 19) FDA Total Diet Study

-- 20) Medline Plus MedlinePlus2012 2 1) United States Patent Office USPTO2011 USPTO2012a USPTO2012b 22 ) Trademark Electronic Search System (TESS)

-- 23 ) Material Safety Data Sheets (MSDS) Multiple found Sigma

- Aldrich2011 24) Dow Chemical Product Safety Assessments

--Appendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 13 Table A

- 3. Data s ources for 1

- bromopropane searches Information type Data sources Synonyms National Library of Medicine databases (e.g., ChemIDplus, Hazardous Substances

Data Base) Metabolites Cheever et al. 2009 , Garner et al. 2006 , Ghanayem and Hoffler 2007 , Ishidao et al.

2002 , Jones and Walsh 1979

.

Table A

- 4

. L i terature search approach for 1

- bromopropane

Substance Search terms Topics (combined with) a

1

- Bromopropane synonyms bromopropane, propyl bromide, and 106

- 94

- 5 None

Chemical class and synonyms bromoalkanes, alkyl bromides, haloalkanes, alkyl

halides Animal tumors Genotoxicity Toxicity Mechanism
1

- Bromopropane brominated Phase I metabolites and their synonyms 3

- bromopropanol, 3

- bromopropionic acid, 1

- bromo

- 2

-

propanol, bromoacetone, 2

- oxo

- 1

- bromopropane, and alpha

- bromohydrin None

1

- Bromopropane deb rominated Phase I metabolites and their synonyms propylene oxide, n

- propanol, glycidol, and 3

-

hydroxypropionate Animals tumors Genotoxicity Toxicity Mechanism

1

- Bromopropane Phase II metabolites 1

- b romo

- 2

- hydroxypropane

- O

- glucuronide
, N

- a cetyl

- S

propylcysteine
, N

- a cetyl

- S

- (2

- hydroxypropyl)cysteine
, N

- a cetyl

- S

- (3

- hydroxypropyl)cysteine
, N

- a cetyl

- S

- (2

- carboxyethyl)cysteine
, N

- a cetyl

- S

- (2

- oxopropyl)cysteine
, 2,3

- d ihydroxypropylmercapturic acid
, N

- a cetyl

- 3

- (propylsulfinyl)alanine
, N

- a cetyl

- 3

- [(2

- hydro xypropyl)sulfinyl]alanine
, N

- a cetyl

- 3

- [(2

- oxopropyl)sulfinyl]alanine
, N

- a cetyl

- 3

- [(2

- propenol)sulfinyl]alanine None

Exposure scenario (Spray* AND Adhes*) or Degreas* Human cancer studies

a Search terms for each of these topics we re developed in consultation with an informational specialist and are listed in Table A

- 5

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 14 Table A

- 5

. S earch terms for monograph topics for 1

- bromopropane
Monograph Topic Search terms used in PubMed, Scopus, and

Web of Science MeSH terms used in Pubme d
Human cancer studies Cancer search terms

- cancer* OR neoplas* OR

carcinogen* OR malignan* OR oncogene* OR tumor* OR tumour* OR adenoma* OR carcinoma* OR adenocarcinoma* OR sarcoma* OR precancer* OR preneoplast * OR lesion* OR cyst* OR lymphoma* OR leukemia* OR metastas* OR cell transform* OR cell proliferat*

Combine with AND Epidemiologic study search terms

- person* OR people OR individual* OR subject* OR participant* OR worker* OR employee* OR staff OR human OR woman OR women OR man OR men OR epidemiolog* OR case report* OR case control OR cohort OR case

- referent OR registry OR prevalen* OR inciden* Cancer search terms

- "neoplasm s"[Mesh] OR "carcinogens"[Mesh]

Combine with AND Epidemiologic study search
ter ms
- "epidemiology"[Subheading] OR "epidemiologic studies"[Mesh] OR "case reports"[publication type] OR "epidemiologic factors"[mh] OR "epidemiologic methods"[mh] OR "persons"[mh] OR "occupational diseases"[mh] OR "occupational exposure"[mh] OR "vital
stat istics"[mh] Animal Tumors Cancer search terms

- cancer OR neoplasm* OR

carcinogen* OR malignan* OR oncogene* OR tumor* OR tumour*

Combine with AND Animal study search terms

- animal* OR mouse OR mice OR rat OR hamster OR "guinea pig" OR rabbit OR monkey OR dog Cancer search terms

-

" n eoplasms"[Mesh]) OR

" c arcinogens"[Mesh]

Genotoxicity General search terms

- "genetic toxicology" OR

genotoxic* a

Endpoint

- specific search terms

- clastogen* OR "DNA strand break*" OR "unscheduled DNA synthesis" OR "UDS" OR aneup loid OR aneuploid* OR polyploid OR polyploid* OR "neoplastic cell transformation" OR "chromosom* aberration*" OR cytogenetic OR cytogenetic* OR "DNA adduct*" OR "DNA damage" OR "DNA repair" OR crosslink* OR "germ

- line mutation" OR micronucle* OR mutagen OR mutagen* OR mutation OR mutation* OR oncogen* OR "sister chromatid exchange" OR "SCE" OR "SOS response*" OR "Ames test" OR "gene expression" OR "cell proliferation" OR cytotoxi c OR cytotoxic* OR "comet assay " "DNA Damage"[Mesh] OR "DNA Repair"[Mesh] OR "M utagens"[Mesh] OR "Mutation"[Mesh] OR "Cytogenetic Analysis"[Mesh] OR "Oncogenes"[Mesh] OR "Mutagenicity Tests"[Mesh] a

Toxicity toxic* OR toxin*OR cytotoxic* OR (nephrotoxic* OR

hepatotoxic* OR pneumotoxic* OR thyrotoxic* "Toxic Actions"[Mesh]) OR "Toxicity Tests"[Mesh]) OR "adverse effects" [Subheading]Appendix A RoC Monograph on 1

- Bromopropane 9/25/13

A

- 15 Monograph Topic Search terms used in PubMed, Scopus, and

Web of Science MeSH terms used in Pubme d
Mode of action (mode* AND “ of action ” ) OR (mechanism* AND “ of

action ” ) OR genetic OR epigenetic OR inhibit* OR promot* OR interact* OR activate* OR detoxific* OR “oxidative damage” OR cytotoxicity

a Only the MeSH terms (or their equivalents (i.e., “ genetic toxicology ” OR genotoxic* OR “ DNA Damage ” OR “ DNA Repair ” OR m utagens OR m utation OR “c ytogenetic a nalysis ” OR o ncogenes OR “m utagenicity tests”) were used in the searches for debrominated metabolites.9/25/13 RoC Monograph on 1

- Bromopropane Appendix A

A

- 16 This Page Intentionally Left BlankAppendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 17 

## Appendix B: Human Exposure Tables and Regulations and Guidelines

Human exposure tables

The eight tables on the following pages contain data discussed in the “Properties and Human Exposure” section (Section 1) for the potential for occupational exposure (Section 1.4).

Data for 1

- bro mopropane exposure are reported for personal (Table B

- 1) and a rea samples (Table B

- 2) during adhesives applications
, personal (Table B

- 3) and area samples (Table B

- 4) during bromopropane manufacturing, personal (Table B

- 5) and area samples (Table B

- 6) duri ng dry

- cleaning applications, and personal (Table B

- 7) and area samples (Table B

- 8) during vapor degreasing applications. The symbol “

– “ shown before a range of concentration values in the tables denotes “data for mean not reported.”

Click here to return to text citing Appendix B

.

Table B

- 1

. Adhesives applications

– personal samples of 1

- bromopropane in air, urinary biomarkers (AcPrCys and Br), and 1

- bromopropane in blood and exhaled air

Location ( s ourc e) Type of j ob Number of workers 1

- B romopropane in a ir Urinary biomarkers

1

- BP in b lood,
m ean c onc. ( r ange), mg/L 1

- BP in

e xhaled
a ir, m ean c onc. ( r ange), ppm TWA ( r ange), ppm Short

- term

c onc. ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/(g

– Cr) Bromide,

m ean c onc. ( r ange), mg/(g

– Cr) Polyurethane seat cushion mfr.

– NC Hanley et al. 2005
, Hanley et al. 2006a
, Hanley et al. 2009 c Sprayers 13 a 92 b (45

– 200)

– 41.1 b (14.3

– 127) d 195 b (119

–

250) e

– 10.4 (3.2

– 20.6) f

Non

- sprayers 17 a 11 b (0.6

– 60)

– 10.2 b (0.373

– 1.5) d 42.9 b (5.5

– 149) e

– 5.8 (0.13

– 12.9) f

Furniture factory

– UT Majersik et al. 2007 Cushion g luer 6 108 g (92

– 127 g )

– – – [

– (440

– 1,700)] (values reported in mg/dL) –9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 18 Location ( s ourc e) Type of j ob Number of workers 1

- B romopropane in a ir Urinary biomarkers

1

- BP in b lood,
m ean c onc. ( r ange), mg/L 1

- BP in

e xhaled
a ir, m ean c onc. ( r ange), ppm TWA ( r ange), ppm Short

- term

c onc. ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/(g

– Cr) Bromide,

m ean c onc. ( r ange), mg/(g

– Cr)

Furniture foam cushion mfr.

– NC Harney et al. 2003
, Toraason et al. 2006 h Exposed

workers (1999 HHE) 16 81.2 b (18.1

– 253.9) – – – – –

All workers (2001 HHE) 40 3.7 b (0.1

– 280.5) – – [465 mg/L i (150

– 5,950)] [48 i (17

– 435)]

–

Unexposed workers (2001 HHE) 27 1.1 b (0.1

– 4.9)

– – [285 mg/L i (150

– 1,510)] [27 i (17

– 110)]

–

Exposed workers (2001 HHE) 13 i 45.7 b (7.2

– 280.5) – – [1,518 mg/L i (270

– 5,950)] [149 i (30

– 435)]

–

All sprayers (1999 HHE) 12 107.6 b (57.7

– 253.9) – – – – –

All sprayers (2001 HHE) 8 101.4 b (38.0

– 280.5) – – – – –

Commercial aircraft industry seat cushion mfr.

– NC Reh et al. 2002 All workers

(1998 HHE) 69 168.9 (60.0

– 381.2) – – – – –

All workers (2000 HHE) 30 19.0 (1.2

– 58.0)

– – – – –

Assembly workers k (1998 HHE) 36 169.8 (60

– 250.7) – – – – –

Assembly workers (2000 HHE) 11 18.8 (6.1

– 32.0)

– – – – –

Sprayers 15 193 (115.3

– – – – – –Appendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 19 Location ( s ourc e) Type of j ob Number of workers 1

- B romopropane in a ir Urinary biomarkers

1

- BP in b lood,
m ean c onc. ( r ange), mg/L 1

- BP in

e xhaled
a ir, m ean c onc. ( r ange), ppm TWA ( r ange), ppm Short

- term

c onc. ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/(g

– Cr) Bromide,

m ean c onc. ( r ange), mg/(g

– Cr) (1998 HHE) 250.7) Sprayers (2000 HHE) 12

– – (12.3

– 95.8) – – – –

Assemblers (1998 HHE) 20 154.7 (60.0

– 234.9) – – – – –

Cover workers (1998 HHE) 21 197.0 (117.3

– 381.2) – – – – –

Cover workers (2000 HHE) 12 29.2 (2.8

– 58.0)

– – – – –

Saw workers (1998 HHE) 12 117.1 (85.1

– 59.2) – – – – –

Saw workers (2000 HHE) 6 1.8 (1.6

– 2.0)

– – – – –

Sew worker (2000 HHE) 1 1.2 (

– )

– – – – –

Furniture company sofa cushion mfr.

– NC Harney et al. 2002
, Toraason et al. 2006 m Sprayers

(2000 HHE) 12

(TWA), 9 (Short

term) 65.9 (41.3

–

143.0) – (33.7

–

173.9) – – – –

Sprayers l (2001 HHE) 12

(TWA), 10 (Short

term) 16.6 (8.8

– 31.9)

– (0.2

– 56)

– – – –9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 20 Location ( s ourc e) Type of j ob Number of workers 1

- B romopropane in a ir Urinary biomarkers

1

- BP in b lood,
m ean c onc. ( r ange), mg/L 1

- BP in

e xhaled
a ir, m ean c onc. ( r ange), ppm TWA ( r ange), ppm Short

- term

c onc. ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/(g

– Cr) Bromide,

m ean c onc. ( r ange), mg/(g

– Cr)

Non

- sprayers (2001 HHE) 10

– (1.1

– 5.8)

– – – – –

Floaters (2000 HHE) 2

– (6.3

– 14.1)

– – – – –

Exposed workers (2001 HHE) 7

– – – 7.7 n (2.5

– 38.0)

– –

Sprayers (2000 HHE) 11

(TWA), 1 (Short

term ceiling) – – (39.5

– 151.9)

Sprayers (2001 HHE) 10

– – (< 0.14

– 8) Furniture company sofa cushion mfr.

– NC Ichihara et al. 2002 Sprayers 11 133 (60

– 261)

– – – – –

Furniture foam cushion mfr.

– NC Raymond and Ford 2007 Gluers 4

– – – – [

– (240

– 1,000)] o

–

Unidentified foam cushion fabricators Raymond and Ford 2007 Gluers 5

– (52

– 137)

– – – – –

Adhesives mfr.

– Exposed 3 a,p 3.79 b (0.264

– – 0.485 b (0.111

– 4.51 b (1.87

– – 0.10 q (ND

–Appendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 21 Location ( s ourc e) Type of j ob Number of workers 1

- B romopropane in a ir Urinary biomarkers

1

- BP in b lood,
m ean c onc. ( r ange), mg/L 1

- BP in

e xhaled
a ir, m ean c onc. ( r ange), ppm TWA ( r ange), ppm Short

- term

c onc. ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/(g

– Cr) Bromide,

m ean c onc. ( r ange), mg/(g

– Cr)
OH Hanley et al. 2007
, Hanley et al. 2010 workers 18.9) 1.22) 12.4) 0.18)

Unexposed workers 8 a,p 0.325 b (0.072

– 1.59) – 0.128 b (ND

– 1.33) 2.01 b (0.90

– 3.55) – –

a Workers in this study were sampled on two consecutive days so the total number of samples is twice ; e.g., for sprayers in Hanley et al. 2009, N = 13 x 2 = 26

. b Geometric mean.

c Raw data from Hanley et al. 2005 field study were used for analysis in Hanley et al. 2006a and Hanley et al. 2009

. d As cited in Hanley et al. 2009 . Forty

- eight hour composite u rinary AcPrCys concentrations, adjusted for creatinine.

e As cited in Hanley et al. 2006a . Forty

- eight hour composite urinary bromide concentrations, adjusted for creatinine.
f Combined mean, calculated from raw data reported for Day 1 post

- shift samp ling for 2 plants in Hanley et al. 2005 field study. Day 2 sampling data were mostly similar to Day 1 data.

g S even hour time

- weighted average and range; mean ambient air concentration = 130 ppm (range = 91

– 176 ppm).
h Toraason et al. 2006 study conducted on a sub

- population of 42 workers from Marx Industries NIOSH HHE who consented to participate in the study

. i End

- of

- week concentration in mg/L; geometric mean. Values reported in mg/dL. j Exposed workers included 8 sprayers and 5 other workers who were not actively spraying.
k As noted per Reh et al. 2002, d ata from 1 supervisor omitted.
l Day 2 sampling results: 11 sample s, mean = 16.8 ppm, range = 7.7

– 29 ppm. Day 3 sampling results: 11 samples, mean = 23.3 ppm, range = 14.3

– 34.9 ppm. Day 1 sampling results are shown in the table.

m Toraason et al. 2006 study conducted on a sub

- population of 22 workers from STN Cushion Company NIOSH HHE who consented to participate in the study

. n End

- of

- week concentration in mg/L; geometric mean.

o Value s reported as 3

– 12.5 mEq/L. Conversion factor: 8 mg/dL = 1 mEq/L
, Golomb 1999

. p As cited in Hanley et al. 2010

. q As cited in Hanley et al. 2007 for Day 1 post

- shift sampling for 11 total workers. Day 2 sampling data were mostly similar to Day 1 data. Click here to return to text citing Table B

- 1

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 22 Table B

- 2

. Adhesives applications

– area samples

Location ( s ource) Type of j ob/ a rea Number of samples Mean c onc. ( r ange), ppm Polyurethane seat cushion manufacturer, Plant A

– NC Hanley et al. 200 5 a Cloth cutting 2 0.9 b Sewing, south 2 14.1 b Sewing, north 2 20.4 b Spray table 1, farthest north 2 68 b

Pillow fill 2 16.7 b Polyurethane seat cushion manufacturer, Plant B

– NC Hanley et al. 2005 a Main glue, south of glue lines 1 36.9

Main glue, between glue lines 1 59.4

Cutting machine cage 1 1.0 Cutting table, near auxiliary glue line 1 10.5

Sewing table, near auxiliary glue line 1 2.7

Furniture foam cushion manufacturer

– NC Harney et al. 2003 Focus saw area near springs line (1999 HHE b ) 1 8.7

Cutting area adjacent to glue line (1999 HHE) 1 5.3

Commercial aircraft industry seat cushion manufacturer

– NC Reh et al. 2002 Sew department, randomly selected stations (1998 HHE) 11 128 .1 (107.3

– 160.9)

Sew department, randomly selected stations (2000 HHE) 5

– (1.1

– 1.9)

Furniture company sofa cushion manufacturer

– NC Harney et al. 2002 Middle of the saw room (2000 HHE) 1 7.7

Middle of the fabrication room (2000 HHE) 1 7.2

Middle of the poly cut room (2000 HHE) 1 1.7

Non

- sprayers (2001 HHE) 7

– (0.01

– 6.1) Furniture factory

– UT Majersik et al. 2007 Cushion glu ing 6 130 (91

– 176)

a Sampling conducted on two days; data shown for Day 1 sampling. Day 2 sampling data were mostly similar to Day 1 data.
b Time

- weighted average; two samples were collected at each location for approximately four hours each. For cloth cutting, the morning (AM) sample was 0.8 ppm and the afternoon (PM) sample was 1.0 ppm. For sewing, south, AM sample = 6.4 ppm, PM sample = 22.1 ppm; for sewing, north, AM sample = 12.3 ppm, PM sample = 28.8 ppm; for spray table 1, farthest north, AM sample = 43.2 ppm, PM sample = 94.0 ppm; for pillow fill, AM sample = 9.6 ppm, PM sample = 23.9 ppm.

c HHE = Health Hazard Evaluation. NIOSH conducted health hazard evaluation surveys at three facilities in the adhesives use sector (Reh et al. 2002, Harney et al. 2002)

. Click here to return to text citing Table B

- 2

.Appendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 2 3 Table B

- 3

. 1

- Bromopropane manufacturing

– personal samples

Location (Source) Type of Job Number of samples Air

TWA (Range), ppm Short

- term Conc.

(Range), ppm Mfg. plant, China Ichihara et al. 2004a Operators (Female

workers) 24

– (0.9

– 170.5)

–

Various (Male workers) 13

– (ND a

– 43.3)

–

Mfg. plant, China Ichihara et al. 2004b Material/Product

handlers (Female workers) 23 2.92 b (0.34

– 49.2)

–

Mfg. plants, China Li et al. 2010 b Material/Product

handlers (Female workers) 60 6.6 c (0.07

– 106.4)

–

Material/Product handlers (Male workers) 26 4.6 c (0.06

– 114.8)

–

Mfg. plant, unspecified location Ichihara et al. 2006 Not reported 40 15.3 (0.65

– 73.7)

–

a Not detectable; detection limit = 0.13 ppm.
b Geometric mean.

c Median. Click here to return to text citing Table B

- 3.

Table B

- 4

. 1

- Bromopropane manufacturing

– area samples

Location ( s ource) Type of j ob/ a rea Number of samples Mean c onc. ( r ange),

ppm Mfg. plant, China Ichihara et al. 2004a Various; in front of reaction pot, in

front of stock vessel, above bottle when pouring solution into bottles, product analysis room, site outside plant for washing vessel Not reported

– (1.1

– 90.2)

Mfg. plants, China Li et al. 2010 b Various; reaction pot, distillation pot,

raw product collection 30

– (2.2

– 22)

Various; reaction pot, distillation pot, recording spot 9

– (ND

– 16.5)

Various; reaction pot, distillation pot, raw product collection 64

– (ND

– 88)

Various; reaction pot, operation desk, aisle 72

– (ND

– 22)

ND = Not detected. Click here to return to text citing Table B

- 4

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 24 Table B

- 5

. Dry

- cleaning applications

– personal samples of 1

- bromopropane

Location ( s ource) Type of j ob Number of
s amples Air

TWA ( r ange), ppm Partial shift

c onc., ppm (minutes) Dry

- cleaning facility 1 Eisenberg and Ramsey 2010 Operator 2 40 (23

– 56)

– Cashier 2 17 (10

– 24)

–
Dry

- cleaning shops Blando et al. 2010 a Operator, shop A NR

– (12.7

– 54.55)

– Operator, shop B NR 41.64

– Operator, shop C NR

– (< 0.004

– 0.35)

– Clerk, shop A NR

– (8.31

– 21.85)

– Clerk, shop B NR 0.65

– Seamstress, shop C NR < 0.004

– Dr y

- cleaning facility 2 Eisenberg and Ramsey 2010 Operator 1

– 7.2 ( 209 min)
Cashier 1

– 1.5 (212 min)

Dry

- cleaning facility 3 Eisenberg and Ramsey 2010 Operator 1

– 11 (163 min)

Dry

- cleaning facility 4 Eisenb erg and Ramsey 2010 Operator 1

– 160 (241 min)
Cashier 1

– 2.4 (246 min)
NR = Not reported.

a Ranges are reported because data points were collected over a 4

- day period depending on the shop owner’s willingness to participate in the study (i.e., Shop A has sampling data for all 4 days , Shop B for only 1 day, and Shop C for 3 days ). Click here to return to text citing Table B

- 5.

Table B

- 6

. Dry

- cleaning applications

– area samples of 1

- bromopropane in air

Location ( s ource) Type of j ob/ a rea Air concentration , ppm a
Dry

- cleaning facility 1 Eisenberg and Ramsey 2010 Behind dry

- cleaning machine, morning 103 Behind dry

- cleaning machine, afternoon 48 In front of dry

- cleaning machine, morning 66 In front of dry

- cleaning machine, afternoon 36

Dry

- cleaning facility 2 Eisenberg and Ramsey 2010 Behind dry

- cleaning machine 1.5 In front of dry

- cleaning machine 6.4

Dry

- cleaning facility 3 Eisenberg and Ramse y 2010 Front counter 8.6Appendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 25 Location ( s ource) Type of j ob/ a rea Air concentration , ppm a
Dry

- cleaning facility 4 Eisenberg and Ramsey 2010 Behind dry

- cleaning machine 170 In front of dry

- cleaning machine 33

Dry

- cleaning shops Blando et al. 2010 Rear left of shop by machine, shop A 17.66 Front right of shop b y customer counter, shop B 3.8

Front left of shop by customer counter, shop B 2.67

Rear right of shop, shop B 3.17 Rear left of shop by machine, shop B 5.4 Rear right of shop, shop C < 0.004 Rear left of shop by machine, shop C < 0.004
Rear left of shop by machine, shop D 20.47 Unidentified New Jersey dry

- cleaning facility MMWR 2008 During handling of clothes 75

– 250 times bac kground levels

a One measurement per location was reported. Click here to return to text citing Table B

- 6

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 26 Table B

- 7

. Vapor degreasing applications

– personal samples of 1

- bromopropane in air, of urinary biomarkers (AcPrCys and B r - ), and of 1

- bromopropane in exhaled air

Location ( s ource) Type of j ob Number of TWA samples 1

- BP in a ir U rine

1

- BP in e xhaled a ir,
m ean c onc. ( r ange), ppm Mean TWA ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/L Bromide, m ean

c onc. ( r ange), mg/L Helicopter transmission factory Hanley and Dunn 2006 b Plating (Day 1) 5 a 1.55 (0.077

– 3.23) [2.134 (0.028

–

7.551)] c 8.5 (4.7

– 12.5) 0.17 (0.12

– 0.22)

Aerospace components mfr., Plant A , Plant B
, Hanley et al. 2006b b Cell/corrosion
t reatment , non

destructive testing, paint and wire dept. (Plant A ) (Day 1) 7 a 0.69 (0.19

– 1.1) [0.25 (0.0156

–

0.883)] c 4.1 (1.9

– 8.1) 0.23 (0.12

– 0.38)

Assembly prep, repair

- overhaul, paint and wire dept. (Plant B ) (Day 1) 4 a 1.5 (0.82

– 2.1) [1.35 (0.607

– 2.390)] c 14 (7.6

– 21) 0.23 (0.11

– 0.33)

Hydraulic power control component mfr. Hanley and Johnson 2007b b Assembly dept. (Day 1) 4 a 0.85 (0.22

– 1.4) [1.01 (0.15

–

3.21)] c 3.9 (1.1

– 7.9)

– (ND

– 0.20 d )

Optical prism and assemblies mfr. Hanley and Dunn 2007 b Milling and maintenance workers (Day 1) 7 a 5.1 (0.52

– 9.8 ) [2.52 (0.289

– 5.92)] c 13 (3.7

– 23) 0.90 (0.10

– 2.5)

Printed electronics circuit assembly mfr. Assembly dept. (Day 1) 5 a 7 .0 (1.3

– 14) [5.54 (0.351

– 13.3)] c 34 (8.6

– 67) 2.9 (0.30

– 6.1)Appendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 27 Location ( s ource) Type of j ob Number of TWA samples 1

- BP in a ir U rine

1

- BP in e xhaled a ir,
m ean c onc. ( r ange), ppm Mean TWA ( r ange), ppm AcPrCys,

m ean c onc. ( r ange), mg/L Bromide, m ean

c onc. ( r ange), mg/L Hanley and Johnson 200 7a b

F acilities in the five rows shown above, near degreasers and away from degreasers Hanley et al. 2010 b Near degreasers (Day 1) 22 a 2.63 e (0.078

– 21.4) 1.33 f (0.0108

–

24.2) 8.94 f (1.69

– 115)

–

Away from degreasers (Day 1) 9 a 0.308 e (0.077

– 1.69) 0.115 f

(0.00512

– 0.726) 3.74 f (1.69

– 15.6)

–

Below

- boiling vapor degreaser Reh and Nemhauser 2001 Assembler 20

– (0.01

– 0.63)

– – –

a Number of workers is reported; note that each worker was sampled on two consecutive days so the total number of samples is x 2 ; e.g., for Hanley and Dunn 2006, N = 5 x 2 = 10

. b Raw data for TWA air concentrations and urinary bromide and AcPrCys concentrations from Hanley and Dunn 2006
, Hanley et al. 2006b
, Hanley and Du nn 2007
, Hanley and Johnson 2007a
, and 2007b field studies were used for summary analysis presented in Hanley et al. 2010 . Data categorized by workers “near degreasers” and “away from degreasers” not presented in Hanley and Dunn 2006
, Hanley et al. 2006b
, Hanley and Dunn 2 007
, Hanley and Johnson 2007a
, and 2007b field studies.

c Data reported in μg/L.
d ND = not detected. 1

- B romopropane was only detected in one sample for this collection period.

e Geometric mean.
f Geometric mean. Forty

- eight hour composite c oncentration, adjusted for creatinine; units are mg/(g

- Cr). Click here to return to text citing Table B

- 7

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 28 Table B

- 8

. Vapor degreasing applications

– area samples

Location ( s ource) Type of j ob/ a rea Air concentration , ppm a

V apor degrease

r Reh and Nemhauser 2001 On exhaust duct above degreaser 4.42 On cart, 5 feet from degreaser 1.70 Outside of cleaning room (5 samples) 0.02

– 0.03 On metal rack, near degreaser room door 0.02 Near degreaser room window 0.02 Five feet from degreaser room window 0.02 Office next to degreaser room 0.02

a One measurement per location was reported. Click here to return to text citing Table B

- 8

.Appendix B RoC Monograph on 1

- Bromopropane 9/25/13

A

- 29 Regulations and guidelines

Table B

- 9 . Existing U.S. standards and guidelines with exposure limits for 1

- bromopropane (ppm) a

Type of Guideline Duration of exposure

8 hours

Threshold Limit Value Time Weighted Average (ACGIH) 10

Permissible Exposure Limit (PEL)

– Time Weighted Average (California OSHSB) 5

Acceptable Exposure Limit

– Time Weighted Average (EPA) b 25

a As cited in CDC 2008
, FR 2003

. b The EPA acceptable exposure limit is a non

- binding, recommended, voluntary workplace exposure limit. Because there is currently no OSHA PEL for 1

- bromopropane, EPA

– under the Significant New Alternatives Policy ( SNAP ) program

– determined a safe workplace ex posure to evaluate whether the use of 1

- bromopropane would pose significantly greater risk than the use of other substitutes available in the same end uses
, EPA 2007

.
Note: The EPA SNAP progra m reviews alternatives to ozone

- depleting substances and approves the use of alternatives that do not present substantially greater risk to the public health and environment than the substance they replace or other available su bstitutes. Table B

- 10 lists EPA SNAP pr ogram determinations regarding different end uses of 1

- bromopropane ( EPA 2007
, FR 2007

- information is current as of 1/18/13 )

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix B

A

- 30 Table B

- 10 . EPA SNAP program determinations regarding different end uses of 1

- bromopropane

1

- bromopropane end use Substitute EPA SNAP program determination Solvent in industrial equipment for metals cleaning, electronics cleaning, or precision cleaning 1

- bromopropane as a substitute for CFC

– 113 and methyl chloroform Acceptable a

Coatings 1

- bromopropane as a substitute for CFC

– 113, HCFC

– 141b, and methyl chloroform Acceptable subject to the use condition that use is limited to coatings facilities that have provided EPA data which demonstrates their ability to maintain acceptable wor kplace exposures b

Aerosol solvents 1

- bromopropane as a substitute for CFC

– 113, HCFC

– 141b, and methyl chloroform Unacceptable b

Adhesives 1

- bromopropane as a substitute for CFC

– 113, HCFC

– 141b, and methyl chloroform Unacceptable b

a EPA final rule
, EPA 2007

. b EPA proposed rule
, FR 2007

.
Note: The American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit value (TLV) of an 8

- hr time

weighted average of 10 ppm is being considered for a change to 0.1 ppm in the Notices of Intended Changes (NIC) for the 2013 TLVs ( ESIS 2012 ) . Exposure limits propos ed by vendors of 1

- bromopropane

– based products range from 5 to 100 ppm ( EPA 2007 )

. Click here to return to text citing Table B

- 10

.Appendix C RoC Monograph on 1

- Bromopropane 9/25/13

A

- 31 

## Appendix C : Assessment of the Q uality of the Individual Animal Cancer S tudies

Only two studies were identified that met the inclusion criteria and th e s e stud ies was evaluated for study qualit y. Because similar protocols were used for the NTP 2

- year bioassays in rats and mice and results of assessments were similar, t he studies are considered together in the table below. Each primary study was systematically evaluated to determine if it is informative for a cancer assessment. Studies that were given the most weight in the evaluation are those t hat we re of sufficiently long duration to identify a cancer endpoint (ideally an exposure approaching the lifetime of the animal), and provide d a detailed account of the study design and data collection

. Ideally, studies should use an exposure route comparable to human exposure an d appropriate statistical methods in reporting of results. Comparison with historical control values is sometimes helpful in assessing the significance of a finding, especially in the case of rare tumors, lower powered studies
, or assessment of background tumor incidences. The number of animals used in a study, the incidence of tumors in control vs. treated group, and the rarity of a tumor influence the statistical power of a study to detect an effect and are parameters that need to be taken into account in study design and results assessment. Post hoc power calculations can be performed. However, rare tumors will be considered in the assessment even if their incidence does not reach significance. Study performance elements for evaluating the different compo nents of study quality are described below.
Click here to return to text citing Appendix C in the foreward

. Click here to return to text citing Appendix C in Section 4.

NTP TR 564 Inhalation Toxicology and Carcinogenesis Studies of 1

- Bromopropane (CAS No. 106

- 94

- 5) in Rats and Mice

Substance c haracterization Independent experiments were conducted in rats and mice at Battelle Toxicology Northwest (Richland, WA) Is the chemistry of the substance well characterized? Are the purity, solubility and stability adequate for attributing any adverse effects to the substance? Yes. Overall purity of the chemical was determined by gas chromatography and three impurities were identified as 1

- pr opanol (0.03%), 2

- bromopropane (0.02%), and di

- n

- propylether (0.02%); stability of bulk chemical, and vapor concentration throughout the experiment monitored against a standard by gas chromatography.

Animal husbandry
Are the source, species, and stra in of the animals adequately described? Yes . Rats (F344/N) and mice (B6C3F 1 ) were from Taconic Laboratory Animals and Services (Germantown, NY).

Are the care, diet, housing and maintenance of the animals adequate for attributing any adverse effects to the substance? Yes. The studies were conducted in and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) inspected and approved facility; testing was also done on bedding, water and diet for possible chemical contamination; sentin el animals were used and9/25/13 RoC Monograph on 1

- Bromopropane Appendix C

A

- 32 sera tested for subclinical disease

. Were control animals housed in the same room, and tested at the same time under the same conditions as the dosed groups? Yes . Each animal was housed individually. Animal care and maintenance we re described.

Study design Animal model: Are the species and sex appropriate for determination of any exposure

related effect? Were the dose groups randomized? Yes. Rats and mice of both sexes were tested; there is an a dequate historical control data bas e on these species and strains for inhalation studies from this laboratory.

Dosing and observation conditions: Are the study period, dosing period, route of exposure, and doses used adequate for determination of any adverse effect? Yes. The animals were exposed throughout most of their lifespan (2 yr) by inhalation at a route relevant to human exposure.

Statistical Power: Does the study have adequate number of animals per group to detect an adverse effect, if present? These studies follow NCI/NTP guide lines wi th respect to number of animals (Haseman JK. 1984 . Environ Health Perspect, 58: 385

- 392 ). Whether the adverse effect is statistically significant will depend on 1) what the tumor endpoint is and 2) the incidence of spontaneous tumors for that endpo int. Based on available historical NTP control data, skin tumors and intestinal adenomas in rats and the lung tumors in mice

were were detected at approximately 70% power; mesotheliomas and pancreatic islet

- cell tumors in rats were below 50% power.
Clinic al observations, necropsy and pathology

Were clinical observations performed? Yes. A timetable of clinical observations was reported.

Was a full necropsy done on these animals and was histopathology done on tissues from at least all major organs? Yes. Complete necropsies were done on all animals. All organs and tissues were examined for gross lesions and complete histopathology was performed on all major organs.

Are pathology procedures well described and adequate for determination for any exposure

rel ated effect? Yes , tissue fixation method, microscopic evaluations and quality assessment of the data are presented

.

Data reporting and statistical methods
Is data reporting well characterized? Yes . Data are presented in a tabular format; individual animal data are provided in appendices. Have tumors (benign/malignant) from the same organ been appropriately combined? If so, do they originate from the same cell type? e.g. , fibrosarcoma would not be combined with adenoma. Yes (Rats) Yes (Mice)

We re statistical analyses performed on the data and adequately described? Yes (Rats) Yes (Mice)Appendix C RoC Monograph on 1

- Bromopropane 9/25/13

A

- 33 Are appropriate historical control data available? Historical control values for studies by inhalation and by all routes are reported.
Are these studies inform ative for cancer assessment ? Yes (Rats) Yes (Mice) No major limitations on cancer study quality were found.9/25/13 RoC Monograph on 1

- Bromopropane Appendix C

A

- 34 This Page Intentionally Left BlankAppendix D RoC Monograph on 1

- Bromopropane 9/25/13

A

- 35 

## Appendix D : Genotoxicity Studi es

The five tables on the following pages contain data discussed in the “Mechanisms and Other Relevant Effects” section (Section 5) for genetic an d related effects (Section 5.1)

. Data are reported for in vitro studies of 1

- bromopropane mutagenicity in bacteria (Table D

- 1), in vitro genotoxicity studies of 1

- bromopropane in mammalian cells (Table D

- 2), in vivo studies of cytogenetic effects of 1

- bromopropane in rodents (Table D

- 3), in vivo studies of cytogenetic effects of 1

- bromopropane in humans (Table D

- 4), and a summary of in vitro and in vivo studies of genotoxicity of 1

- bromopropane metabolites (Table D

- 5)

. Click here to return to text citing Appendix D

.
Table D

- 1. In vitro studies of 1

- bromopropane mutagenicity in bacte ria

Reference Strain Method LED/HID Results Cytotoxicity Evaluation: limitations and conclusions a

– S9 + S9

– S9 + S9

– S9 + S9 Barber et al. 1981 S. typhimurium

TA98
, TA100 TA1535 Plate

incorporation; closed

- system incubation TA98 (HID)

2,497 μg/plate b

TA100 (LED) 1107 μg/plate b

TA1535 (LED) 603 μg/plate b TA98

(HID) 2
, 497 μg/plate b

TA100 (LED) 1107 μg/plate b

TA1535 (LED) 603 μg/plate b –

+

+ –

+

+ NR

NR

NR NR

NR

NR No toxicity was observed

up to and including the highest dose tested ( 2,497 μg/plate b ) for each strain.

For strains showing mutagenicity, positive effects were observed at the same doses for with or without S9.

Test results with other strains, TA1537 an d TA1538, reported as negative (data not provided by study authors).9/25/13 RoC Monograph on 1

- Bromopropane Appendix D

A

- 36 Reference Strain Method LED/HID Results Cytotoxicity Evaluation: limitations and conclusions a

– S9 + S9

– S9 + S9

– S9 + S9 Elf Atochem 1994 , as cited in NTP 2003 a S. typhimurium

TA98, TA100, TA1535, TA1537, TA1538 Protocol (plate

incorporation

or preincubation) not specified; closed

- system incubation 10,000

μg/plate 10,000

μg/plate – – 10,000 μg/plate 10,000

μg/plate A brief description of this

study was presented in the NTP 2003 review, but protocol not specified, and number of replicate plate s and resultant data (i.e., numbers of revertants/ plate for each dose of the tested strains) were not provided. Insufficient information to evaluate because protocol not specified

. Kim et al. 1998 , as cited in NTP 2003 a S. typhimurium

TA98, TA100 TA1535, TA1537 and Protocol not

specified and no indication if closed

- system was used 5,000

μg/plate 5,000

μg/plate – – NR NR A brief description of this study was presented in the NTP 2003 review, but the protocol was not specified and details on methods (e.g., s olvent ) and observations regarding cytotoxicity were not given. Also, the number of replicate p lates and resultant data (i.e., numbers of revertants/ plate for each dose of the tested strains) were not provided. Insufficient information to evaluate because protocol not specified

. E. coli WP2uvrA 5,000 μg/plate 5,000

μg/plate – – NR NRAppendix D RoC Monograph on 1

- Bromopropane 9/25/13

A

- 37 Reference Strain Method LED/HID Results Cytotoxicity Evaluation: limitations and conclusions a

– S9 + S9

– S9 + S9

– S9 + S9 NTP 2011a (two studies, independent contract labs) Study 1

S. typhimurium TA97, TA98, TA100, TA1535 Preincubation All strains: 10,000 μg/plate
, but ≥ 3,333 g/plate was too toxic to evaluate All strains:

10,000 μg/plate
, but ≥ 3,333 g/plate was too toxic to evaluate – – ≥ 3,333 g/plate ≥ 3,333

g/plate A ll strains were tested to

10,000 μg/plate ; unable to adequately evaluate mutagenicity at doses ≥ 3,333 μg/plate due to high toxicity. Not mutagenic at non

toxic doses

. +S9: 10 % and 30% rat or hamster. Study 2 used same chemical lot as 2

- year NTP bioassay. Not mutagenic. Study 2 S. typhimurium TA98, TA100 Preincubation Both strains: 5,000 μg/plate Both strains:

10,000 μg/plate – – ≥ 3,500 μg/plate TA98:

10,000 μg/plate +S9: 10% rat.

TA100: not toxic at highest dose (10,000 μg/plate) tested. Not mutagenic.
E. coli WP2uvrA/ pKM101 Standard

protocol 5,000

μg/plate 10,000

μg/plate – – ≥ 5,000 μg/plate +S9: Not toxic at highest

dose (10,000 μg/plate) tested. Not mutagenic. LED/HID = lowest effective dose / highest ineffective dose, NR = not reported
, + = positive,

– = negative.

a Evaluations of some studies (as indicated) presented in this table are limited by the information provided in the cited revie w paper. b Reported dose levels of 1

- bromopropane were determined by using gas liquid chromat ography to analyze samples of distilled water that were in the test chambers during treatment. T o facilitate comparison with other studies, data reported by these authors as μmole s per plate were converted to μg/plate. Click here to return to text citing Table D

- 1.9/25/13 RoC Monograph on 1

- Bromopropane Appendix D

A

- 38 Table D

- 2. In vitro studies of 1

- bromopropane in mammalian cells

Reference Effect Test system Concentration (LEC or HIC) Cytotoxicity Results Evaluation: limitations and conclusions a

- S9 +S9
Elf Atochem 1994 , cited in NTP 2003 a Mutation L5178Y m ouse lymphoma cells (2 experiments) - S9: 1,000mg/L

+S9: 1,500 mg/L ≥ 2,000 mg/L

(10 %

– 60% RTG) + + Adequate information provided in NTP review on methodology ; reproducible two

- fold increase in mutation frequency and evidence of dose response, but actual numbers of revertant colonies not available. Evidence of mutagenicity.
Toraason et al. 2006 DNA

damage (dose response) Comet assay,

using human leukocytes from venous blood from unexposed adult males. LEC = 1 mM

8

- hr exposure Dose Comet tail (mM) moment a
0 1000 0.01 1000 0.1 1250 1.0 3500* ND Did not perform assays in presence of S9, since Barber et al. 1981 had previously shown 1

- bromopropane to be mutagenic with or without added metabolic activation in the S. typhimurium assay. Evidence of DNA damage. DNA damage (temporal response) Comet assay,

using human leukocytes from venous blood from unexposed adult males. LEC = 1 mM

4

- hr exposure Exp Comet tail (hr ) moment a
1 750 2 750 4 1250* 8 3250* ND

Apoptosis DNA diffusion

assay using human leukocytes LEC = 0.1 mM Dose Apoptotic (mM) cells (%) a
0 2.75 0.01 2.50 0.1 3.25* 1.0 4.75* ND

Exp = Exposure, LEC/HIC = lowest effective concentration/highest ineffective concentration, ND = not done, RTG = relative total growth.

* P < 0.05 (ANOVA)

. a Data estimated from graph. Click here to return to text citing Table D

- 2.Appendix D RoC Monograph on 1

- Bromopropane 9/25/13

A

- 39 Table D

- 3. In vivo studies of cytogenetic effects of 1

- bromopropane in rodents

Reference Endpoint Species/sex/# Exposure Results Comments and evaluation a

Kim et al. 1998
, cited in NT P 2003 a Micronuclei Rat (Sprague

Dawley) bone marrow males and females 10 animals/ sex/group Inhalation

0, 50, 300, 1,800 ppm 6 hr/ day for 5 days/ week for 8 weeks No increases in bone

marrow micronucleated polychromatic erythrocytes Information limited to that provided in summary of study in review; values for micronuclei were not provided.
NTP 2003 a stated that animals exposed to 1
, 800 ppm had decreased bodyweight and ataxia.
Treatment doses differed by a factor of 6 ; intermediate doses

m ight have been informative. Negativ e

. Elf Atochem 1994 , cited in NTP 2003 a Micronuclei Mouse (Swiss mice) bone

marrow males and females 5 animals/ sex/group Intraperitoneal

injection M: 0, 100, 400, 600, 800 mg/kg F: 0, 100, 400, 800 mg/kg Two injections; animals sacrificed 24 hr after last injection. Bone marrow

micronucleated erythrocytes M: 600 mg/kg

- no increases F: 800 mg/kg

- no increases Information limited to that provided in summary of study in review; values for micronuclei were not provided. Only 800 mg/kg for females and 600 mg/kg for males were evaluated for micronuc lei because the PCE/NCE ratio in controls from other doses (100, 400) were outside the historical control range Negative

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix D

A

- 40 Reference Endpoint Species/sex/# Exposure Results Comments and evaluation a

NTP 2011a Micronuclei Mouse (B6C3F 1 ) peripheral blood eryth rocytes males and females 5 animals/ sex/group Inhalation: 3 mo

0 ppm 62.5 125 250 500 NCE b

Males Females 2.0 0 0.61 1.80 0.25 3.10 0.81 1 .70 0 .25 2.70 0.64 1.60 0.19 1.30 0.41 1.40 0.33 2.30 0.46 1.80 0.20 Percent of polychromatic erythrocytes (reticulocytes) was unaltered indicating a lack of bone marrow toxicity

. Negative

.

Saito

- Suzuki et al. 1982 Dominant

lethal mutation
assay Rat (Sprague

Dawley) 15 exposed males mated with females (1 female/ week/male) for 8 weeks, examined vital sta t us of fetuses 13

- 14 days after mating Gavage

400 mg/kg 5 days Week DLMI c

1

- 2.1 2 1.8 3 0.4 4 1.3 5 3.3
6 8.0 7 0.9 8 9.3 An increase in the number of dead implants in fetuses from rats mated 8 weeks after 1

- bromopropane exposure compared with controls was observed but the mutational index was not increased

. Negative

.

Yu et al. 2008 Dominant

lethal mutation assay Mouse (ICR) 20

males /exposure group, mated with 40 unexposed females (2 females/week/ male) for 6 weeks ; examined vital status of fetuses at 15 to 17 days gestation Gavage

Males exposed to 300 or 600 mg/kg/day 10 days Week DLMR d
300 600 1 0.17

- 0.26 2 2.17 0.88 3 0.3

- 2.71 4 3.14

- 2.03 5 2.98

- 4.66
6 3.68 0.27 Negative

.

DLMI = Dominant Lethal Mutation Index, DLMR = Dominant Lethal Mutation Rate
, NCE = normochromatic erythrocytes.

a Evaluations of some studies (as indicated) presented here are limited by the information provided in th e cited review paper.
b Micronucleated NCEs/1000.

c (1

- live embryos per test female/live embryos per control female) x 100.
d (1

- [{ mean of live fetuses in treated group/mean of implants in treated group } x { mean of implants in controls/m ean of live fetuses in controls} ] ) x 100. Click here to return to text citing Table D

- 3.Appendix D RoC Monograph on 1

- Bromopropane 9/25/13

A

- 41 Table D

- 4. In vivo studies of 1

- bromopropane in humans

Reference Effect Population and analyses Exposure Results Evaluation: limitations and conclusions

Toraason et al. 2006 DNA damage

Comet assay: Tail moment and dispersion coefficients a; 100 leukocytes per sample Population

64 workers (18 males and 46 females) at two spray adhesive facilities (A and B)

Facility A (42 ) 29 non

- sprayers 13 sprayer s

Facility B (22) 16 non

- sprayers 6 sprayers

Analyses Exposure to 1

- bromoprop a ne and DNA damage were evaluated by analyses involving (1) facility and job type, and (2) exposure indices (workplace air, urine and serum) in multivariate models controlling for age, gender, facility, cigarette smoking and GSTM1 and GSTT1 polymorphisms. Exposure assessed by TWA ( ppm ) and bromide serum (mg/d L ) and urine levels (mg/d L ). Facility/ TWA Urine b Serum b worker A/NS 2 ± 2 28 ± 9 2.6 ± 0.7 A/SP 83 ± 85 23 8 ± 17 19.5 ± 11.4 B/NS 5 ± 1 2 ± 2 0.3 ± 0.1 B/SP 21 ± 5 10 ± 14 0.9 ± 0.3

TWA significantly correlated with both
start

- of

- week and end

- of

- week urine and serum bromide conce ntrations Analysis by work type and facility Facility A

NS SP TM/Start 2517 2867 TM/End 3080* 3178 TMD/Start 562 496 TMD/End 678 752* Facility B NS SP TM/Start 2856 3430 TM/End 2770 2974 TMD/Start 580 596 TMD/End 653 616

Analysis by exposure indices Tail moment

- P values

Start End TWA (log) 0.654 0.148 d Urine (log) 0.075 c 0.108 d Serum (log) 0.191 0.171 d TWA (EQ) 0.567 0.016 d Urine (EQ) 0.106 c 0.141 Serum (EQ) 0.007 c 0.049 d
Dispersion coefficient

– no statistically significant End

- of

- the

- work week DN A damage (TMD) was higher, albeit not statistically significant, among workers (sprayers and non

- sprayers) at both facilities with GSTM1

- positive genotypes. In multivariate analysis, GSTM1 had a significant effect in models of end

- of

- work week DNA damage ( T MD) and 1

- bromopropane TWA log

transformed levels. The exposure quartile analys es might have had greater statistical power than the models using log

- transformed values since participants with missing data for one exposure indices could be included in the

a nalyses based on their ranking for another exposure indices. Strengths : Wide range of exposures allowed for evaluation of exposure response. Assessment of 1

- bromopropane exposure was at the individual level. Multivariate analyses was considered to be more informative than the analysis by job and facility
Limitations : Small numbers of9/25/13 RoC Monograph on 1

- Bromopropane Appendix D

A

- 42 Reference Effect Population and analyses Exposure Results Evaluation: limitations and conclusions
associations observed between DNA damage and exposure to 1

- bromopropane in any of the models. subjects, no unexposed controls, multiple comparisons.
Conclusion : Limited evidence that exposure to 1

- bromop ropane causes DNA damage in leukocytes from workers

.

EQ = exposure quartiles model, ppm = parts per million, NS = non

- sprayer, SP = sprayer, TWA = time weighted average
, TM = tail moment, TMD = tail moment dispersion coefficient. *End

- of

- the

- work week measure s significantly higher than start

- of

- the

- work week measures for the same individual ( p aired t

- test , P < 0.05).

a Dispersion coefficient = variance divided by mean of tail moment from 100 leukocytes

. b End of week measure.

c Significant association of facility in model.
d Significant association of gender in model. Click here to return to text citing Table D

- 4

.Appendix D RoC Monograph on 1

- Bromopropane 9/25/13

A

- 43 Table D

- 5. Summary of i n vitro and in vivo studies of 1

- bromopropane metabolites

Test System Effect Glycidol Propylene oxide -

B romohydrin 3

- Bromo

- 1

-

propanol 1

- Bromo

- 2

-

propanol

- S9 +S9

- S9 +S9

- S9 +S9

- S9 +S9

- S9 +S9 In vitro

Bacteria Mutation # + a + a + b + b + c, d + c, d + * , d + * , d

DNA damage + a + * b + * , b + *, e + *, e DNA adducts + f, g
Yeast Mutation + a + *, a + b + *, b

Gene conversion + *, b
Insects Mutation + *, a + b, h, i

Heritable translocation + *, a DNA adducts + *, h
Mammalian cells (other than human) Mutation + a + *, a + b

Chromosomal damage + a + a + b + *, b DNA damage + a, j + *, a + b + *, b DNA adducts + *, a + *, k
Human cells Chromosomal damage + *, a + b

DNA damage +/

– a + *, a + b, l, m, n In vivo Mammals (rodents, dogs, monkeys) Mutation (germ cell)

– b

Chromosomal damage +/

– a +/

– b DNA adducts + b, k, o, p, q Binding to protein + b, p, r Human: exposed workers Chromosomal damage ? b

DNA damage + *, s DNA adducts + b , s Binding to protein + b , s Sources: a IARC 2000
, b IARC 1994
, c Stolzenberg and Hine 1979
, d Stolzenberg and Hine 1980
, e Hyman et al. 1980
, f Mazon et al. 2009
, g Snow et al. 1994
, h Nivard et al. 2003
, i Vogel and Nivard 1997
, j El Ramy et al. 2007
, k Plna et al. 1999
, l Chovanec et al. 2001
, m Kolman et al. 1997
, n Fabiani et al. 2012
, o Segerbäck et al. 1998
, p Ríos

- Blanco et al. 2000
, q Ríos

- Blanco et al. 2003
, r Couch et al. 1996
, s Czene et al. 2002

. + = Positive in all or most of available studies;

– = negative in all or most of available studies; +/

– = available studies are mixed positive and negative, ? = inconclusive (variable response in adequate study).

# Mutation test results were positive for multiple bacterial strains, except for

- bromohydrin, which was positive for S. typhimurium TA100 but not TA98, and for 3

- bromo

- 1

- propanol, which was only tested in TA100.

* Result is based on one study

. Click here to return to text citing Table D

- 5

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix D

A

- 44 This Page Intentionally Left BlankAppendix E RoC Monograph on 1-Bromopropane 9/25/13

A- 45 

## Appendix E: Relevant Toxicological Effects

Studies on neurological, developmental, reproductive, immunological, and hepatotoxic effects were identified to determine whether they could inform potential mechanisms of carcinogenicity. Several studies indicate that metabolic activation and glutathione depletion are important factors for many of the toxic effects observed in rodents. Appendix E provides a brief review of the toxic effects that have been linked to metabolic activation and/or glutathione depletion and oxidative stress and other alterations and provides background information for Section 5.3, which discuss es these mechanisms as they related to carcinogenicity.
Click here to return to text citing Appendix E in Section 4.
Click here to return to text citing Appendix E in Section 5.
Click here to return to text citing Appendix E in Section 6.

Reproductive toxicity NTP (2003a) evaluated the reproductive toxicity of 1-bromopropane. There was convincing evidence that 1-bromopropane caused reproductive effects in experimental animals but the evidence in humans was limited to a health hazard survey conducted by NIOSH at a plant that used a spray adhesive that contained 1- br omopropane. Three of 42 workers reported fertility problems (2 males and 1 female). Ichihara et al. (2002) presented case reports for three female workers who used a spray gun with 1- bromopropane as a solvent. Most of the symptoms and signs were neurological in nature but two of the women reported irregular periods and decreased sexual desire.
NTP (2003a) also reviewed a two-generation reproductive toxicity study that reported significant effects in males, females, and offspring. Reproductive capabilities were examined in the F 0 and F 1 generations, and neonatal survival, growth, and development were evaluated in the F 1 and F 2 offspring. Whole-body inhalation exposures (6 hours/day, 7 days/week at nominal concentrations of 100, 250, 500, or 750 ppm) began at 7 weeks of age for the F 0 parents and at weaning for the F 1 generation. Exposures began at least 70 days prior to mating. Prior to weaning on postnatal day 22, the F 1 offspring were indirectly exposed to the test chemical in utero and through nursing. Effects in F 0 parents included reduced sperm motility and prostate weight, abnormal sperm, increased estrous cycle length and ovarian follicular cysts, decreased numbers of implantation sites and litter size, and complete infertility in the high-dose group (750 ppm). Reproductive effects in F 1 offspring were similar. The only significant effect reported in the F 2 rats was reduced postnatal weight gain. Other studies reported that Wistar rats exposed to 1-bromopropane for 12 weeks had decreased sperm count and sperm motility, irregular estrous cycles, and a decrease in the number of normal growing follicles (NTP 2003a
, 2011a).
Some of the reproductive effects have been linked to metabolic activation. Garner et al. ( 2007 ) investigated the relationship between 1-bromopropane oxidative metabolism and9/25/13 RoC Monograph on 1

- Bromopropane Appendix E

A

- 46 sperm toxi city in mice. Wild

- type and Cyp2e1 – /

– (knockout) mice (4 per group) were exposed to [1,2,3

- 13 C]

- 1

- bromopropane at 800 ppm for 6 hours in an inhalation chamber. In addition, ex vivo experiments were conducted using caudal sperm (collected from the cauda epididymis) from unexposed wild

- type and knockout mice incubated with either 1

- bromopropane or its metabolite 1

- bromo

- 2

- hydroxypropane (1

- bromo

- 2

- propanol) in a sealed test tube. Exposed wild

- type mice had a 37% reduction in the percentage of motile sperm compared with unexposed controls (Table E

- 1 a ). In contrast, the percentage of motile sperm in exposed knockout mice was not significantly different from unexposed controls. In addition, liver glutathione levels were reduced by 76% in exposed wild

- type mic e compared with 47% in exposed knockout mice (Table E

- 1 a ). Epididymal sperm were isolated from unexposed wild

- type and knockout mice and were incubated with 0.05 mM 1

- brom

o propane or 1

- bromo

- 2

- hydroxypropane for 2 hours (Table E

- 1 b ). Sperm isolated from wi ld

- type mice had significantly reduced motility when incubated with either test compound. In contrast, sperm from knockout mice did not show a significant change in motility when incubated with 1

- bromopropane but motility was significantly reduced when inc ubated with 1

- bromo

- 2

- hydroxypropane. The authors did not address the apparent differences in sperm motilit y between wild

- type and knockout mice in the control groups for the ex vivo experiment. Although the sample sizes used in these experiments were smal l, t hese data suggest that products of CYP2E1

- mediated oxidation of 1

- bromopropane (specifically 1

- bromo

- 2

- hydroxypropane) contribute to male reproductive toxicity.

Table E

- 1 a. 1

- Bromopropane effects on sperm motility and glutathione levels in wild

- type o r Cyp2e1 – /

– mice

Genotype Dose (ppm) % Motile sperm (N = 8) GSH (mM ± SE) (N = 3 to 4)

Wild

- type 0

800 % change 63 40*

– 37 10.6 ± 1.7 2.6 ± 2.5**

– 76 Cyp2e 1
– /

– 0

800 % change 57 48

– 16 13.8 ± 1.4 7.36 ± 1.0*

– 47 Source: ( Garner et al. 2007 )

. * P < 0.05 ( compared with unexposed controls). ** P < 0.01 (compared with unexposed controls)

.

Table E

- 1 b . Sperm motility following 2

- hour incubations with 1

- bromopropane or 1

- bromo

- 2

- hydroxypropane

Genotype % Motile sperm (N = 3)

Control 1

- Bromopropane 1

- Bromo

- 2

- hydroxypropane

Wild

- type 73 39* 26* Cyp2e 1
– /

– 57 43 23* Source: ( Garner et al. 2007 )

. * P < 0.05 (compared with unexposed controls , 3 animals/group).Appendix E RoC Monograph on 1-Bromopropane 9/25/13

A- 47 These authors believed that reduction of sperm motility might be mediated by disruption of energetic pathways by metabolites (bromoacetone and -bromohydrin) derived from CYP-mediated oxidation of 1-bromo-2-hydroxypropane (see Figure 2 -3). Studies with - bromohydrin and its chlorinated analogue have shown that these compounds are converted in situ by spermatozoa into halolacetates. Halolacetates are metabolic inhibitors that can cause reduced sperm motility. Bromoacetone also may be further metabolized either to 1-hydroxy-1 -bromoacetone, ultimately forming pyruvate and CO 2 , or 3-bromo-1-hydroxypropanone. 3-Bromo-1 -hydroxypropanone can inhibit sperm motility by conversion to bromolactaldehyde and bromopyruvaldehyde, and ultimately yielding the metabolic poison bromopyruvate.

Neurotoxicity Neurotoxic effects of 1-bromopropane were first described in rats and were later used to identify and analyze the initial human cases (Ichihara et al. 2011, Li et al. 2010b
, MeyerBaron et al. 2012)

. Although the molecular mechanisms of neurotoxicity are not completely understood, recent studies show that the hippocampus is especially susceptible to 1-bromopropane

– induced effects and involves oxidative stress, loss of ATP production, altered GABA metabolism and reduced GABAergic feedback inhibition, inhibition of the ubiquitination-proteosome system, changes in neurotransmitter receptor expression, and modifications of intracellular signaling cascades (Fueta et a l. 2004
, Fueta et al. 2002b
, Huang et al. 2011
, Mohideen et al. 2009)

. Other studies indicate that the neurotoxic effects of 1-bromopropane involve glutathione depletion, protein adducts, and degeneration of noradrenergic axons (Mohideen et al. 2011
, Valentine et al. 2007
, Wang et al. 2002
, Wang et al. 2003)

. Studies in humans include more than a dozen case reports from the United States and an epidemiologic study of 1-bromopropane production factory workers in China (Ichiharaet al. 2011
, Li

et al. 2010b). Signs and symptoms from the case reports were similar and included numbness, diminished vibration sense in the lower extremities, distal latency, and ataxia suggesting that sensory nerves were affected. Other effects included hyperreflexia, suggesting damage to the central nervous system, and neurobehavioral effects (memory disturbances and depressive or unstable mood). Li et al. (2010b ) evaluated neurologic abnormalities in 60 women factory workers compared with age-
,sex-, and region-matched controls. Significant neurological effects included dosedependent increase in the distal latency of tibial nerves, increased threshold for vibration sense in the toes, and decreased sensory nerve conduction velocity of the sural nerve. However, the exposure assessment was based on recent exposure measurement, which may not accurately reflect past exposure.
Reported effects in rats include prolongation of motor distal latency, reduction of motor nerve conduction velocity, myelin sheath degeneration, decrease in cerebral weight, pyknotic shrinkage and degeneration of Purkinje cells in the cerebellum, ataxia, and decreased limb muscle strength (Ichihara et al. 2011). Wang et al. (2002
, 2003) investigated the biochemical changes in the central nervous system of rats exposed to 1-bromopropane vapors for 7 days or 12 weeks. Groups of 9 male Wistar rats were exposed to 0, 200, 400, or 800 ppm 8 hours/day, 7 days/week. Both studies reported a9/25/13 RoC Monograph on 1

- Bromopropane Appendix E

A

- 48 dose

- dependent decrease in neurospecific

- enolase in the cerebrum and cerebellum (suggesting functional or cellular loss of neurons) with concomitant decreases in nonp rotein sulfhydryl bases, total glutathione, and creatine kinase activity. Creatine kinase also has a critical active

- site sulfhydryl group and may be representative of other proteins with a functional sulfhydryl group. Therefore, the mechanisms of 1

- bromopropane neurotoxicity may involve glutathione depletion and modification of functional proteins containing a sulfhydryl base. A study by Valentine et al. ( 2007 ) demonstrated that 1

- bromopropane produces S

- propyl cysteine adducts on globin and neurofilaments in rats and globin adducts in humans and provide s further support f or this mechanism proposed by Wang et al. ( 2002
, 2003 ) , which is discussed below

.
Valentine et al. ( 2007 ) investigated the dose responses for urinary N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine (AcPrCy s) and S

- propylcysteine adducts on globin and neurofilaments as a function of 1

- bromopropane exposure in male Wistar rats and humans . Two experiments were conducted in rats . In the first experiment, rats w ere divided into four groups (8 per group) and expo sed to 1

- bromopropane vapor at 0, 50, 200, or 800 ppm for 8 h ours /day for 2 weeks. The second experimen t included 2 groups of rats (12 per group) exposed to 0 or 50 ppm for 8 h ours /day, 5 days/week for 4 weeks. Globin adducts were measured in both experime nts , but neurofilament adducts were measured only in the first experiment. In humans, urinary AcPrCys and globin S

- propylcysteine adduct s were determined in workers at a 1

- bromopropane production factory. Both globin and neurofilament adducts showed a line ar dose

- dependent increase , and a significant increase in globin adducts was observed in exposed workers compared with control workers . The authors concluded that the formation of S

- propylcysteine adducts on rat spinal cord protein represents a potential

m echanism to explain the observed decrease in sulfhydryl groups reported by Wang et al. ( 2002
, 2003 ) . Thus, the neurotoxic effects of 1

- bromopropane may be explained in par t by its ability to covalently bind to sulfhydryl groups in the nervous system either by direct addition or from reactive metabolites.

Subramanian et al. ( 201 2 ) reported that several oxidative stress markers (e.g., th i obarbituric acid reactive substances, protein carbonyl, ROS, and reactive nitrogen species [RNS]) were increased in a dose

- dependent manner in the rat cerebellum following exposure to 1

- brom opropane vapor for 28 days. In addition, morphological changes in microglia were reported. Microglia activation in response to pathological stimuli in the CNS is a major source of ROS and RNS. Imbalance in the formation and removal of ROS and RNS results i n disturbances of cellular homeostasis and cytotoxicity.

Huang et al. ( 2011 ) analyzed the differential protein expression in the hip pocampus of F344 rats exposed to 1

- bromopropane at 0, 400, or 1,000 ppm, 8 hours/day, for 1 to 4 weeks. 1

- Bromopropane was shown to modify the hippocampal proteome in both a dose

and time

- dependent manner. Twenty

- six protein spots were identified with sig nificant changes (increase or decrease) in their levels of expression compared with controls. From these 26 protein spots, 19 proteins were successfully identified. The altered proteins were classified into six groups according to their functional properti es and included nucleocytoplasmic transport, immunity and defense, energy metabolism, purine metabolism, neurotransmitter metabolism, and ubiquitination

- proteosome pathway.Appendix E RoC Monograph on 1-Bromopropane 9/25/13

A- 49 These data suggest that 1-bromopropane

– induced damage to the hippocampus involves oxidative stress, loss of ATP production, dysfunction of GABAergic feedback inhibition
, and inhibition of ubiquitination-proteosome system. Several studies have reported an association between 1-bromopropane exposure and GABA inhibition (Fueta et al. 2004
, Fueta et al. 2007
, Ueno et al. 2007 ). Fueta et al. (2004, 2007) reported that excitability and convulsive behavior in rats following inhalation exposure to 700 or 1,500 ppm 1-bromopropane was related to dysfunction of GABA-mediated feedback inhibition in the hippocampus. Ueno et al. (2007 ) also reported dysfunction of the hippocampal GABAergic system in male Wistar rats following subchronic inhalation exposure to 1-bromopropane. Reduced function was related to decreased levels in the expression and function of GABA receptors. Although the relevance of GABA inhibition to the carcinogenicity of 1-bromopropane is unknown, several studies have reported that GABA is involved in the proliferation, differentiation, and migration of various cell types and that increased expression of GABA and GABA receptors have been reported in some tumor cells (Maemura et al. 2003
, Schuller et al. 2008
, Watanabe et al. 2006
, Young and Bordey 2009). These data are briefly reviewed in Section 5.3.3.

Hepatotoxicity Several studies have investigated the mechanisms underlying the hepatotoxic effects of 1-bromopropane in mice (Lee et a l. 2007a
, Lee et al. 2005b
, Li et al. 2010a
, Liu et al. 2009
, Liu et al. 2010 ) and rats (Ishidao et al. 2 002). Lee et al. focused on the role of metabolism following single oral doses while Liu et al. focused on the role of oxidative stress and biological factors that determine susceptibility in different mouse strain s following inhalation exposure. The findings from these studies are summarized below.
The role of glutathione conjugation in the hepatotoxic effects of 1-bromopropane was investigated in male ICR mice (Lee et al. 2005a
, Lee et al. 2005b) and female BALB/c mice (Lee et al. 2007a). These studies used similar protocols to investigate the dose response and the time course of effects and reported similar results. Two studies were conducted with male ICR mice. In the first study, male ICR mice (5 per group) received a single oral dose of 0, 200, 500, or 1,000 mg/kg of 1-bromopropane in corn oil and were sacrificed 12 or 24 hours later (Lee et al. 2005b). For the time-course study, groups of mice were administered a single oral dose of 1,000 mg/kg and sacrificed at 6, 12, or 24 hours. The second study was similar to the first but also included groups pretreated with phenobarbital or SKF-525A, a general CYP inhibitor (Lee et al. 2010a). Female BALB/c mice were divided into the same treatment groups as reported above but all mice were sacrificed after 12 hours in the dose-response study and at 6, 12, 24, or 48 hours in the time-course study (Lee et al. 2007a). Hepatotoxicity parameters measured in these three studies included serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or malondialdehyde. Also liver homogenates were analyzed for glutathione (GSH), 1-bromopropane glutathione conjugate, or S -propyl GSH.
Body and liver weights were not affected by 1-bromopropane exposure in male ICR mice; however, the activities of serum ALT and AST were significantly increased at the high dose 24 hours after treatment (Table E-2 ) (Lee et al. 2005b). Hepatic GSH levels decreased and S -propyl GSH levels increased with dose 12 hours after treatment but returned to near normal levels after 24 hours. Levels of malondialdehyde, a marker of9/25/13 RoC Monograph on 1

- Bromopropane Appendix E

A

- 50 lipid peroxidation, also increased with dose and were significantly elevated in groups exposed to 500 or 1,000 mg/kg.

Table E

- 2 . 1

- Bromopropane effects on serum enzymes in male ICR mice

Gr oup (N = 5) ALT (Karmen unit/mL ± SE ) AST (Karmen unit/mL ± SE )
Dose

- response study (mg/kg) a

0 200 500 1000 46 ± 10 33 ± 6 34 ± 2 1972 ± 1648** 58 ± 6 70 ± 9 76 ± 7 653 ± 478**
Time

- course study (hr) b

0 6 12 24 46 ± 10 38 ± 3 1031 ± 613 1972 ± 1648** 58 ± 6 106 ± 12 293 ± 120 653 ± 478** Source: Lee et al. 2005b

. ALT = serum alanine aminotrans f erase, AST = serum aspartate aminotransferase

. ** P < 0.01

. a Measured at 24 hours.
b 1,000 mg/kg treatment dose.

Lee et al. ( 2010a ) reported similar results. Serum ALT and AST were significantly increased by a single treatment of 1,000 mg/kg 1

- bromopropane. Mice pretreated with phenobarbital to induce metabolic enzymes had significantly increased serum ALT and AST in groups treated with 750 mg/kg and above; however, groups of mice pretreated with the CYP inhibitor (SKF

- 525A) had significantly l ower serum ALT and AST levels than mice treated with 1

- bromopropane alone. In addition, thiobarbituric acid

- reactive substance (TBARS), a byproduct of lipid peroxidation, also was significantly increased by 1,000 mg/kg 1

- bromopropane. TBARS was not increas ed in animals pretreated with SKF

- 525A. Hepatotoxicity was associated with glutathione depletion by formation of GSH conjugates. Specifically, S

- propyl and 2

- hydroxypropyl GSH conjugates were identified in the liver
, and hepatic GSH levels were significant ly decreased 6 hours after treatment with 750 or 1,000 mg/kg. Pretreatment with phenobarbital resulted in significantly decreased hepatic GSH levels 6 hours after treatment with 500 or 1,000 mg/kg compared with mice exposed to 1

- bromopropane alone. Mice pr etreated with SKF

- 525A showed decreased GSH only at 500 mg/kg compared with 1

- bromopropane alone. GSH levels were restored to control levels 24 h ours after 1

- bromopropane treatment in all groups except the high

- dose groups pretreated with either phenobarbital or SKF

- 525A.

Effects of 1

- bromopropane exposure in female BALB/c mice were consistent with those reported for male ICR mice ( Lee et al. 2007a )

. Glutathione levels in the liver and spleen were significantly decreased in a dose

- dependent manner (Table E

- 3 ). S

- Propyl glutathione conju gate showed dose

- related increases in the liver, spleen, and serum. Maximum amounts were detected at 6 to 12 hours after dosing.Appendix E RoC Monograph on 1

- Bromopropane 9/25/13

A

- 51 Table E

- 3 . 1

- Bromopropane effects on hepatic GSH and GSH conjugate ( S

- propyl GSH) levels in female BALB/c mice

Group (N = 5) ALT

(Karmen unit/mL ± SE ) GSH

(nmol/mg protein ± SE ) S

- propyl GSH (nmol/mg protein ± SE )

Liver Spleen Liver Spleen Serum

Dose

- response study (mg/kg) a

0 200 500 1000 28.4 ± 4.1

35.2 ± 6.4 151.2 ± 100.7 3367 ± 3111** 576.6 ± 23.8

102.6 ± 34.9** 102.2 ± 38.0** 24.2 ± 4.9** 161.5 ± 3.6

117.6 ± 8.5 126.2 ± 6.9 86.3 ± 8.7* N.D.

3.2 ± 1.0 25.8 ± 3.2 315.6 ± 162.7 N.D.

N.D. 1.4 ± 0.5 10.3 ± 1.3 N.D.

0.04 ± 0.02 0.11 ± 0.02 5.98 ± 1.54
Time

- course study (hr) b

0 6 12 24 48 28.4 ± 4.1

18.3 ± 8.9 3367 ± 3111** 10
, 641 ± 3592** 2209 ± 849** 576.5 ± 23.8

29.6 ± 10.8** 24.2 ± 4.9** 28.8 ± 10.2** 114.8 ± 28.0 161.5 ± 3.6

93.8 ± 10.0* 86.3 ± 8.7* 110.6 ± 10.2 135.2 ± 7.9 N.D.

409.4 ± 72.2 315.6 ± 162.7 33.1 ± 9.2 1.2 ± 0.6 N.D.

6.3 ± 2.8 10.3 ± 1.3 1.9 ± 0.7 1.3 ± 0. 9 N.D.

7.20 ± 1.52 5.98 ± 1.54 0.38 ± 0.15 0.01 ± 0.01 Source: Lee et al. 2007a

. ALT = serum alanine aminotransferase, GSH = glutathione, N.D. = not detected

. * P < 0.05

. ** P < 0.01

. a Measured at 12 hr.
b 1,000 mg/kg treatment dose.
Hepatotoxic effects occurred in parallel with changes in glutathione and glutathione conjugate levels and were prevented by pretreatment with a general CYP inhibitor (SKF

525A) ( Lee et al. 2007a
, Lee et al. 2005b
, Lee et al. 2010a ) . Increases in ALT levels were proportional to glutathione depletion and formation of S

- propyl glutathione. Hepatotoxic effects included centrilobular cellular swelling and vacuolization of hepatocytes, congestion, hem orrhage, and centrilobular necrosis. In addition, lipid peroxidation was significantly increased and liver catalase activity was decreased in mice treated with 1

- bromopropane. These data suggest that the hepatotoxic effects, including lipid peroxidation, c ould be related to two different metabolic pathways. First, hepatotoxicity may be closely related with glutathione depletion associated with GSH conjugate formation and subsequent formation of reactive oxygen species. Further, metabolism of 1

- bromopropane by CYP enzymes to toxic metabolites that are not associated with GSH conjugation might be an additional factor.

Liu et al. ( 2009 ) compared the susceptibility of male mice in three strains (C57BL/6J, DBA/2J, and BALB/cA) to 1

- bromopropane

– induc ed hepatotoxicity. Male mice (6 per group) were exposed to 0, 50, 110, or 250 ppm for 8 hours/day for 28 days. Hepatic CYP2E1 levels, glutathione

- S

- transferase (GST) activity, tot al GSH, oxidized GSH (GSSH), and NAD(P)H:quinone oxidoreductase (NQO1) and heme oxygenase

- 1 (HO

- 1) mRNA levels were measured. All three strains exposed to 250 ppm developed focal necrosis and hepatocellular degeneration
, and both parameters showed a signif icant correlation between response and dose as measured by Pearson’s coefficient (Table E

- 4 ). However, BALB/cA mice were the most susceptible based on liver histopathology and9/25/13 RoC Monograph on 1

- Bromopropane Appendix E

A

- 52 DBA/2J mice were the most resistant strain. Baseline CYP2E1 protein levels were higher while total GSH content and GST activity in the liver were lower in BALB/cA than DBA/2J mice. NQO1 and HO

- 1 mRNA levels were increased at 250 ppm in BALB/cA but not in DBA/2J mice. NQO1 protects cells against redox cycling chemicals and HO

- 1 defends against oxidant

- induced injury during inflammation. Increased expression of NQO1 and HO

- 1 in the susceptible strain indicates increased oxidative stress compared with the resistant strain . These data indicate that CYP2E1 activity, GSH levels, and GST acti vity might explain the differences in susceptibility among the three mouse strains to 1

- bromopropane

– induced hepatotoxicity.

Table E

- 4 . Comparison of liver histopathology among three mouse strains exposed to 1

- bromopropane

Strain N Dose (ppm) % Necrotic area ( m ean ± SD) 1 % Lobule degeneration ( m ean ± SD) a

DBA/2J 6

6 6 6 0

50 110 250 Pearson’s coefficient 0.00 ± 0.00 0.15 ± 0.02 0.23 ± 0.09 0.46 ± 0.27* 0.780* 0.00 ± 0.00 15.44 ± 9.45 14.32 ± 13.18 52.60 ± 21.88* 0.807*
C57BL/6J 6

6 6 5 0

50 110 250 Pearson’s coefficient 0.00 ± 0.00 0.28 ± 0.11* 0.49 ± 0.25* 0.88 ± 0.24* 0.879* 0.00 ± 0.00 24.27 ± 11.12* 35.78 ± 22.00* 73.03 ± 21.07* 0.819*
BALB/cA 6

6 6 4 0

50 110 250 Pearson’s coefficient 0.00 ± 0.00 0.55 ± 0.21 b * 1.69 ± 0.53 b * 3.80 ± 2.19 b * 0.841* 0.00 ± 0.00 43.76 ± 15.16 b * 62.30 ± 8.18 b * 91.42 ± 9.93 c * 0.920* Source: Liu et al. 2009

. * P < 0.05 (compared with strain

- matched controls).

a Percent values were converted by arcsine transformation before statistical analysis

. b Significantly different ( P < 0.05) from either DBA/2J or C57BL/6J strain at same dose.

c Significantly different ( P < 0.05) from DBA/2J strain at same dose.

Liu et al. ( 2010 ) investigated the role of oxidative stress in 1

- bromopro p ane

– induced hepatotoxicity using nuclear factor erythroid 2

- related factor 2 ( Nrf2 )

- null mice. Nrf2 is a transcription factor involved in the cellula r defense against oxidative stress. Male Nrf2

- null and wild

- type mi ce (8 per group) were exposed to 0, 100, or 300 ppm 1

- bromopropane for 8 hours/day for 28 days. At the high dose, diffuse hepatocellular degeneration, focal and widespread necrosis, and foc al inflammatory cell infiltration were observed in both genotypes. However, significantly larger areas of liver necrosis occurred in Nrf2

- null mice compared with wild

- type mice (Table E

- 5 ). Nrf2

- null mice also had a higher prevalence of fatty degeneration, greater malondialdehyde levels, higher ratio of oxidized glutathione/reduced form of glutathione (GSSH/GSH), and lower total GSH content. GST activity was significantly increased in wild

- type mice at 300 ppm but wasAppendix E RoC Monograph on 1

- Bromopropane 9/25/13

A

- 53 unchanged in Nrf2

- null mice where the b asal expression levels were low. Significant changes in the mRNA levels of several oxidative stress

- related genes (including NQO1 and HO

- 1) occurred in exposed wild

- type mice compared with controls. Only GST Yc2 mRNA levels were significantly increased in the high

- dose Nrf2

- null mice. Thus, these data demonstrated that Nrf2

- null mice were more susceptible to 1

- bromopropane

– induced liver injury and had a reduced antioxidant response compared with wild

- type mice. The compromised antioxidant response and higher level of lipid peroxidation (as indicated by higher malondialdehyde levels) in Nrf2

- null mice suggest that liver injury is related to oxidative stress. However, since liver necrosis also may contribute to lipid peroxidation, further studies are needed to clarify the role of oxidative stress in liver injury.

Table E

- 5 . Comparison of liver necrotic area in wild

- type and Nrf2

- null mice exposed to 1

- bromopropane

Genotype Dose (ppm) a

0 100 300

Wild

- type Nrf2

- null 0.00 ± 0.00 0.00 ± 0.00 0.43 ± 0.20* 0.99 ± 0.28 b
, * 1.08 ± 0.36* 1.94 ± 0.60 b
, * Source: Liu et al. 2010

. *P < 0.05 (compa

red wi th strain

- matched controls).

a Percent values ( ± SD ) were converted by arcsine transformation before statistical analysis ; N = 8 except for high

- dose Nrf2

- null mice where N = 6.

In contrast with the studies in mice, Ishidao et al. ( 2002 ) reported that male Wistar rats exposed to 1

- bromopropane vapor 6 hours/day, 5 days/week for 3 and 4 weeks at 1,500 ppm or 4 to 12 weeks at 700 ppm showed significantly decreased plasma ALT levels (Table E

- 6 ). Plasma AST levels were not significant ly affected. Although the reason for the decreased ALT levels was not clear, the data indicated that plasma ALT activity was affected by 1

- bromopropane. Another surprising finding was that the levels of P450 in hepatic microsomes were significantly decreas ed after 1

- day and 1

- month exposures to 700 ppm. There is some experimental evidence that exposure to ethylene oxide may decrease hepatic P450 levels by attacking the heme moiety and altering heme balance in the liver. Propylene oxide , a structural a nalogu e of ethylene oxide, is a possible intermediate metabolite of 1

- bromopropane that might affect hepatic P450 levels.9/25/13 RoC Monograph on 1-Bromopropane Appendix E

A- 54 Table E-6 . 1 -Bromopropane effects on plasma enzymes in male Wistar rats

Treatment (ppm) N Duration (weeks) AST (U/L ± SD ) ALT (U/L ± SD )

0 700 30

15 4 77.4 ± 16.3 80.2 ± 11.0 44.8 ± 11.5 23.6 ± 3.6* *
0 700 30

10 12 110.0 ± 35.2 90.4 ± 21.6 60.6 ± 14.0 31.0 ± 5.3**
0 1500 10

10 3 119.7 ± 24.3 141 ± 58.5 56.8 ± 18.8 30.2 ± 9.5* Source: Ishidao et al. 2002. AST = aspartate aminotransferase, ALT = alanine aminotransferase. *P < 0.05 (compared with group controls). **P < 0.01 (compared with group controls).
Immunotoxicity 1-Bromopropane has induced immunotoxic effects in mice (Lee et al. 2007a). Tdependent antibody response to sheep red blood cells, intracellular IL-2 production, and the absolute numbers of splenocyte subpopulations (total T-cells, CD4 + cells, CD8 + cells, macrophages, and B-cells) were all reduced in a dose-dependent manner. Thus, dose levels that resulted in decreased cellular glutathione and increased production of glutathione conjugate in spleen cells (see Table E-3) also suppressed immune function. These findings are consistent with studies that have shown immune function to be affected by intracellular glutathione (Dröge and Breitkreutz 2000). Studies in humans indicate that the immune system requires an optimal level of glutathione. Individuals with intermediate levels of glutathione generally have a higher number of CD4 + T-cells than individuals with lower or higher intracellular glutathione levels. Some immune functions, such as DNA synthesis in lymphocytes, are very sensitive to reactive oxygen intermediates and are favored by high levels of glutathione while certain signal pathways are enhanced by oxidative conditions that are favored by low intracellular glutathione levels. IL-2 -dependent functions (including T-cell proliferation, generation of CD8 + Tcell blasts, cytotoxic T-cell activity, lymphokine-activated killer cells, and natural killer cells) are particularly sensitive and are inhibited by a partial depletion of intracellular glutathione levels (Dröge et al. 1994). Thus, the immunotoxicity of 1-bromopropane could be related to glutathione depletion from formation of glutathione conjugates and increased oxidative stress.

Anderson et al. (2010 ) also reported immunotoxic effects of inhaled 1-bromopropane in female B6C3F 1 mice and F344/N rats. Animals (8 per group) were placed in inhalation chambers and exposed to 0, 125, 250, or 500 ppm (mice) or 0, 250, 500, or 1,000 ppm (rats) for 6 hours/day, 5 days/week, for 4 or 10 weeks. Spleen immunoglob ul in (IgM) responses to sheep red blood cells (plaque-forming cell assay) were significantly decreased in mice (all exposed groups) and in rats (high-dose group only) after exposure for 10 weeks (see Table E-7); however, the serum IgM response (ELISA assay) was not affected. Although the mechanism underlying these contradictory results is unknown, it has been observed following exposure to other chemicals (Johnson et al. 2000
, Temple etAppendix E RoC Monograph on 1

- Bromopropane 9/25/13

A

- 55 al. 1993 ) . The sensitivities of these assays can vary depending on the compound being tested.

Table E

- 7. Suppression of splenic IgM response to sheep RBC in rodents after inhalation exposure to 1

- bromopropane for 10 weeks

Exposure (ppm) B6C3F 1 M ous e Fisher 344 Rat

PFC/ 10 6 splenocytes PFC/

spleen PFC/

10 6 splenocytes PFC/

spleen

0 125 250 500 1000 17 52

11 24 * 8 59 * 681 * ND 4 49

2 63 * 1 81 * 1 44 * ND 3 09

ND 21 1 2 09 1 64 * 14 2

ND 10 5 10 2 79 * Source: Anderson et al. 20 1 0 ( mean values from graphs in paper; actual data provided by author s )

. IgM = immunoglobulin M; RBC = red blood cells; PFC = plaque

- form ing cell ; ND = not done

. *P < 0.05 (compared with air control).
Total spleen cells and total T

- cells (CD3+) were significantly reduced in mice (all exposed groups) and in high

- dose rats after 4

- weeks exposure ( Anderson et al. 2010 )

. This trend was not observed after 10

- w eeks exposure, with the exc eption of a decrease in total T

- cells in hi gh

- dose rats. The apparent recovery of splenocyte numbers by the end of the 10

- week exposure period might be due to the ability of 1

- bromopropane to induce its own metabolism to increase production of CO 2 and other nontoxic metabolites. However, rats expos ed to 500 or 1,000 ppm for 10 weeks also had a significant decrease in the CD4 + /CD8 – T

- cell subpopulation. There were no consistent changes in natural killer cell activity or biological alterations in B

- cell or macrophage numbers in either species. These d ata suggest that T

- cells are a possible target for 1

- bromopropane immunotoxicity, which could increase the risk of infection.

An unusual non

- neoplastic finding in rats in the 2

- year carcinogenicity study was the presence of inflammatory lesions with Splen dore

- Hoeppli reaction material ( Morgan et al. 2011
, NTP 2011a ) . These lesions were exposure related and were more common in males than females. Although these lesions occurred primarily in the nose and skin, other sites were affected. Swabs were collected from abscesses on the tail, Harderian gland, head, and salivar y glands from five rats and cultured under aerobic and anaerobic conditions and Splendore

- Hoeppli bodies were later observed microscopically in these lesions. No bacterial growth occurred under anaerobic conditions, but Pseudomonas aeruginosa was observed in four of five aerobic cultures. Splendore

- Hoeppli bodies may be formed by deposition of antigen

- antibody complexes and debris from host inflammatory cells, or from glycoproteins, lipid, and calcium derived from host leukocytes. Infections from fungi, hel minthes, or bacteria are the typical causative agents. Although immunosuppression might have contributed to the development of Splendore

Hoeppli bodies, it is not clear why these lesions occurred only in rats since mice were also immunosuppressed by exposu re to 1

- bromopropane in sub

- chronic studies ( Anderson et al. 2010 )

.9/25/13 RoC Monograph on 1

- Bromopropane Appendix E

A

- 56 This Page I ntentionally Left BlankRoC Monograph on 1

- Bromopropane 9/25/13



# Part 2

RoC Substance Profile9/25/13 RoC Monograph on 1

- Bromopropane

This Page Intentionally Left BlankRoC Monograph on 1-Bromopropane 9/25/13

1 

### 1-Bromopropane
CAS No. 106- 94 -5 Reasonably anticipated to be a human carcinogen

First listed in the Thirteenth Report on Carcinogens (2014)
Also known as n -propyl bromide

Carcinogenicity

1 -Bromopropane is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals. 1-Bromopropane, either directly or via reactive metabolites, causes molecular alterations that typically are associated with carcinogenesis, including genotoxicity, oxidative stress, and glutathione depletion. These alterations, observed mainly in vitro and in toxicity studies in rodents, are relevant to possible mechanisms of human carcinogenicity and support the relevance of the cancer studies in experimental animals to human carcinogenicity.
Cancer Studies in Experimental Animals Inhalation exposure to 1-bromopropane caused tumors in two rodent species and at several different tissue sites, including one tissue site in rats at which tumors are rare (NTP 2011)

. In male rats, 1-bromopropane caused significant dose-related increases in the incidences of several types of benign and/or malignant skin tumors (keratoacanthoma; keratoacanthoma and squamous-cell carcinoma combined; and keratoacanthoma, squamous-cell carcinoma, basal-cell adenoma, and basal-cell carcinoma combined). Both female and male rats showed an increased incidence of large-intestine tumors (adenoma of the colon and rectum), which are rare tumors in rats. In females, the incidence was dose-related and statistically significantly higher than in concurrent controls, and it exceeded the historical control range for all routes of exposure used in studies, including inhalation exposure. In males, the incidence of large-intestine adenoma was not significantly increased, but exceeded the historical control range for inhalation-exposure studies, and its occurrence was considered to be biologically significant because of the rarity of these tumors (which occurred in less than 0.2% of the historical controls). Although no carcinoma of the large intestine was observed in male or female rats in th is study, adenoma of the large intestine has been shown to progress to carcinoma in other studies and forms a morphologic continuum with carcinoma (Deschner 1983, Chang 1984, Nigro 1985)

. In female mice, 1-bromopropane caused significant dose-related increases in the incidence of benign and malignant lung tumors combined (alveolar/bronchiolar adenoma and carcinoma). These findings are supported by the observation of additional tumors in rats that may have been related to 1-bromopropane exposure, including malignant mesothelioma9/25/13 RoC Monograph on 1

- Bromopropane

2 of the abdominal cavity and pancreatic islet tumors in males and skin tumors (squamous

cell papilloma, keratoacanthoma, and basal

- cell adenoma or carcinoma) in females.

Other Relevant Data
1

- Bromopropane is well absorbed following ingestion, inhalation, or dermal exposure. Occupational exposure occurs primarily by inhalation and dermal contact. U nmetabolized 1

- bromopropane has been detected in the urine of exposed workers at levels significantly correlated with exposure to 1

- bromopropane in air (Kawai et al. 2001, Ichihara et al. 2004)

. 1

- Bromopropane is metabolized via several pathways; 16 urinary metabolites have been detected in rodents, and several other me tabolites have been proposed (Jones and Walsh 1979, Ishidao et al. 2002, Garner et al. 2006) . The primary metabolic pathways in rodents are oxidation reactions catalyzed by cytochrome P450 (primarily CYP2E1) and glutathione conjugation. The available data on human metabolism of 1

- bromopropane, although limited, suggest that some of its metabolic pathways in humans are similar to those observed in rodents. Four mercapturic conjugates identified in the urine of rodents were also identified in the urine of workers exposed to 1

- bromopropane (Hanley et al. 2009) . The major metabolite, N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine
, has been detected in the urine of exposed workers at levels that increased with increasing levels of 1

- bromopropane in ambient air (Hanley and Dunn 2006, Valentine et al. 2007, Hanley et al. 2009, 2010) . This metabolite is produced in hu mans by conjugation of 1

- bromopropane with glutathione, and that reaction also releases free bromide ions, another useful biomarker for human exposure to 1

- bromopropane (Jones and Walsh 1979
, Hanley et al. 2006)

. N o studies were identified that tested for the occurrence in humans of t he oxidative metabolites tha t are obligate intermediates to the measured conjugates

. Studies on Mechanisms of Carcinogenesis The mechanism(s) by which 1

- bromopropane causes cancer are not known. However, exposure to 1

- bromopropane has been shown to cause molecular alterations related to carcinogenicity, including genotoxicity (mutations and DNA damage), oxida tive stress, glutathione depletion, and immunomodulation. Studies have shown that 1

- bromopropane can bind to macromolecules; it formed S

- propylcysteine

– globin adducts in exposed animals and humans (Valentine et al. 2007)

. Although 1

- b romopropane did not induce mutations in bacteria under standard assay conditions, it did indu ce mutations in bacteria both with and without exogenous mammalian metabolic activation in the only reported study whose design was appropriate for testing a highly volatile chemical (Barber et al. 1981) . It also caused mutations in cultured mammalian cells with or without mammalian metabolic activation ( Elf Atochem 1996 , as reviewed in NTP 2003 ) and DNA damage in cultured human cells without metabolic activation (Toraason et al. 2006)

. In addition, there is limited evidence of DNA damage in leukocytes from 1

- bromopropane exposed workers (Toraason et al. 2006) . In rodents exposed in vivo
, 1

- bromopropane did not increase micronucleus formation in bone marrow ( Kim et al. 1998 , as reviewed in NTP 2003 ) or peripheral blood erythrocytes (Elf Atochem 1996 , cited in NTP 2003 ; NTP 2011 ) or cause dominant lethal mutations. However, the dominant lethal mutation assay is generally regard ed asRoC Monograph on 1

- Bromopropane 9/25/13

3 relatively insensitive for the detection of mutagenic agents (Saito

- Suzuki et al. 1982, Yu et al. 2008)

. There is evidence that metabolic activation plays a role in the genotoxicity and toxicity of 1

- bromopropane. Several reactive metabolites (or intermediates) of 1

- bromopropane have been identified in rodents, including glycidol and

- bromohydrin, and propylene oxide has been proposed as a metabolite (Garner et al. 2006). These compo unds cause genotoxic effects in vitro , including DNA adduct formation, mutations, and DNA or chromosome damage ( Stolzenberg and Hine 1979
, IARC 1994, 2000 ). Glycidol and propylene oxide cause cytogenetic effects in vivo and are carcinogenic in experimental animals, and both substances are listed in the Report on Carcinogens as reasonably antic ipated to be human carcinogens . These reactive and genotoxic metabolites may be responsible for at least some of the carcinogenic effects of 1

- bromopropane. As with 1

- bromopropane, oral exposure to glycidol caused rare tumors of the large intestine in rats , as did oral exposure to two halogenated alkane analogues of 1

- bromopropane, tribromomethane and bromodichloromethane (NTP 1987, 1989, 1990). Chronic exposure to 1

- bromopropane may produce levels of oxidative metabolites that exceed the glutathione

- conjug ating capacity or may inhibit enzymes required for glutathione synthesis. Because glutathione is an important cellular defense mechanism, reduced levels can lead to oxidative stress, increased toxicity, and carcinogenicity. Numerous studies have shown that 1

- bromopropane induces both oxidative stress and glutathione depletion (Lee et al. 2005, 2007, 2010a, Liu et al. 2009, 2010, Huang et al. 2011). Studies with Cyp2e1 -/- knockout mice, cytochrome P450 inhibitors, or a glutathione synthesis inhibitor showed that this metabolic activation pathway is involved in 1

- bromopropane

– induced toxicity, including neurological and reproductive effects, hepatotoxicity, and immunosuppression (NTP 2003, 2011, Lee et al. 2007, 2010a,b)

. Neurological effects of 1

- bromopropane exposure ha ve also been reported in humans (Li et al. 2010, Ichihara et al. 2012) It is unclear whether induction of immunotoxicity by 1

- bromopropane plays a role in tumor development. Recent studies have shown that 1

- bromopropane causes immunosuppression in rodents (Lee et al. 2007 , Anderson et al. 2010) . In particular, it reduced the numbers of T cells and T

- cell subpopulations. In addition, there is evidence that 1

- bromopropane causes an inflammat ory response. It induced dose

- related increases in gene expression and production of proinflammatory cytokines in mouse macrophages (Han et al. 2008) and an inflammatory response in rats (NTP 2011). However, chronic respiratory inflammation and lung tumors were not associated in rodents; respiratory inflammation occurred in rats but not mice, whereas lung tumors occurred in mice but not
rats.

Cancer Studies in Humans No epidemiological studies or case reports were identified that evaluated the relationship between human cancer and exposure specifically to 1

- bromopropane.
Properties

1

- Bromopropane is a halogenated alkane that exists at room temperature as a colorless to pale

- yellow volatile liquid with a strong, characteristic odor (NTP 2011) . It is slightly soluble in water and in most organic solvents
, including acetone, ethanol, ether, benzene,9/25/13 RoC Monograph on 1

- Bromopropane

4 chloroform, and carbon tetrachloride. It is less flammable than many other halogenated alkanes at room temperature. T hermal decomposi tion of 1

- bromopropane produces hydrogen bromide. 1

- Bromopropane can react with oxidizing agents to form hazardous flammable compounds and with water to produce acids. P hysical and chemical properties of 1

- bromopropane are listed in the following table

.

Pr operty Information Molecular weight 123.0 a Specific gravity 1.353 at 20 C / 20 C b
Melting point

– 110 C a Boiling point 64.7 C a Log K ow 2.10 b
Water solubility 2

. 45 g/L at 20 C b
Vapor pressure 110.8 mm Hg at 20°C a Vapor density relative to air 4.25 b

Sources: a NTP 2003

, b HSDB 2006

. Use

1

- Bromopropane is used primarily as a solvent cleaner in vapor and immersion degreasing operations to clean optics, electronics
, and metals and as a solvent vehicle in industries using aerosol

- applied adhesives
, such as foam cushi on manufacturing

. However, its use as an aerosol solvent or adhesive could be affected by the proposed U.S. Environmental Protection Agency (EPA) rule that finds 1

- bromopropane to be unacceptable for these uses (see Regulations). In recent years, 1

- bromopr opane usage has increased as a result of new industrial and commercial uses as a substitute for ozone

depleting chemicals or suspect ed carcinogens (e.g., as an alternative to tetrachloroethylene in the dry

- cleaning industry) (Blando et al. 2010) . 1

- Bromopropane also has potential for use as a spot remover in the textile industry ; however, an evaluation of 1

- br omopropane as a substitute for trichloroethylene concluded that chronic toxicity data were insufficient, and use of 1

- bromopropane was not recommended until more data were available (Mirza et al. 2000) . In the past, 1

- bromopropane was used primarily as a solvent for fats, waxes, and resins and as an intermediate in the synthesis of pharmaceuticals, insecticides, quaternary ammonium compounds, flavors, and fragrances in generally well

- controlled, closed processes (Hanley et al. 2006, NTP 2003)

.
Production

1

- Bromopropane is a high

- production

- volume chemical. In 2012, 1

- bromopropane was manufactured by at least 21 companies worldwide, including at least one company in the United States (SRI 2012) . Reported recent and historical volumes of U.S. production, imports, and exports of 1

- bromopropane are listed in the following table.RoC Monograph on 1

- Bromopropane 9/25/13

5 Category Year Quantity (lb) Production + imports a 2006 1998, 2002 1994 1986, 1990 > 1 million to 10 million

1 million to < 10 million > 500K to 1 million 10K to 500K U.S. imports: b recent 2011 10.3 million
historical 2007 10.9 million U.S. exports: b recent 2011 15.1 million
historical 2007 8.8 million
Sources: a EPA 2012; EPA Chemical Data Reporting Rule, f ormerly the Inventory Update Rule. b USITC 2012; r eported as “brominated derivatives of acyclic hydrocarbons.”
Exposure A significant number of people in the United States are exposed to 1

- bromopropane as a result of wide spread us age , high production volume, and high levels of 1

- bromopropane in commercial and industrial settings. Occupational exposure to 1

- bromopropane may occur through inhalation or dermal contact at workplaces where 1

- bromopropane is produced or used (HSDB 2006)

. Concentrations of 1

- bromopropane in air (8

- to 12

- hour time

- weighted averages [TWAs]) from all studies identified across several U.S. industrial sectors ranged from not detected to 380 ppm, with the highest concentrations being for adhes ive use and the lowest for vapor degreasing. Sprayers in the adhesive industry had the highest exposure, which ranged from 18 to 380 ppm across several studies. Exposure data for 1

- bromopropane manufacturing were not available for the United States. Manufa cturing exposure reported from China (Ichihara et al. 2004) ranged from not detectable to 170.5 ppm for processes that included adding materials to large reaction pots. However, production methods reported in a patent application by a U.S. manufacture r included numerous control processes to contain 1

- bromopropane, which would likely reduce potential exposure substantially. The graph below shows TWA 1

- bromopropane exposure levels from representative studies of adhesive application ( Hanley et al. 2006 ), manufacturing (in China; Ichihara et al. 2004 ), dry cleaning (Eisenberg and Ramsey 2010) , aerosol solvent

use (Graul 2012) , cleaning and painting in workshops using 1

- bromopropane solvents (Kawai et al. 2001) , and vapor degre asing (Hanley et al. 2010)

.9/25/13 RoC Monograph on 1

- Bromopropane

6 Time

- weighted

- average 1

- bromopropane exposure levels as geometric mean s (Adhesives, Other, and Vap. Deg.) ; arithmetic mean (Dry Cln.) ; or not reported (Manuf. and Aer. Solv.)

. Note: the dashed, vertical line represents the ACGIH threshold limit value

– time

- weighted average (TLV

- TWA) of 10 ppm.
Among workers at polyurethane foam furniture cushion manufacturing facilities
, g eometric mean values for daily urinary bromide excretio n and urinary N

- acetyl

- S

propylcysteine concentrations were approximately 4 times as high for adhesive sprayers

as for non

- sprayers (Hanley et al. 2006, 2009)

. C oncentrations of 1

- b romopropane in exhaled breath also were consistently higher among sprayers than among workers performing other jobs. A National Institute for Occupational Safety and Health ( NIOSH ) Health Hazard Evaluation ( HHE ) of a furniture foam cushion manufacturing facility found the average difference between end

- of

- week and start

- of

- week serum bromide concentrations to be 23 mg/L for exposed workers, compared with 3 mg/L for unexposed workers (Harney et al. 2003)

. NIOSH HHEs and follow

- ups at two facilities showed that 1

- b romopropane air concentrations (TWAs) could be reduced by 80% or more through implementation of NIOSH recommendat ions for engineering controls, such as ventilation improvements and enclosure of spray tables (Reh et al. 2002)

. The general population may be exposed to 1

- bromopropane through inhala tion of ambient air in the vicinity of industrial facilities where 1

- bromopropane is used as an adhesive. EPA used air dispersion modeling to estimate 1

- bromopropane concentrations in ambient air at a distance of 100 m from model facilities. The estimated concentrations were 0.138 mg/m 3 [0.0274 ppm] for facilities with average adhesive use and 1.38 mg/m 3 [0.274 ppm] for facilities with high adhesive use (Morris and Wolf 2003) . EPA also estimated daily inhalation uptake of 1

- bromopropane for a pers on living 100 m from a model facility to be 0.0537 mg/kg for average

- adhesive

- use facilities and 0.537 mg/kg for high

- adhesive

- use facilities. Based on its production levels and industrial uses, 1

- bromopropane may be released to the environment through va rious waste streams. 1

- Bromopropane has been detected in temperate marine macroalgal tissue and is believed to be transported from these algae to the marine environment (HSDB 2006)

. No data on levels of 1

- bromopropane in ambientRoC Monograph on 1-Bromopropane 9/25/13

7air, drinking water, surface water, soil, food, or consumer products and no data on nonoccupational exposure to 1-bromopropane were found.
Regulations
California Occupational Safety and Health Standards Board (OSHSB) Permissible exposure limit (PEL) = 5 ppm.
Environmental Protection Agency (EPA) Significant New Alternatives Policy (SNAP) Program The EPA SNAP program reviews alternatives to ozone-depleting substances and approves the use of alternatives that do not present substantially greater risk to the public health and environment than the substance they replace or other available substitutes. The EPA SNAP program has made the following determinations regarding various end uses of 1-bromopropane: Solvent in industrial equipment for metals cleaning, electronics cleaning, or precision cleaning as a substitute for CFC

– 113 and methyl chloroform: acceptable (final rule). Coatings as a substitute for CFC

– 113, HCFC

– 141b, and methyl chloroform: acceptable subject to the condition that use is limited to coatings facilities that have provided EPA data which demonstrate their ability to maintain acceptable workplace exposures (proposed rule).
Aerosol solvents as a substitute for CFC

– 113, HCFC

– 141b, and methyl chloroform : unacceptable (proposed rule).

Adhesives as a substitute for CFC

– 113, HCFC

– 141b, and methyl chloroform : unacceptable (proposed rule).

Guidelines
American Conference of Governmental Industrial Hygienists (ACGIH)
Threshold limit value

–

time-weighted average (TLV-TWA) = 10 ppm.
Environmental Protection Agency (EPA) Acceptable exposure limit (8-hour time-weighted average) = 25 ppm.

References Anderson SE, Munson AE, Butterworth LF, Germolec D, Morgan DL, Roycroft JA, Dill J, Meade BJ. 2010. Whole-body inhalation exposure to 1-bromopropane suppresses the IgM response to sheep red blood cells in female B6C3F1 mice and Fisher 344/N rats. Inhal Toxicol 22(2): 125-132. Barber ED, Donish WH, Mueller KR. 1981. A procedure for the quantitative measurement of the mutagenicity of volatile liquids in the Ames Salmonella/microsome
assay. Mutat Res 90(1): 31-48.9/25/13 RoC Monograph on 1

- Bromopropane

8 Blando JD, Schill DP, de la Cruz MP, Zhang L, Zhang J. 2010. Preliminary study of propyl bromide exposure among New Jersey dry cleaners as a result of a pending ban on perchloroethylene. J Air Waste Manag Asso c 60(9): 1049

- 1056. Chang WW. 1984. Histogenesis of colon cancer in experimental animals. Scand J Gastroenterol Suppl 104: 27

- 43. Deschner EE. 1983. Adenomas: preneoplastic events, growth and development in man and experimental systems. Pathol Annu 18(Pt 1): 205

- 219. Eisenberg J, Ramsey J. 2010. Evaluation of 1

- Bromopropane Use in Four New Jersey Commercial Dry Cleaning Facilities . Health Hazard Evaluation Report HETA 2008

- 0175

- 3111. National Institute for Occupational Safety and Health. 28 pp.
Elf Atoc hem. 1996. In Vitro Mammalian Cell Gene Mutation Test in L5178Y TK+/

- Mouse Lymphoma Cells of n

- Propyl Bromide . Study No. 13293. Miserey, France: Centre International de Toxicologie.

EPA. 2012. Non

- confidential IUR Production Volume Information. U.S. Environmental Protection Agency. http://cfpub.epa.gov/iursearch/index.cfm and search by CAS no. Garner CE, Sumner SC, Davis JG, Burgess JP, Yueh Y, Demeter J, Zhan Q, Valentine J, Jeffcoat AR, Burka LT, Mathews JM. 2006. Metabolism and disposition of 1

- bromopropane in rats and mice following inhalation or intravenous administration. Toxicol Appl Phar

macol 215(1): 23

- 36.
Graul F. 2012. Summary of Data on Workplace Exposure to n

- Propyl Bromide

. Public comment submitted by F. Graul, Executive Director, Halogenated Solvents Industry Association, Arlington VA, to R. Lunn, NTP, Research Triangle Park, NC, February 28, 2012. 8 pp

. http://ntp.niehs.nih.gov/go/37663

. Han EH, Hwang YP, Lee KJ, Jeong TC, Jeong HG. 2008. 1

- Bromopropane induces macrophage activation via extracellular signal

- regulated kinase 1/2 MAPK and NF

- κB pathways. Cancer Lett 262(1): 28

- 36. Hanley KW, Dunn K. 2006. Workers’ Exposures to n

- Propyl Bromide at a Helicopter Transmission Factory . Report no. IWSB 232.11. Cincinnati, OH: National Institute for Occupational Safety and Health. 21 pp. Hanley KW, Dunn K, Sollberger R. 2006. Workers’ Exp osures to n

- Propyl Bromide at an Aerospace Components Manufacturer . Report no. IWSB 232.12. Cincinnati, OH: National Institute for Occupational Safety and Health. 26 pp. Hanley KW, Petersen MR, Cheever KL, Luo L. 2009. N

- acetyl

- S

- ( n

- propyl)

- L

- cysteine in urine from workers exposed to 1

- bromopropane in foam cushion spray adhesives. Ann Occup Hyg 53(7): 759

- 769. Hanley KW, Petersen MR, Cheever KL, Luo L. 2010. Bromide and N

- acetyl

- S

- ( n

propyl)

- L

- cysteine in urine from workers exposed to 1

- bromo propane solvents from vapor degreasing or adhesive manufacturing. Int Arch Occup Environ Health 83(5): 571

- 584. Harney JM, Nemhauser JB, Reh CM, Trout D. 2003. HHE Report No. HETA 99

- 0260

- 2906. Marx Industries, Inc., Sawmills, N orth Carolina

. NIOSH Health Hazard EvaluationRoC Monograph on 1

- Bromopropane 9/25/13

9 Report. Cincinnati, OH: National Institute for Occupational Safety and Health. http://www.cdc.gov/niosh/hhe/reports/pdfs/1999

- 0260

- 2906.pdf

HSDB. 2006. Hazardous Substances Data Bank . National Library of Medicine. Last updated: 4/20/06. http://toxnet.nlm.nih.gov/cgi

- bin/sis/htmlgen?HSDB and search on CAS number. Huang Z, Ichihara S, Oikawa S, Chang J, Zhang L, Takahashi M, Subramanian K, Mohideen SS, Wang Y, Ichihara G. 2011. Proteomic analysis of hippocampal proteins of F344 rats expos ed to 1

- bromopropane. Toxicol Appl Pharmacol 257(1): 93

- 101. IARC. 1994. Propylene Oxide. In Some Industrial Chemicals . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 60. Lyon, France: International Agency for Research on Cancer. pp. 181

- 213. IARC. 2000. Glycidol. In Some Industrial Chemicals . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 77. Lyon, France: International Agency for Research on Cancer. pp. 469

- 486. Ichihara G, Li W, Ding X, Peng S, Yu X, Shibata E, Yamada T, Wang H, Itohara S, Kanno S, Sakai K, Ito H, Kanefusa K, Takeuchi Y. 2004. A survey on exposure level, health status, and biomarkers in workers exposed to 1

- bromopropane. Am J Ind Med 45(1): 63

- 75

. Ichihara G, Kitoh J, Li W, Ding X, Ichihara S, Takeuchi Y. 2012. Neurotoxicity of 1

- bromopropane: Evidence from animal experiments and human studies. J Adv Res 3(2); 91

- 98. Ishidao T, Kunugita N, Fueta Y, Arashidani K, Hori H. 2002. Effects of inhaled 1

- bromopropane vapor on rat metabolism. Toxicol Lett 134(1

- 3): 237

- 243. Jones AR, Walsh DA. 1979. The oxidative metabolism of 1

- bromopropane in the rat. Xenobiotica 9(12): 763

- 772. Kawai T, Takeuchi A, Miyama Y, Sakamto K, Zhang ZW, Higashikawa K, Ikeda M

. 2001. Biological monitoring of occupational exposure to 1

- bromopropane by means of urinalysis for 1

- bromopropane and bromide ion. Biomarkers 6(5): 303

- 312. Kim H, Chung J, Chung Y, et al . 1998. Toxicological Studies on Inhalation of 1

- Bromopropane Using Rats . Report submitted to the Industrial Health Research Institute

– Korea Industrial Safety Corporation. Lee SK, Jo SW, Jeon TW, Jun IH, Jin CH, Kim GH, Lee DJ, Kim TO, Lee ES, Jeong TC. 2005 . Hepatotoxic effect of 1

- bromopropane and its conjugation with glutathione in male ICR mice. Arch Pharm Res 28(10): 1177

- 1182. Lee SK, Jeon TW, Kim YB, Lee ES, Jeong HG, Jeong TC. 2007. Role of glutathione conjugation in the hepatotoxicity and immunotoxicity induced by 1

- bromopropane in female BALB/c mice. J Appl To xicol 27(4): 358

- 367. Lee SK, Kang MJ, Jeon TW, Ha HW, Yoo JW, Ko GS, Kang W, Jeong HG, Lyoo WS, Jeong TC. 2010a. Role of metabolism in 1

- bromopropane

- induced hepatotoxicity in mice. J Toxicol Environ Health A 73(21

- 22): 1431

- 1440.9/25/13 RoC Monograph on 1

- Bromopropane

10 Lee SK, Lee DJ, Ko GS, Yoo SH, Ha HW, Kang MJ, Jeong TC. 2010b. Role of glutathione conjugation in 1

- bromobutane

- induced hepatotoxicity in mice. Food Chem Toxicol 48(10): 2707

- 2711. Li W, Shibata E, Zhou Z, Ichihara S, Wang H, Wang Q, Li J, Zhang L, Wakai K, Takeuchi Y, Ding X , Ichihara G. 2010. Dose

- dependent neurologic abnormalities in workers exposed to 1

- bromopropane. J Occup Environ Med 52(8): 769

- 777. Liu F, Ichihara S, Mohideen SS, Sai U, Kitoh J, Ichihara G. 2009. Comparative study on susceptibility to 1

- bromopropane i n three mice strains. Toxicol Sci 112(1): 100

- 110. Liu F, Ichihara S, Valentine WM, Itoh K, Yamamoto M, Sheik Mohideen S, Kitoh J, Ichihara G. 2010. Increased susceptibility of Nrf2

- null mice to 1

- bromopropane

- induced hepatotoxicity. Toxicol Sci 115(2): 5 96

- 606. Mirza T, Gérin M, Bégin D, Drolet D. 2000. A study on the substitution of trichloroethylene as a spot remover in the textile industry. A m I nd H yg A ssoc J 61(3): 431

- 438. Morris M, Wolf K . 2003. Alternative Adhesive Technologies in the Foam Furnit ure and Bedding Industries. Prepared for the U.S. Environmental Protection Agency. Los Angeles: Institute for Research and Technical Assistance. 260 pp. Nigro ND. 1985. Animal model for colorectal cancer. Prog Clin Biol Res 186: 161

- 173.

NTP. 1987. Toxicology and Carcinogenesis Studies of Bromodichloromethane (CAS No. 75

- 27

- 4) in F344/N Rats and B6C3F 1 Mice (Gavage Studies) . NTP Technical Report Series no. 321. Research Triangle Park, NC: National Toxicology Program. 185 pp.

NTP. 1989. Toxicology an d Carcinogenesis Studies of Tribromomethane (Bromoform) (CAS No. 75

- 25

- 2) in F344/N Rats and B6C3F 1 Mice (Gavage Studies) . NTP Technical Report Series no. 350. Research Triangle Park, NC: National Toxicology Program. 198 pp.
NTP. 1990. Toxicology and Carc inogenesis Studies of Glycidol (CAS No. 556

- 52

- 5) in F344/N Rats and B6C3F 1 Mice (Gavage Studies) . NTP Technical Report Series no. 374. Research Triangle Park, NC: National Toxicology Program. 231 pp.

NTP. 2003. NTP

- CERHR Monograph on the Potential Human Reproductive and Developmental Effects of 1

- Bromopropane . Research Triangle Park, NC: National Toxicology Program, Center for the Evaluation of Risks to Human Reproduction. 88 pp.

NTP. 2011. NTP Technical Report on the Toxicology and Carcinogenesis Studie s of 1

- Bromopropane (CAS No. 106

- 94

- 5) in F344/N Rats and B6C3F1 Mice (Inhalation Studies) . NTP TR 564, NIH Publication No. 11

- 5906. Research Triangle Park, NC: National Toxicology Program. 195 pp. Reh CM, Mortimer V, Nemhauser JB, Trout D. 2002. HHE Repo rt no. HETA 98

- 0153

- 2883. Custom Products, Inc.

, Mooresville, N orth C arolina

. NIOSH Health Hazard Evaluation Report. Cincinnati, OH: National Institute for Occupational Safety and Health. 46 pp.RoC Monograph on 1

- Bromopropane 9/25/13

11 Saito

- Suzuki R, Teramoto S, Shirasu Y. 1982. Dominant lethal studies in rats with 1,2

- dibromo

- 3

- chloropropane and its structurally related compounds. Mutat Res 101(4): 321

- 327.

SRI. 2012. Directory of Chemical Producers . Menlo Park, CA: SRI Consulting. Database edition. Last accessed: 2/13/12. Stolzenberg SJ, Hin e CH. 1979. Mutagenicity of halogenated and oxygenated three

carbon compounds. J Toxicol Environ Health 5(6): 1149

- 1158. Toraason M, Lynch DW, DeBord DG, Singh N, Krieg E, Butler MA, Toennis CA, Nemhauser JB. 2006. DNA damage in leukocytes of workers occu pationally exposed to 1

- bromopropane. Mutat Res 603(1): 1

- 14.

USITC. 2012. USITC Interactive Tariff and Trade Data W eb . United States International Trade Commission. http://dataweb.usitc.gov/scripts/user_set.asp and search on HTS no. 2903391550. Last acces sed: 10/11/12. Valentine H, Amarnath K, Amarnath V, Li W, Ding X, Valentine WM, Ichihara G. 2007. Globin s

- propyl cysteine and urinary N

- acetyl

- S

- propylcysteine as internal biomarkers of 1

- bromopropane exposure. Toxicol Sci 98(2): 427

- 435. Yu WJ, Kim JC, Chung MK. 2008. Lack of dominant lethality in mice following 1

- bromopropane treatment. Mutat Res 652(1): 81

- 87.9/25/13 RoC Monograph on 1

- Bromopropane

12 This Page Intentionally Left BlankNIH # 13-5982 ISSN # 2331-267X Office o f t he R eport o n C arcinogens National T oxicology P rogram National I nstitute o f E nvironmental H ealth S ciences National I nstitutes o f H ealth P.O. B ox 1 2233, M D K 2-14 Research T riangle P ark, N C 2 7709